var title_f35_0_35840="Porcelain gallbladder";
var content_f35_0_35840=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Porcelain gallbladder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 312px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE4AUQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDobcho/nwc9D2rYh+SFN3YcZ71zljJvRQBk8/e6V0un/vvLDAFdvIIq7s5lsPhgaRsjjJweOn0q4tt+7XCgfwnP860tOsvNH7teuO4BFaU+mxxQjzj82DmgE7MwI4FGSV+VRyB3qcKeqIAvUA9quCKNULMMk8cVCx2ryPbjpSuF2VpcRjEX3+pA/nms+5fALOAfr1q98qsfl4z0z0qpOgkl38Eeh70FJsz5N7KN3HfrzioPLMkoIAEY/DNX3RjycFuvIqKaM7GGPl6gii4WuZMh3byqj0BIxz6UJESygxjdjFXvKH3WXIqQWzAKFBLNzknp70mOzQ2BY7eIMYwzdDuGcflUF3aF9sjAfN0z1Aregt/LthGwBP3i2etU7pfNKrGvB75xx/SgGzIKIi4XbgnGKqSxF5SxAGfTtV+SIEYb5SD1AqGeNRxvYKRz7/WhE6sybwOQoQjb1JBqMsyBIwcbucH0rQigO7Py7R1yKz72LdN5iE5XoT1pFam94W+a8YKQfl5J/hr2rw0mzS4eACRkkd68W8KBYrsZGd+A3vzXumljFnFgDGOOMUgitS3RRRTNgpPxpaa5wOelAmIwOCV5PvTGDNhWAwaeD8p4phONpJOM44pmTsSICFwe1OzSKcik470jRaIUkKMkgV5R468OmfXp72GEtGzKxxjaPlGT+lepuu4EMAVrmdamVWnjcfusbVx1zj/APXT2M5Ntnini62DWxZchmXqP4jnvXnqogm2lASOua9R8RxpNKFC8hTxnjrXBahYLauzkbm+8DigLrocvrE4WUKqdBnI6k1yV0ZJbgNwME//AK/rW/qEzGb7u6XGQOgx9ay5lMsDHaodQxppD9TKdzGzFy3Xk+tQz6qoChGwRySf60y/kVk2DcrMeTWNMWV9ue3SmnZFWua/9piXiTYT/e55FIg86UjJ2nrg9PasIN2HH07Vq2Ep3D0HoOc0tirEdxbNuY8KAcAdutJaQyCQkDHPBNbd1aMvzPwe/cVqWGigwyzHBKjcAaLCbOdnmKuA4GcCiodVkxeMFUYHHWikGp9O6IjuoLZJHQEZxzXXWbESqofhh6dK5Cwul+VsYxwcHt710lnJGu0rkgj+9zRd3MWjq9PuTFJGyAYxjcR0OKs3FxLM27AGKxba4QgoPu+xzmr9rIzKDuAxnr0+lO5NhHRgu7afUimFfMRckYB5A9aldmfLlsL0OP0qWOPOVZlKnoB1oBdjO2ZBwQO2cc/596WOGLa24gc55PWr0gUOUQDNV5QOMgE5xigrQrXEarACqrv7/wCe1VCiHGVXn1GauyxliuzA2+/GamS1ITzCAzY4X+tJ6DRSjtAVBbcpx3HarMVuNwMqH8en4+1SBxCu58Fvbriq11I4T94SS/3R7elFkO5HfMsrhPlRE4GBx+dV9q7Agwzd+OtTKCdrEFSeBntSkBiEKgkHtxmi4NlCa1OCVb5G6hUxmq0sIwFCKPbAzWqQ2MLuBU9BziozEAjOy7t5zn0FF31BMxZyY/ugZJ67efpWYVLk5wDk9OM1uMhOCfpyOlUXty9wsSgjnJxzj/OKBGv4KjDaiSwGxFBI25xXsGmMv2VcALg4x6V5t4dj2TBFCA4HI4Jr0CzYWsAiwWcAnb6VIbO5rZ96WmR8xqSMcdD2p3XoaZsmBYDvVZpgVIfGBz61JMF29/bFZUrspJWdWVeqtjPNOxjKTvY1JMtCNhCk98U5U2og6kd8Vk2s0rrkliobGT9atXEriGTD7MYwcZo0FzW6Ftpdr7cD1NMadduWIJHOMcist7yVYmKvET0J9Kz9XvLmxtHuD0IAz/jQHMyfVr+S0WV4puTnaOg6VzV5qyTQBi8bSAc4OOe+ax9c1NzjdJuLnKnPoPSuH1zxEltbSh1VM/LuXvVWBGnqc0b3ruWX3XHWqL2CX6/xOTw20f0rgjrcr3GVkBZTlWznP1rqvDOo31nI8jSqfMI+Xsfcf57UnoVpujlfEGjx2kqtbwsSTtORXnviGdbW4dUfhvvDOAa+gdU23cBkj2bs4O0fyr528dWclprEiSA7WJIO337UFR1ZizSszElcj07ZqnKN/wA20JjqAe/tUaM5OGJBPQE8VKA+zbnjODnsapammi2IETLjdn34zW1Y26sEY5DMM8c1HbWjSAYHfP1+tbui2Y+1Rhvm3dVFT1sJ7HQaXpou9OgaQEsBtDY9Mdajv5BFKsET+XFjDAHqa62VkstHZsKI1jDFBwScV5PdXkiXpJJZNx4Y9BRYW+xlXwJvZy4yd5wcYyKKkuAGmYhtwPPXp7UU7F2R9OWTwxJ5nlvvPG3r/WtNLtWhVcEMSCOK80/t1YpNqyCSQDHXitjSb8zvGZWOW/h9vWhnNdnotrK0hxkKGOOlacNxtXAbgHHTvWPoIaUAn5FHADHlhgV0UcUaxqQFAB5HWpQnoOS4ckkYx9OM1aDZ3DOM84ArNlut0gWJCqryOasWzb5cEk+hJzRYEzTjCvEudw5wAoyaR7NsjeDgtjIqOCZIm+cBznGM96nW9ZlcQfJx97rTumFxTb+UvzEAgZwe9VHnOQsQJJB+YgYqF5WlY7mLMR97NLFFlsYOO5FIrQTyio3k5OORis+Zt8zFzgjsK2YkZjiRML025xVWWDdO2xdvPTHQUtLCuUkVhj7wHpjOfzo24yxySetXfLYAjLFOhpI4RlNoww4JPb3oHzFVQGOeTgc9h+lNuirqrjIUdAPxq40axHkgqfRsc1EVDJ5a9Se9AJoy/K3yY3EE9ccgVYggVUBBO4dCRV6K0kVi2xTjgZH8qsyWyxQkrjYRlj3Pt+dAuaw7QY4xeo7ls+wHU/0rsRayRFpRtO/pgk49OtctoKF51eRSFRQVXH3fpXZ2ceLcbpNwzkcY/CiwXLjqXQAMVJ9qeOOKoXMl0odUVVUc7jzxVWC7uHEpYhghwMcZoK50uhd1GbyreRlPzAZNcNdalieMgEg9iBzXT6oAmlmRw7tIMEZ9q8r1u8W3IdVKkcCqSuQ5a3OqtNVMc+FXOXUdelT3PiI2iFWXzCOSBjmuCsdQkJIePJc8ue1c3r2tSpPIJZSVHAwccUWGz1iz8WrPJst4FGDyWri/H3iK71aFrKEpGjud/H3sHsa4nSNbme8ZY59wA5zzkZ6ZpmueIvss20r5ozhyW4U01boG25Z8ST3kHh0STMJWQ4yoAI+U8/pXjM+t3JZ1kyzsTjgYxmu713VC9ms0cRU/MroO6kV5Tq5IkBVuC24bf4RnpTRpF32N7StSKyDd1B43DqK9A0rXn8hW2qWUbcivGrSVi4LHG0YGOcD0+tdFpV+EiPmOBHH0yam1wd2ew2Gord/ujGyuecLXKfEHTlvVErkrIi9u3SuJuvFF2kwMLCM9verFv4iu7yQvPJvD8Nu7H1p2E7nMXemiOU7XYrngMMVZ0/T8QkyP8meMVo6hOkkpXAQ+/cVLZx+Yg2Lgdwo6/WhpDvoS2Si2OxELbhhie1b/AId04yXfmk7uP4e9VtLsZLq4RGBVR1PbHtXdtFFZ2yrEA2MD/azU2JlK+6KHiM/ZtGuNwzGwAPAyORXjeoORM+TgjIBr0HxxqJKta5ICqo+vSvMr2Yu77fmwSPUYqtkVBopTS5kPFFQOcsSBiildGh6FbXe+XLzcY4I7mvRvB8EshgkmU8DcFJGRXlOn2zyTK5PloDk57+1dzY+Iv7P2sy5CjbsDUO7Mm2esQarIZMsqR44HNacmstPxvRQqgA9MmvK7bxSLtowUeIE/d9ffpXWaZqVsYQWO456dqWxnfqzr7ecv0PAHfnJrRhlJjAWQqM/Xmuctb63wwXoccZrUt7tX+ZTuUdiMcUDbbNtedrZ47g9vxqzuCqBncxPIU1lC7AKhgAGGcZ5H1qzaSZAdyFyePXFP0En3LyHJGRyR3NWFdYyhC5PQAHpVWNcyj5g27GAO31q1J+7b5goXH3qVg5kWlYsM7gzZ4Ud6rR7vtCnOSe4HSpIXAAZRkEce1VldhcKyqAmecnrSsPmuSzJvwQPmBIx61RkLAAbScHJA4yPU1eaYGUrtGPr90+1NWIsSYlG727GmIqeWH9wBn5f8KWOIoodlK5GOen51NhbbiVtznv0x7Vm32oBkdckKDjHvSsNTNBb1IgwLgg9gaqXesiaVIFXEZ+XKnPP0xWFPeg7YwxVuSQMVnrdOL6PAAIIwM96YHqWiolusbuT90BQfX2rqLaWIIq5UN0I6c1yOl3BM8W8B1RRnPAHHWt63u1IKKRzynPQ1IKWtzVaWPcUZhu6bTWfDKyXUkZgCq/Kg/wCPQ0y4kBkJ3g/LhuRjP+cVm3GoGCPIlXMfYEc+1OwObZc1nUALTCYDcjGcdvevG/Et1NPMxyAR04zXWaprQnLsUPdevSuS86Ke8Rrpx5Y4OOntVDv3Mo30lrbF3jG1vlIPfPFeeeINSEt9cIUK4+64bPOPTFdZ44uQlw9rZyAqwGOe1cFrqjy45ZXXLDBHQn3ppWDmLfh6fbNJtkBYr3HSor6XO4SF3Oc4zyfwrCttSW1cgSAFiFye4rXjureSZ7hpckjCJjr/APWpPzHe2qIZTvgdZEaMOpCMx4HFcTcx7JGhJ3DJwcjBOa3td1dplRUPlxK3GPXH0rmLictGSGBOfwJp30uVzMrKrQuEAxuPT/61SXTNFIAen1604OJWJXGc4IPXNJduN7P6igNinM4ZiMgEd+5NS6bMxm2uDk4JYnrVSRckjOT3q7pWVlD7Rxjr/SjpYps6S4tUuLeOaMnzFHzYHFaegWrwlhtZiT/F6ViQ3XTGSmRW1YX2ZkO7ADcj1NFiFI73T7GN49ykIAclcc1O+JHwWY/U5xis7RNQRpYw7nEgwNvatG4URuyRtgilewnJ9jzDxezy6pdFsgAkDB54NcbO2Q44z0x1rufFcDpeXJ4GT+XPWuOuoCQdqDK9CP50FpmO3Wip3tnDdQaKZVzqjcYJDYwfyq5ZnzZApO5upxWXHuMnyA8+h6it7TQI2VBwTzkcVNyeh0ulQZC7huYYPHbiuo09DHGdp3Z5JFc5ZzBFA3cdu5HpW/aTqsYZgvzDkkdaWxFr6nQ2vI7ZPatixkaTcikgDknOcVg6cFuXQSFkixksB1ro0uoIVxZJlWGCzcn+lHoI17GJS4kmORnJ961THHM22DjHTmsDTpSww7AHODxwelbIU2xQRPkE8nuKAuadjEUi3t8/Ocg4/P1pzsZ8FcFU5INQ295DCwJIYE4bJ9aRMJMSuWUnIJ/lTQcxbhTbEZOkffB5rPllCE89M59KuTTNGpIbg9D3+lc9fX0VnK5kIklHVc9KBLc1YFkkIaNSF9SaklvRaqyRISVJzk/pXHah4haNN4ZAewIPFULLxC0oCM0e4dvWixR0+oX5KZTBOeRk1zeoan/pDLg+aewPAqG51HDhgQFzyOwrLnKylplbDMePTFFhWLH2sMrNj5QOvcVc0jE1z5jsVCkce9YMCGWZASQoPJx/I10ejuxkSIgZ3Zodh2sd5ZXYVNrZLNjgdv8A61b1lhGG0ZVueDyK5SUjykXJznlfaug8MTrPZTQkbZFzg4zgY6VAmkW711a3nbO0KdpPoeO341zN3crBIE3o2085B6V0giUQOC4EYBy3v71zGo2S3DPNFJvwOWAOPpVIlamRqLhY2KMpUksPWuKu7/y7eWT5W+bkYPHNdPr1yYFSEYDBRuHfp0rzXV5t1lOu1dxfIPtk1St1LMrWNXM10kwAGw9GHB5rltb1Jb3UHkkTbIF29eMVHeTEu25c7c4/x/CsgSBlnBGB1AHSqbtsNLyLce18Hg+hxyfpTri6FqockOy8DP8AWotPQSRhizBO5FOuonYHcWIfkDHX3oWo27bmctw0sTgkNHnp2BqlLlYWRBnPpVuFfLmIIJ7c1DI4Ack5AYn1pWHEi09N9ypHGfSrlzbmNypGX9f6VoeG4TNcqfLyAwJ9PrTNYcfapBtwOh9VpJh5GN5USbgSzMMHjqBUyt+7UxjC8YBFVmOFAXGM8DtU0ePKU4JBGCD1x6U7Ai1AfKYNwQD07k1fs5D5ink7j1/xrMVvLBOflIwD3q5p53ENsBHfPb/69CfcZ1+iT+bPDsYEBv8AvmuwnZAztvKr1zzXBaG7NdQhVO0twT2NbXizUjDCkSEfe+b16UlqQyj4jvrW4SSIK3mEbckdea4uVYvus7bgcY/wpbq7Ys5IAYE81lzXEpYlwAw/MD29qZZfEMWO65557+9FZy3uBgKv4CilYNex0MYG7aq/d5HH3RWlaSKFXn5yMjPb61nbgrfLkjGD2J/GrFoQQoOW56AYJ/xoFvqdJbTsRlDtIGQMda6CyRpCmSSMAkfzrC0aFp9soB8tcbjnIH0rpoIZJlY2YYrjaPlwSaT0ZDaOggv1KYGFVQFUAfhzVprhpJ0EasuOeOhrDhjeG3XIB28Hnv71t6U0gR8xsdgyDikF0dfbRPPp0TxoqsCN/GM89vfpV9GjtoirEEsOM84PvXP2F0WOGc9M4HQHitGJ98nIL5GDjqKCdC0sgZWIwG6cDv2q/byPDCpOMgc9yPpVWBRawmRsN1x3z9as32o2GnabLdSvicr8qkg5b6U0O6ZV1e+W1RnZgs2N23HSvM77VZJLhsFgpbkt2qTWtcM80rFyd3JHf6e1cz9qErkhxtb1NN6AkmXtQuz5mWdiMZGf6VmC6eS5Tyic54x6U+eN5kGMEg9TV7RdMm3eY8OMZAxzSuVZItNJIbsIzFgRzj1xWtbBAsedr5GTx1H+NPs9PZyvmq+5RglRjNaMcVtbzAzBwE6gHoaSDQqrADARH06EjgZrU0mB7d1Zx83oOg4NWZ40EKYQDJyBnGahVztIcgc9mxSDRmvD5l3cJFDkY+Zj6Z/rXeeFo4rRFt0TcTnfKRkk1w+kSiFwyupcgYFdLpGpNFcRu+Fj3DOBnuKCWxmszzJdPAgQIWOT69ahtV8m0mDKQJW+U+wqv4iknOpzhIpNrNuRtvBB9/TrVm1Bi0UvJkyBmAGciqEcD41QNqEkkHQjsenBrzfUULxoAR97BzXdeKGka9u2iYGPJz/s9a831K6DYCOu7P3Qf8800M5C+t/LuZkIbaSSPQe9Y5hzK6g4yw4PQ112pRj7VCArszoQe+DwOaw5bcJd+WSN2cYz096bWmhcZdybT7MRLK5OERdxA7mqlxLM0kJLEY5Paugt4FOjTQKcyYLZzyRjFZNxCr7PmHyrlufb9KQ7jpbNLiznuogVlRDg/geP0rjY0dn2uxByTtruxDNDpLZBBl6qeTgZ5rB/sqWe8BhjZi429MAUbblJm/4IhIt7qRwMjAB7Gub1Vg11IQ2Tk9K7jToBYxxW5wuQN2GzXH61YzQ3ci+UwX+A9iPrQiU1cwH4ZVVeOfepk3Y5PQYJ6moVVlI4/DoBVnBUnG7OMgYxg9s+tDZd0gVcyLjoOuPX29K0LFDu5z16dc1RgO9wvcHJAPWtS2kEZDDseMckUWIv2Oo0UH7SgbjaN1Zuuyvdktu+fcTx6e9a+mYEMs8nGFO361hzhGkLLkKc8Zwfy7U0kNM5u6Ryj7+vfg1nyoScNye1dO+xlKnBGcfX8fWsadUUsqlTk4IBycf0qdeg00tzLkjw3T9c0VqiNAAAOKKWo9DR3FiePvc5PWrlrwC+AOi59KpKTuDYIPbng1esxiZMKT/s9abJW2p1tiHSCJY3McXGR6nAro9NvnsSxYgk8qRz+dc7axCOONmZjGeRn1wP/rVoRKrrgEqc569aEZy8jWlufNl3IpBPzH3NdLpl+G0lYY22ZOHP94+9cdZRsrFHbg85JHFbsZWGUBQpA5xnIouI63SJIo7Yyy5LDIXj2pV1SdyfLSNG7HHQVhG+c2WIowZGOB1xjvUV1qCWWnmSR1WZPuKQcUINFuddBqgstPmmu5WIOdijqeK5/wAQNNDdtFqlrLBNJypdOCOxDdCPcVwWp65Jco2ZCQeBzjFe/fB/V9P8Y/Dz7BrccF02mHyJhOAcIBlH56fLkZ/2TRsUo3PAdRjPmSsDujX+VV7aNN6Jnr6c/lXWeMrPSbHxzPZaTHOmnrgDzSTuyAdyE9U54PORznmnQ6fZ2rq0cS7x0JPem3pqDTKumaM8yh3+SMcgngmumt5FhgCj+AbQRyfr9azZpWXblhg9j0/SoPtE0l3hSOP7vFIXkbRvo4RjceewqnNcxm7Ck9+AOao3aM0pzwSOMVJYwj7R5kqqGIwOee1GiHsdPazm4j+YBSD8vFVZ22EAv+uaaWCqArY4yD/Ss5mEr/vQQ/qehoJ0Ok0e4EzhAy5UAH/arXjd4HdWbIPTI4+lcnpsWyQyM+Dt4IrZOtTiPyfkZQOFbr9aQWL9/rL4ERONgwOOnWsrV9eMVla20LMOpcFeuaz5dSDTEPgE8E4JrN1acyKpiYHKn5j1qkhWRha5qrBpS/LEnLbccVxcKQXV8IwSrvlgccVr6tcSMxUncOvSs6w8yOYug/fuuEDDOBQx2sU5AIvEFtFGxyjqCvUbSRk1BrNtENWnMSlkZgCMc9B19au62ZrNI3eFVndTx3I9eKz9OvGLLLLEN2drHnj0p30KWhqaNaqSU8li+OQVOMVoWOg207GR0255wDwT71s+GbsXS4naOONF6jvz0p99JbWzGTeAFzjGTn8qS1C76GTc6VFJLmTLdvYelN+xR2XEYVWIxuNY19q/DgHYC3bP8qyn15w+Nyseh3ZOBSa7BZmvMwSZ+eR0K0y4iWWPEoBjA4GagF55+xwy7sY46CpFYncCcAnkAZA96Y1cwtR0SGJnaNTtKjr1z7VQktsRoxX5iOvr7n3rsL4AFSD+dYxJeUxFOGbGKE+hV29TAjtJHmG0NvPHPpVp7douGyF/nXRW1uEjJbjPXuQKq6lAUYPjcNuQT0ppXFcbc32LV0hbgDIUCuekklI3hgWPJYdae5dFJBZcdDUEpbG5B8w7DsKewrA8smCcrjGMetUpUbzAwyT6DvUylhIvHGe/NWyqvHwuQO3T8am+o1sUlkcIucjjp6UVO9ruOVyM89aKeg7eZbP3wCePZa09MGJQcHf2xxx6VlpyxBxj3OMVr6REHnJGRHjO4DipYWOmQs6qirgIAcZx/npTsPHENoJIJJDGoIpWUEklfl/z9K5jXdXuFuisLAoBhjmhLuRc6OPUG835nOE7bsZq7HrKmd4YAzEclwetef2F1t3PcSLhsEBv4etaUOsKluRAEjkbgkHt60WHax6XDq4tNPaR5AwQZAzyG7GuQ1rxE97JveQkAYwec+9Y1xqH+ghMZccEg5JHPWufluWz8oIYEgcZP5U9kJam7cXrs3B+Unk5q3Y6pdwQT20FzcJBcBRLGkhVZAORuAPOM965NZ2JIPr0/wAPWtC1lyQNwU+3U0noVY9Y8N6jFrVnbaPqUyx3EPy6deO2BEc58mQ/88yTwf4SfQmtyaKW3vHtrtXjmgbDpIPukdRXnnhqP7XeQjdgdffivQpbm4uzCbuUytEqxKW67R0B9TzjntiluJlpkDoMLyB6VXC7QrMChDdO/wCdWIxgjDEEe3FR3Y/eAFgoI7jnFUtCbIkd/MGcbdvYc0QZMwJGR0zjtVGRmUBwcIehK4/KrdtvCKySZZvyB/xpWQb7l+VwF3Fs44AH86zZ5dsiYycH14NS3LupHlglSOcCs26mCkK23eRxk4oSBvodTZXQCZMYZQo4BqexeOS/lE1qW4zwen+fWsDwwHkN9G/3EjD8dRg/yrUtrkLGxh/1jHBPt3oFyoLm4sovNc2h3BjtG7p/nmsxL2Ca2lZrZdmDtGcE8Uy+2xwzB2+VmO3I61i3kotrXyuWZlJ49cU0x6Mw9SuYPPfAK4H3d36ZrJt76Wa8tlgO2XLZYHt2qjqMpK9eCcAHuaZpat9r3qvCjGKelxtI3PGN6be2tLqYmRo8IynuN2Ovpx0rnLbUorm7Te3lxHlgDx+NUNfvpLo3UTZwHAVM88VzguFjm4JA6Zp6DR6HdXUcQCW8jBWGcBz09qhW+VJIwL5tpYhuCdn+Nculzvt1kLj5TleeTUMd25LynqB8xI/KkJo2r+dTeyoZhIvG0gdu9Y0hZJvlbcoPfg1dcLc7H2L5hxk425HvWPdTK0hjGdu7uOOPenvuOLOg0qYNceXkgMfXABreSSSNsdT61x9nIFkXOSeua6uKVZESUuFyMA/4VLQmtS1fNiNNjZGep7VlwyBXRnVsl+DnOBUWpamwYJCAD/CPQViG7kaY4bofu5/lTuPfY7hZFdQ0RwAPTrTpGD27K+D8v1x9K5G11KVHX5xjP3Sc1u2upRyLslKrznOetJWFaxk3KEsVzt7gntVFoz8pUY/HArrnsIJ2BBO0HnA6n0qwNHtCqs8LbcYIz1/Cq31Fe2hw6bA+1k5JyOxP+FTRwbQzRMzZHANdLLYWquSBlVP0x7U0W0EeAgBJ77elTZMu/kZ8FnKYUOwcjNFabBmPyyHA44op2FdnLHIYDHPp61uWdyIrQdFY/ePvWFN33ADnnJqGW4csI1LAcEe49Kl7jtpqbN/rAMA2bhuO3jgn3rnZJyWkOM46gnOc1HdNuTBYsSTz6VCGHHAx0XjqaLsdi66qix5f5iOV9Ki+2m24AX5vUdvSoN5xgDDevrQsLSHByNvNK4KN1ctRTOsWHbk88VCrl85J4PHSpVtypAU++c8ikmi2IcMck5B96dx2sRAgYJJAU5PtW3ZbHdApw2MjjvWArkkZUc5z7Va09n+0L5ZOdwBz3pIG7rc9s8LWCW+lQyNtV2BLHGeK3NwDHaCCTg9K5nS9USGKCF8ZCjIrbtbjIDBs+59KEZtX3ZqQuqEhl+Vhyay9WnYysOm736e1WFcFdpZgH4yOlULgq90Qr7go9OKq4rJE5fzEjX72Ocnj8KuRzLHHhDtYDpjgVWtYHZA+36HPFMlWRZGdiCp4IJ5BpBYbq195dsTCD83AJ61jRzuW3tIW29Aa07pI5YyJWJAOaoXmEjREXDZ+6B1HGKSCyRt+E7l5v7bO0cWwA7Y+b2qS4uipijhOGADFjxkU/wAM262j7SN3nLiULyQOvNbkGmWIkY3Uy7ApO4/e+lNiMS6zdQI6ruAYDGfz/nXOeLJkW7KRHaY02nHeur19raxucae5ktnjV1YjoTnP8q4HWr7fcMTjcwI6c00hqzOLvZV3jBJO0HaSfzrS0AO7zMTwAuDVC7jDTHBBYHp61ueGUza6g0kZUDbszxg55psp2tscfdr5l5qAOCdxwPQgGucbh9p6E8+1dVqk0UV1cLtwxypJHc965a4YqxOMMf1FDuNF3BNvHjoCcH0pIX2KQck9hTbVy9uFGAFOQfeo3QxxlmzvLfgf/rUlfYbTNWwnKwsGZvlU/eHesaSUF2PILE8/jVq1d/3hk5TaRz/Ss8ttbb79+1MSVjWtJBt3McAfniuge822USHh8ZBHpXKW8/CkkhvXHGK0BNlsMSF/hHc0dAtcfNMS+/I46fSqk0o3ZUnLDcMdDUJmJILYA/lTDKdmGPGMYHUUAtNi2s27Bz+Q6/WrtrdAZCsQOnPesW3lCZDnG7oB1zUySEZBIB6DPemu4Ox2FrqnlbBubY5x06VqJPK0pQvx1GOhFclZSrJt3tyDg4rrI95jjyeCOoFITaFYD5icnPOM9aZCiqpkfdxwT6VcgQITIQuO31qOXDIyl9rE5wKVguV2lyeHHHtRUe5O2T79M0Uagcpe3KqGKknHynByfpWXLcMzfLjPTOM1LdvucldoOMEk9KzyeM5GOlIpLTVF6PdMNqHJ7n0H9Ke6mJig3sWHUck0ywDYyPmBOCOlWLhPnxIvbselA0NtoCGBcr5n94/1rY+x+dtaFcZ6g81jLcbCGUYC8D39q2dNvyFEcrKM9z2oDWwj2jKw8xAuOemKjubPzLR8rkZ4JrprY2Vwg8x1644NWru1sXsSoILg9jyR7UiVc83MBVxnGc4BHb/GtfTLTbMjlUAX5m461oy6ZEHUq3B4AJx+AqRgkUeBwAOtNLUHIuw3+2UuDjH3ifXtVq38VlJtisQpbDbsZJ9q5qeUrBJvUhmIxz096qWyMZkZscMOB1NNoSjfVno134gYOCZWG5R949aqW+ryibYsj7+vXPNYcrsrICTjHalg37i0Y6ZAU9aQOLsdza67JGRHkkHs39a0hdw3EPmBd2771cIjyIoOW2foa2NMuyqyCY7EC5JPpxTtpsJRNa7u4ynyZVOxxnFJbSQyTxvePsQH5QTyff6dK5PUNe8lj5aZXHIJ6+9VY9cmuHj3j5c4x6ChIGmj1uyQtKrW06P5h6R9cfTtVq4gk3PEWkj7fOTiuS8ParB58Z8xg20D5eRXS3esQyyNvd2zgDgc0rEkWq6XLJYKrSjMQwp3EgDnH864nV7OMMWmYmUKeA/UjvXRS6zE9pcRuz+UpIx3xxXDazNm6k8mUCPb0b0qkhq5U8qFm3EqR1xu4I/wroNFk+2RXEcEdsNqg5bCjj271wk1w0bbPMPlgkgd61/CV+IbiYShmR1PQ96T0HYq+MLZY1MuLXdtIYQsMn8BXGNslAyFDDvjB/8Ar10vilY0gQRvlndsk/wgt0rkXyo27sdcjtTLiupcRCrbQV54OTk5/pT5Fk2NmM5bG5jzj3qnbNh1Jf5V5x7VZa5V2ZXYleoxxxRaw/MaXkkUYyQODs/qKqyIcnBGT+dTZRD8knTofWoHfLZA69DmjcNSeBiu0KR0wD71OznewXKk9G65qim8ZGeCO/HFWiHdEI+bjBoXmFkV5HHIIbnqM0hfJyDgj8zRPuLZ24HtTFAyPUii9gSuKHIblic9eanSRicglT7HH4VAqnt+oqREDr8wIP8AKmHU0LKUq5G4jsNx/Wu3028WS0RerKMDmuBSMKm4Mcdcd61tPvLgIiKwUjOOOcUWREl3OveViUAcIoPQt0qIzogJcjB4OOnNZkNzK6kO2Se3b6Us9y24FiuF+7zyaTBK2haknjjYqV3e5orLLSOSx5yc0U7eRPzOYuJCxCgYI7etU2JDc44q1dEmTaccenTFV5cfwn8Khmy2Jba5eNhhsj09a0pm8wIwOBtySD39KyIT6nFaFmfMQBcfKSev9KAK7zFFKdec8ihLh053j155qKXJdgQQxz171EM4ximBuWOousg6fMeffjrWw2pyLCNpXcOmea48NluMEitG3fcuGz36n8qEyWlc1G1G5eVWOwgdfl/z+lW2m82FWUhs8kdhWIEKkYUbuxArVghcwLhM8ZPrQFuxI6iSMLJkr2I46Vs6PoiTgTu7Bc/Kvfp3qhBYEIDKCBnn/wDVXQwXK8AMuEGB9fSlcm7ego0lHkw/mbQMA560z7CYslSc+uP881r2zqWA3YJ5x2Jq7cKkkagBc9vpVLUG2lqYkIV4VVky3UgcCnanJHbWbH5QzLznPA9/yqV4fLYrI/TnrmsLWpxPOyAAKg7Dp/nNAkjBu3MzIegAwdtRx3SxbkTGc4PfFF+NgwNpHc9P/wBdQWk4QMoA83I256/hQ9S+V9TsPC1063OMBuMYx0967S4ilgtlIQLK43gtz+Fcd4T1IWt07Xsas6RgYzjnt+NdtFf2+rQQC4AinQYcBvSpv2Jae5lG2KWMgmkG98s2Bjk//qrktTt2DnzHGSOmD+Vds9zZNcGMynywSoIGSK5zXRYveY81yEXJHv8ASqTsLc4iYNkkqQc8k1oaUHEgEYBJyWBFWlSzkcMZmLHAwB1FdNFpNnb2ssonlVsKEGORmlfXUeyOL8SwgwRkKSevP1rkZoyGPfFetXunwPp7rJLKAFJxt6151q1rGtyyq7MM4QEdKZSZi9CO9AUliMHNX/s2yEH+I9AeKWMKqks+QBkAGi41coMCoHy47cimr2I7V0F/BFLFHJCCQQTyeRxWcluhwT8mOetFwIbe3eXkKWToTWtHbJFCEckZ/i9PrVmyWIQIA2F6571XusyTnYPl6BvWmTq9ihd2rRyDO4juariPPRT0zitlnby9pA9iev41UhiZn+9kZ4DHB96Vx3KjRYVefx9PanwxEsPrxnnPtWtFpyynDS/K36fSrkdisER2cnP50xXMmGAyBgVKgDIPpVnT4wcdS57mr4tSgyuW9cjipYIQigKDg8nPFDF6jo1HlZA5HQ+tNW1aQLuU+4qxawqHDsWOCcqasLtYYZQB0B68UXHa5XERAwNpxxyBxRVqSJAwDBQcfSihMLPueeXZAbaOg755NVvTnnvVy9XbMxPy59BmqYGT7e9QWtgJJ681JE2whgSD3xxUeaAx3Z70gLrLvYEfeHbdnNMa1cNtIK98/wBM0kUmxSTg5rYttsqBgw3AY575oGY6JhxkcDrz0qz/AAkHp7rk/hWkbJXckHkLg0xrEgY4xx35oBtEdszq6jYTk/eJ6VsmfEaxrwCRmqEeIJCX5ZRxj6U0S7nBcEDOcDtTI16G3FIXCqWLntkEHFaEEocqoHB5LAYH1rEhuBtAY5B5z0qzDcgTAblU559KNQaXQ6aC48vptbjBLDP5VbTUI0DjHIHTHWucW+EeCfmJGOnBrPbUwk5z8w7n0p6Mmx0N1fhpUbaq4H8XGRWJe3SkSbQMt0Ge1UPtjSyu6k8+2aTzNxLHG4HAPv6Ueg1FFOclhllI7DPU/WnWdi880OMllcZK1qRQmZ2KbWI6rjmt7QtCZU3swjy3Utmk2PYo3tg8dy7Rsx25kJbpjt9KPt8gRfkyw6cEDFeo6j4dgj0WObzYjI0YUEN97j0rg5dHhF3kXMSj0J6GkhXuZtneFgQ3BJLZA6f59aqahi6uN9vKTgdWH8zVvVFtbRphbtvkPXk4yfT8qwmeSMyKnQrgGnqHKu5qaXGInJVl3jBKlc4Ga6e0hvbqzwiIFMmQS3NcTaSNtUk7VB2t+HWvTY59thZtBiRXG3C8Z4H60A1oc7qU72FyFkQ8rt+bjB6Vymp2Mkk7T5UMfmKDnIrp/GzxtqVskSsu1AXDHPPFc8cNcbkyF6FWNUKz3MW4s3K8jj1/p9aq/YjuIBI7cDqPrXbaTbQXXmJcIcsNqlTwp9T7VZHhO5EZZQrhT99T/Si4JtHHxr/orxrHkryMfSqN6uyRYcckA/jXrOg+C5ZlKshDONoJPf8Aya4/XtAmsr65im274225/CgadzmLfcFK7Mc8k8Vcity68DB/u9cfSpktVtnAkIz2UHOfxqY6hEisijBJ4470/QdrEUlq+wMeccHsf/1VkhgJQCvPTI/pV+XUBIMZORyOO/f61lPMAWbGOMn3/wAKXoCZpW0nllSx4BwMnk+1a1q6SrkuM5Oe4H0rkDchj82evWtOy1FUj2Bud3DY5P4U9g5Tau5iqPEhHvnoKitbxflV/l4+UtyPoazGuPMJUt83fHpSRsQQxK88A9aVxWOmim+TLDHXhT/WklAYqQcA9Rjhaq28hkjXAORgYPQfWpZZgspBHynnI6UkFiWWQowALdOuOtFVQwcZBPf+dFHMLlZia1Gvm528DsOvSsUxgk4GRn9K1tXO5mYg9R256VkOTkgA5+nShotbCGLAz69KjPB55p5HQg8j+dNf73NIoT0PNT2sjRuCr7cd+uKrinKCzD69qBGrFdSq/wArcAEH3rRiZpY/mcFgOc9MVRt7ad4VZVPPHzHH41egtZYcGQhQOeSMn6e1FhadCDad2SRzwc/56UqocqSfmHbPWpZGjA+6BjrxnH1xT4+RhS208nPGaAZKtvtA4GOhyf51Zt4k/dqeDnPXn/8AVSoPkUqAO3sKbGF+4FKgHIHqfXFC1BMmkjG07GCCszUBsbcNpyMfKelXpn8qNj90k/ieP5VnXH7xfmGQD+B9qpKwN3HaYwZyrZyR1xUjBlzg4BPOR3plsuyfIGUxjB4pLmTE7DIU9jjpSbuF0kW9PunhnMocLgZ5rtLB21KzCrlVB2tzjJP0rzuSbLBQMlfTrXY+DYZWaNt5AWQMMc8+5pN2Bnd6rpJj0+xgeR1KKFHzHrtFc9remMbfYQCTgbgOe/NehW8T3sW4qN+Ny49aik0O5uFJ2YIbJ39BTTITseF3geGSSKcneD1PpVuJIWt8sPnYZXAGcV6L4k8DztBJcxQ/NkZw6nHrgVk2nhC9A+SKXr7cCkO9znrCyZEG9Nu07SPUZ7etdzDpcltZwLFuGW3pH+FT2+jiCTym3qqgZx6etal40StALZxuiHykjr+NFiG7nnXia1ll1QygNtYYJ9DwCKzrLSGllMjhuOcV6TrMInnidYiskoA46A9M1mPpbwtL8jMSPvn1/wAKY+bQ5tYRaJmNdqgbl56mtvRdTS3bdKjyJtAO3v8A/XrIvre4aV42R2XGNvaqFxcXMUCokbYUgfKhP0AofYN0eiWWqTssTRtLHtcEA8EjNcz4s3JNfT32HLj5ZPqBjisIaxNbyEzOdsY4DevWub8Sa5c6kGWaXKkjGBinaw1cxbi5kErAtyCep7VUMzdS3PQE9vpTZJGG3np055FQlyx3MM+/pVF6ljzD5g6gjkEdqickL2wM8Goy3A/lQJPlIIznp7VIDB14zU0RZmwPTH0qDJH4UoPzdARRcbNVVLKrr8zentU8PJGAQw61TtZPkI/vHAHYmrSE4G4tx3JxTuSjbsXkeMZPUk5x0+tTthlLsxJPTjr/APWqjpyuRv2YzkButaCRSOwChNx55OM//XpPuIaAQB7/AIYoqQrKhKhQ2OpLAUUai+Zz10gMvQnvhee1RLpxk5wV7575rrNVs7e3jdo0C4bqO3Fc4ZiquGJABzkmp6lK1iJdKUDgFwOSeKqSadJG2GTjOQa1POdApAI6dKS5maXaQ7ZHqBQhmF9ncSEEDk81Z0+3JkcYORznFXRbsZACpO48Yx17VotAIBuC7FPJHqaXUq6JEZYrRfmy3Qqe3vVK6c7M5yR75zTbp8sWBJGMDmqMxKgZLAH+LAqkhaCeYyFRu+U8kHnOK29NX7UAVw/HToaxEzndgbeoxW/oWVnRlzuxyfWpaC3ctrC8bq53EDqCOlTzWyhgzYORnB6k/wCNaaCOdmUj97jG1qmexDBpEXcgHQnr9PShIhvscvNF5jFiOh+UmoHt9i8ckjJA9K6Q2Ks23YW9qZPpojzhGKmrsFzANtsjMrKCDwGzWNdZ85gWwgbpXZ/2bJdxHyA0cWcFeOtYGq6TPbyNvjbaw4Y4P+elA1Yy4TunBAGR+Yr0L4XR3t1dzpaxtKm9fMcDIXr+HauP0bSZb28VNkiLn5iMZr3jwZptvpMEVvoyunnkGUg/eOPr9ah+Y3psel6DYWtlZK3G/YCFK5571Ld20c8RkUKFPRs965+xurt55lR2dIAQFB6HOCKtS6i624AgVgDlkz0pIyFl06K4tG8yUhugwf8APvXJ6pdpZAxC4RdgJ+97VranObdHk82SMlNyJ2XP+TXkHiaK9lvmIkmYMMnnGatIexp23iZGuLkHDO5Oct15rUiu4NiNdLGsGc5znFeYbhauCFJk4Dk/1967BtXgtrCNYrNJQACWk5PI7Ug3Nu+1qxdl+y3KswYbQQVOQe2aQ6oslg5e42k9MkVh601pdR2flRRid49xZRjHsKzTDOUKSxko33Gz0/HrTFZ9TVunzHJMJAxIxweorNbdEH2SMwXqT2qOzW5KSwsjHyuQTjGKzbye4MsnmM0efvH0ppDXYSWcS70nCc/xHox9PrXJao6pJJHGgyDlX9PatS6ieeLIlIIJP0x3rDuzuBO8uR39/emWrGfOVLDbjpz9aiPJGTx3xVgxr95sew7VE0ZBx39qTTKGHIoHbNO2gAkZ4pBnqOo70WEDrjHH1pFHIA5zUwXeCBx3Ip9tC0k2EViPoMinYLlm3hIUZwVHb3rTsrZ5ZMIpI9cZFaGm6JgeZdIV4yRnrW3aLbW8yokRBAzgdh69aGTzIqzRm2iS3i4Xbzj/AD1qnCTCS6tjacAH1rQ1KfdM4ijXLNwO559aoTpsK7sBcZ57VPKO3UtEcAs25iMk0VWXftBBbn14op3ZNizr9xl5IuAAQensK5p+GzjLD+ddL4mXy5DI5ClTjgdOK4y4nZs8tgHnPehocVpoaEN2FLKwwD6/0rVtoop41JAGOpArlQRuXrluM+/rWzpVyI4/LZn25+9nvUjepri12z/MP3f86ZcRiTJ5+UcE9a07UCeNSflZeabLaPBnBwrnJJ5z+VFrsVznTFhDuOWJ6enHWqjxZzu3YI79DW1d221c5IOQMH8/yqDy8OpQc917H3oGjKEKLMoAIwOnrW14YCjUvKJVsqcLVcxKVZdmTngjHHtS2CPBdxzpuVkPUEcUbj5rHcWkBkuIyIypHX1FdDpsIniEbRje/T6Y6ViaHq0MiK7K0coBBYc4NdpYOrW3mJskQD7w4I96nUlyOV1LS5ElzEu0E8j/AArL2Nufqyk4I9D6138Ucd3OwKFwowQcVV1DR1ViVGXfp0Gfr71pdCTuc3pMkaS7fLXaw5JHWr1s6QXsiyxo0MnOHXPBx/hSjTmikxMoAI6inNbuJv3m7Znh1xwKWlibmppWjWInCyooZuE2ryvvXpOk+FYruKK4sImuBEdrEMFI464rzTw/qK2dxPsdmITIbuPcV7J8PX2mN1AAkOSM4zwam9mDGaf4bWCUi4jKu7YEnvnvT7vw4ttKGknLAdAoxn2rr9UXz4SIZExn5vb3GKwLjT5FjMkd4VBPGeCPamrE8zZ5N4mtZJruZVDn5sbAeOM1ymvWt5AOFC71OOnIr1HxINtzKfL82UqMyqOP8e1cHrGn3F5cJcO+wOOh/hqr2Ku9jzG70i4jPnurbWHXuR/hUSwTS6eFkJC7+PX2FdFrlssUqKJmYKcbewGKSCKOS2jEQAw2SBSZV7HO3Flc/bIizNtAXgdxxxXYaLe/ZWjikVNhXbyMkmo9SWCCElQC4XgAcZ9awbK8ZrjBZpCpyqk0WE23udPqUquWe1Q/IfnArC1W1S6Jht4wJX5bHvzWjBLKIXdhy54U+tSmwaU+fGdpT5mAGPypoTutjirzSnjiMjMwOcLx19qzZ9PMEW5lAU8lsV1usTRQt5fmHbu3N9cVxmr6uZppVMeEHAOevHWqSHFvsZN/hZAVwI9uCR0FV41DkbQMdm6/pTzIXYNgcdz3+tPtYyzMVJBX070mabDEjAI3DaT070x4NpPPI4q+bcJ90/L61LaWhmlWL+HI4yKPmHMynZWryzqhxncFwK73RNBtreINNFvud3Q9PpRoHh5/+PiNBhByCBx710VvAUSWKNgzEbi/Q5pXbJkzNvoZIwyyEKpGcY4FY25jMehJHAxx9a6G+VxCTnJHGT0rAH7zzB5YIHduv4UXe5JKCZGCjac43A/zrPuF2TuqFeDnp92rC7QqlATx09KZKoPzR4yRznrijcdyOI/J8xyfUUU9kIPJC8DoPaiquF32KGuTyTb9+SQQSMn0rnJF3lx9Dx2HtW1fbicE8Z+uazmhGDgYUnn1rNlxehUEZkJ2+4x6e1allaSkAg4GBlf/AK9OtYoHB3DksAVNaqvFAAu3jPGOKRRoaSkioSeSOeecDJrckAjk2SKSCAQOtYMerJbsrRxLk9OOBVj/AISIbC3lgv0xjtRqS7PcZrEQB3gDacDkc55rFdyrhjgqOp21o6jqSTZXC4I9etZLESRq6NkqcEe1AJFuMKqsehJyPX86WPLSKCh68AYwT71FDNtIyC4GAakfeLmMIM/MD8vP50DlpqbWjQStMI/9W65bAHGK6SK8lsAlvC3mvLxjJ5NZ3h+0m+3tIwHQnLDHpWpaWgGo+ZON0rHMYB+7QTfujsdCVxpYlYAzMeQB0q/CwnUJMgYfw4GD+NQ6SivZBASArZwRipotwJXcSmPTmgkr3mksIlMeCh6Buaz2t/s6OkwAJ4K4roYrrnaUEqY4GeRUepaf5pDx8I4zhuo+tFw0RhaRoMFxrME0E5SVR8yEZUivY/CWiXLSo+QIomGccdj0rgvDNpGurW/Hljd82DgY+teu206IQsDbIu6jGM/07VLE2ab6fbW2WeUgsT8oHHNZ1zoUd4gIuJAhPXoPyq1NdhrZhK/zjrnA4rBv/FqWsU8WcmMfe4XjB9+aZF10Kt9owidg7xkJ6L1FeZ+NJpbed7ZFiUAFgSvUV2sviqK5hVZVKu4yWyOf15ri/EC2l09zLKXJYHblugx+lP1GmzyLVJLiZ2Ei45J4PGKrab54mYpuKgYxu5FbWo20A+YSsqk8e/1H9aq2dvFbtu83cSeMYp36Gl7FTUridYdrrk5A3elULaB0uVnVSATgDtmt3UYmurOfyNvOGx1bisq2eW3jiWUbm3YwRzQ7jTW5uab5rApOOSd24859q3re2uJN2z5eMNk1n6TGbqFRHtDhuA3BBrrpPIttPjaMAyOAsnPGe+PxzQmS5X2PL/E+jOhLg5Lvg5HSvO9Xt5IbiSFhgDDZ9B7V7jrUkc8Wwsu5TkYwe1cBrljBcyOfLVXIHz4waq44ybPP2i2ZDH5cY4qyk4hRTEgx157/AFqzdWTrICoJU8crnn3psOnvI7bEdxnBBBx/L9KH3KSFtg02VUd+Oe9df4V0Z3fzJ9pj3Ddx0PcVZ0Pwx9lXfeHL9AACWH1roIV+zQ/Z4USLY3DAfeA71PoJs17GSFlWK2IQL8uCOXqKfTjHqHmQN1xuXPSobUujeb8gZh2GPxrTjuAQhdfMVjgFTyKCLlK5sBLvQgLuGFPGM/SuWazkXzYwu0qeGruXbfK6TACRDkMOp/8ArdaoajpiFZJ8uoc/wmn6iRwzptBY98846e9VJLlcskZXIGOnWtvUbKWKIlWXdjauD/SuXZJEJ3gEbucdfrQapl2O/UIFaPkcUVmhWcswwOfSijXsPQfqcKpIwOFIxgZzj61lSEDkhiOnGOvvWvrEMou3Z4ygBHyg57CskxgIeuQcnA5pSvcmOqGx5U4zyOh71NvIOd3NRqoXdgjkcVEzkMOcDvSG/ImLjcOTj3PGahMhLZ3HI4IB4zUU0mRtBAGc9O3p+NRNvZSe2fujGR9aCrdy1NMcJ/CemeMVasZhk+aTtNZ0oDZOPn4J4zj2qWFS2Qc7W6j1oE9DQDFZC0XKZ7dK6TQIhNcL5ilwB90cc1m6ZamSzbcjA7xjA5AHtXS6NaTeem2I84IHqKGuhEnY7nTbAyTwGAYDLhvfParGnaa7azcM0e4Qgqq++B0ra8P2knm2T7SpBztIyQO9bq2htPE11aBQrSMwUjnHA5pWJuYemgW1o3mR7mZuR6U95AxJ2sBznGBV2aApOwkXLDjNVJiqARscjOTjnmnYTdyLPlyq+1wCMZOK1tJaKVHglyQ4JUfl3/OsMyPJh+Qc9x1q/p0xiu4SGVRjaef6U7CLsUDQXSmTdn72QRWomttDujDneRuBx/n0qK7hKISo4Bzt6VkamjMBsYDcOe9LcLlhvFFy8s3mTOQQew4Hv/8AWrndS1mWaT58FG6kDG79ao33nBilvHuZeSxOBisu8m8y0wkZEwOWI5osF+xvNfGS3aRPkwPkyOgH+TXOXeo3MqMGfejAjI42mrX2lY9PA/j2ZyTXJXl6x2oinaPvH1/CixS2GXFw6oFYhgpyDVOS4UndKdnZSvGKrXk3mAhxgjjGMAisq4m3SAbzgDjI6U/Qp7HQtdPCwCt8rDjb3rHvr6U3xCyYCjPbINOvpN1lFIjldp+bjnr2rJRzuDngZyU7mmhGxZazew3CtHK5UEHgYx9a7Ww1i4v7V4w+J0AOGXhsV51DM0jlIlOM8nufau30MxqyAD94y4J9eOfpUsGasbxSQPLJ/rjycqeo9BWbcWtvMdxjKs3UE1ruY5Jhu+RgOfm6j1qF4US5O0hkJBDA8dKpLuSmjlptORW/1fyscNu7VbsrW2jLSspESnIVP4jWlfxF5iyuuwHDAnr/AI0/7MbfTViARmZixPYDApXGmQ+c7lxM+6ST5iQOg7CrEUbEQqCPo39azmDIDgktjBOfvVYgffLlnDtjaCeOlF/Id7Fiacruwx3g4AA4x3rQ0sl2Ef3ATnaR1/GsrzTK+xV2sBgL1z7g1e0tzbSR+cwLKc4z2qkI1L7bJP5sKjGMAj/PSlup3a1WIqGVQCdtI8LLInk5MUjYG3nH1pl4dsbxxYjYHk+tS0K5yuqRzTZlt2GzOCpI657VgXFpkgPgsTkgcZPtXQXEogZ42X7x3FwOBTY7RJZY2Vg+4df7vtmmkxtnPG0cHC4x6Z6UV0T6eCxGMkcEgUU7j0KXibTNt05ZgBkYcr/sjjHauRmh8vd1HYt0/wD1V3nje9gVHSIjcrAjBzk4rzqadnJAJIPX3okhQk7EMhbzGAXAHTFQSKxc7iST2HT/AOsaldQ3zZJIHam4OM7SR6+n1qDW6tqQFfmyvGSBnOcCiFSwckDrkjrj61K0bsMMpweQOx/GpFjIYqqjHvTFfsRAAMGAZ2YdM9ffFX7S3dpVAQrk9McVGsJHzHGAcbcf1q9BL9mcNIM4569qegXvozufC2mC4tZTgHY4yT9P0rsdJ0qNZ0ZgNgGcAcDmue+Gcz3NhezGJ+ZQi59MV6TYWPMIUYDEE96kzejsjo9NtkjtlkiQCULgYHOPrWr4lslt/E2nXyj91KhBI5zk+v4U7TrOYuoRGwOhI4B9639dtxPo8SyAebGmUOOuO4oRndHAatH/AKVIQAOeOeornJ1YzPkEkZyAa7DVozNbRPGuZVyHzxxWNNaO8qPGhYHk4HX3p6jTXUyxGEjC7gGzxnqaSwQtqC7lIXdyc1YuY3ivDu3fKARxUUO/7XK8bDawJ6e4ouNnT62wWDz4JAQvykNwfxrmo5Xkk2YfGeTnP61PHfuLhROGkgK7WB7n1qvNaSW0AbccsxII7DjiheYFXVUFupMSh/NbBPr36VkWtrvupGUDYRjGOM1qTMzzAlST3B6Yp5eMIoiwuB2HWhgkjkrqNhJIsilQuRtDYFc5e26wzEuwCOMjIrrdTw9zIShBByzjoB6V5p441lf7QEdqzCNEKnHeizZSsQ6ldoZMRsu0HAA7Gsie5XzQoYEnr61z895Ix2lm4P8AeoiuC8o3MSBzVXLsb11qQFsyKWKqRkDpn3qCO6VgPN4Y84PWsiWUSF8k+voKWJt0YHO/+HnpS2BW6nU2cqqUdAioSOQe9dTojebqMYMhCdzng1w2iTPHKon5ViFyf54ruvD0TQ3h8xhtAJ3HHP0pEyfY3L+N4WVhhsnaCDuyPSp418y2VEBJY4GONh/pSQywywqsrkgZ2n+6fWpVK27KyEFD1x/OquRuVbeLzn2zAFl4Yk/dPr/9erk8QFkm0DOTnnAUfSq7oZJi0XTPzEcY96skvJGw4Vz69KW6Axlia4P7s4Ocnjn86ivYHss7nB3Dlgf1rS022CMXBJDcZI+77Va1m2ElsBtV5ONp75HtS2HzGDaSSRjeTn09h61q21m12yTeYFXuW5/EVXtLOYElgoXup611ek2pEaDKKpOSOOBVonRkumRmO32r+8Vec+1QXdoTK8kigBz93HA/xrS8PRu2nzuxIctgEjt8tTXVs8d0oOGiJwMVOwJ9Dgdb05jLLFHGvIyGx1x2rMs3aKJFZiFHOAf6eorv9dsz+9KAhhgEY964i5heJjGRkk5Jx2p7orQm3yPhoWAU+pxzRTIXWOMBtx6/zopBfzOT8RnfeyAYyCP5DrXOSgfMxJwOtdT4ns3jvpsocAjqOT8ormSGODzwcFgactxxWhWiPzMN3APUdv8A69WIlJLZG7Pc+tG/HAPzHqetaOjxrL5hkbGCAoI461BdxsWlySxrIACT/CSePpxVmz090fGwIe7Gu20ayEjgkAoq8c8E1tPpFvPt2RLu7k8Zp3IckeeyafuwQgwFyaz7iwYsAqYB6g9K9J/skokjyAbUPUH9MVBDb28su2VUw3HzHp9aWwXNDwXAsenKkYKDeMgH1r1XwnYEXqSTY2leEJ5J/KuB8O2yk+XCCqBxyfX1r2jw/bkRRhUZmVAd3X9aTFc6aws0e2jPl7WGBgnBpmrR5O6WPEMaHrV4GZrRWjGGHB5wcf1pL6XfG3lkk7SBigg81vN1teeXGAI3+YA+lXVto4Fgj4w6g++eOKtX8DXcqqUO5OuOOKTUkY2kMsIZVHCFuv1ouUkZtzYrNCwlVVcHDY69K5iWyw8ix7iwyTjt7V6FZj7TpwMgMjp0HYf/AF6ydSh2SjYHHbdnH5U7sVzkI7I745HiwDnB7f8A66HhmiYLwUYY5J49a62VoIUbewAUZZs4wK4DxF4hhlJ+wB2UAjLdKauPcfqKKVjWAqpz8wz1HoKpvbTIxUxtgrwe/wCNcVeX91PlZZjtUk5U4AqrFd3MatLDcTbTkAA0Fctzotd8yy0ydmDAkE8j/PpXgOs3BkvZ3DZLHBB+leq+LvFF6dGTT2n+cxKC2Mt1bvmvH76WUztubcc8+9McUVnxnqD9KEbYc45pGYkAEnHvSAlTlTSNB7MSScnaeRU1oy9X6D1qtk844z1pUYqc5I9/Si4mjbilRHUxgk5GMc129tMqwLGpLMoB4649a83tLryH4BwetdVoN15jlpxjCZUep7UehLS6naW9y2Nyup24PzDg1o28sdwQoG1z37Vxg1afJHmMuRgkd/apre9nRlnSQcfxeg96didDvLeIgxnYFBGGyThvep5bacMpQDA596qeENfhuisWpOqu5wrr6ex9a6TVGFtH+6k3EjjBzketF3sKxWEcESKxIxjj0zUgj3KDGqnndJn+lWrNfPVWfpgAL+FWrKwKFkgj2wk/MB60XErFOO1ThRECz9B3P0rQWA27vHjY23LADha3dNtTGFnaMbU4J7//AKqfdWiPI0hQYPA560kDsV9DgCaZAGIwzktu78CoL9A945UqF9PSt23tW8pEiJCA9VPf0zWbr8TrGu9TkvjfQh6HP3TblaNiJCedvrzXNX8RknbzUB3HoB0rqLjcC+CWdT681nXyh0jmZgGU49AKdwdjj720K3BChgMCita8u4EnKkSZHpRRZk8yMzxxp0aLLJE37wkA8YPQV5bNlXkCAjtzxRRVSQ4aoh8o4+8B71qaagCkqPmz1zRRUWN7dD0Hw5cH+zxHEAMc4Hrk10SEGRXcDYBgex+lFFLYhxVzN16/mS0kSIjLMuWx/n0rn4WdrgNzgjHT9aKKLg4Kx3WhrJCsOTklhjuc17v4TUR2UQkIZinO7tyaKKGZnUwyJjkfKOQaralK8axXHIjVsFcdQfWiikhboxNSti83mIQoY7sE9qfI8c0fkvkuF5z3HrRRQK9hvh6SO3S6jKFmBBDFSSKxPENz5cU0zcMG5UDPrRRT2HHWx55ql/Nfo8RZRHncw6ZrlNSCbW8r7pH3dpwaKKa1KW9jAa1PmFhwWzuOetOSFWhO7gkHg80UUi2la5x/jFJDdGRl3gRqMHj1rgruFncsgyOnXGKKKt6aBFK1ykV4oxwSMiiik0WBUgc8d8UnpnpRRRYQ+JSXBHY5ro9DgMjsSCw2jnHeiijqKWxsR2Mp+/u5NNuZZgWjTjHy8cD/APXRRTIjqrj7W4kizkZ/vD0Fdr4X1Sa5BjupMlAApIxx6UUUtxHbWyGYIVYEKCGUd/pXYeG7NjFNk4TIC5PRj/kUUVN+gWR1DWPlWkMOCAfvMvPPNU5rQiVAdxAH8Pc0UUxPQt6QgeIx5O9uPmH05qhq1kzJtk+bB5PTB/rRRQnrYTOO1OAQXGST5g/I5qheRBrVvNG1E5Bz2oopspLucVqN7AtyQiqBj060UUVdkPlR/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain abdominal x-ray of a patient with a porcelain gallbladder revealing a calcified right upper quadrant lesion (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Salam F Zakko, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_0_35840=[""].join("\n");
var outline_f35_0_35840=null;
var title_f35_0_35841="CPAM type 1 CT scan";
var content_f35_0_35841=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Computed tomography type 1 congenital pulmonary airway malformation (CPAM)*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 458px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomography of the chest of&nbsp;a one-year-old patient with type 1 congenital pulmonary airway malformation (CPAM). A single, large (5 x 5 x 4 cm), air-filled cyst is demonstrated in the right upper lobe.",
"    <div class=\"footnotes\">",
"     * CPAM was previously known as congenital cystic adenomatoid malformation (CCAM).",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christopher M Oermann, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_0_35841=[""].join("\n");
var outline_f35_0_35841=null;
var title_f35_0_35842="Neomycin, polymyxin B, and dexamethasone: Pediatric drug information";
var content_f35_0_35842=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Neomycin, polymyxin B, and dexamethasone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?33/31/34291?source=see_link\">",
"    see \"Neomycin, polymyxin B, and dexamethasone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/46/21220?source=see_link\">",
"    see \"Neomycin, polymyxin B, and dexamethasone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F158153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Maxitrol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F158154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dioptrol&reg;;",
"     </li>",
"     <li>",
"      Maxitrol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1046958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Ophthalmic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Ophthalmic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1046953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?33/31/34291?source=see_link\">",
"      see \"Neomycin, polymyxin B, and dexamethasone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults: Ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment: Apply a small amount (&sim;",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     &rdquo;) in the affected eye 3-4 times/day or apply at bedtime as an adjunct with drops",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension: Instill 1-2 drops into affected eye(s) every 4-6 hours; in severe disease, drops may be used hourly and tapered to discontinuation",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F158142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, ophthalmic: Neomycin 3.5 mg, polymyxin B sulfate 10,000 units, and dexamethasone 0.1% per g (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maxitrol&reg;: Neomycin 3.5 mg, polymyxin B sulfate 10,000 units, and dexamethasone 0.1% per g (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, ophthalmic [drops]: Neomycin 3.5 mg, polymyxin B sulfate 10,000 units, and dexamethasone 0.1% per 1 mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maxitrol&reg;: Neomycin 3.5 mg, polymyxin B sulfate 10,000 units, and dexamethasone 0.1% per 1 mL (5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F158129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1046961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic: Shake suspension well before using; instill drop into affected eye; avoid contacting bottle tip with skin or eye; apply finger pressure to lacrimal sac during and for 1-2 minutes after instillation to decrease risk of absorption and systemic effects",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1046960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Steroid-responsive inflammatory ocular conditions in which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F158170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1046963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dexamethasone, polymyxin, neomycin, or any component; viral diseases of the cornea and conjunctiva; mycobacterial infection of the eye; fungal disease of ocular structures; dendritic keratitis; use after uncomplicated removal of a corneal foreign body",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F13842153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cutaneous sensitivity to neomycin may develop; discontinue if occurs. Suspension contains benzalkonium chloride which may be adsorbed by contact lenses; contact lenses should not be worn during treatment of ophthalmic infections. For ophthalmic use only. A maximum of 8 g of ointment or 20 mL of suspension should be prescribed initially; patients should be evaluated prior to additional refills.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1046952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prolonged use may result in glaucoma, defects in visual acuity, posterior subcapsular cataract formation, and secondary ocular infections",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F158137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F158138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F158149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1046957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intraocular pressure with use &gt;10 days",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1046956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/46/21220?source=see_link\">",
"      see \"Neomycin, polymyxin B, and dexamethasone: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause temporary blurring of vision or stinging following administration",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13215 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-41275854C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_0_35842=[""].join("\n");
var outline_f35_0_35842=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158153\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158154\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046958\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046953\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158142\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158129\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046961\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046960\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158170\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046963\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13842153\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046952\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299753\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158137\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158138\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158149\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046957\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046956\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13215\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13215|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?33/31/34291?source=related_link\">",
"      Neomycin, polymyxin B, and dexamethasone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/46/21220?source=related_link\">",
"      Neomycin, polymyxin B, and dexamethasone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_0_35843="Enophthalmos trauma";
var content_f35_0_35843=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Enophthalmos from trauma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pseudoptosis: enophthalmos secondary to an orbital blow-out fracture (right eye).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2e. Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_0_35843=[""].join("\n");
var outline_f35_0_35843=null;
var title_f35_0_35844="Exclamation point hairs";
var content_f35_0_35844=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F65864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F65864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Exclamation point hairs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 370px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The arrow points to an exclamation point hair in a patient with alopecia areata. Exclamation point hairs are short broken hairs that can be extracted with minimal traction and where the proximal end of the hair is narrower than the distal end.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter Lio, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_0_35844=[""].join("\n");
var outline_f35_0_35844=null;
var title_f35_0_35845="Tarsometatarsal fracture";
var content_f35_0_35845=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52617&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52617&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Open tarsometatarsal (Lisfranc) fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 426px; height: 587px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Complex open Lisfranc injury in a 14-year-old sustained in an ATV accident. A-C) Initial x-rays showing total incongruity pattern.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Jarvis JG, Moroz PJ. Fractures and Dislocations of the Foot. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_0_35845=[""].join("\n");
var outline_f35_0_35845=null;
var title_f35_0_35846="Indapamide: Drug information";
var content_f35_0_35846=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Indapamide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?42/36/43588?source=see_link\">",
"    see \"Indapamide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F182444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Indapamide&reg;;",
"     </li>",
"     <li>",
"      Dom-Indapamide;",
"     </li>",
"     <li>",
"      Indapamide Hemihydrate;",
"     </li>",
"     <li>",
"      JAMP-Indapamide;",
"     </li>",
"     <li>",
"      Lozide&reg;;",
"     </li>",
"     <li>",
"      Mylan-Indapamide;",
"     </li>",
"     <li>",
"      Novo-Indapamide;",
"     </li>",
"     <li>",
"      Nu-Indapamide;",
"     </li>",
"     <li>",
"      PHL-Indapamide;",
"     </li>",
"     <li>",
"      PMS-Indapamide;",
"     </li>",
"     <li>",
"      PRO-Indapamide;",
"     </li>",
"     <li>",
"      Riva-Indapamide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F182484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diuretic, Thiazide-Related",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F182447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Edema:",
"     </b>",
"     Oral: Initial: 2.5 mg/day; if inadequate response after 1 week, may increase dose to 5 mg/day.",
"     <b>",
"      Note:",
"     </b>",
"     There is little therapeutic benefit to increasing the dose &gt;5 mg/day; there is, however, an increased risk of electrolyte disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 1.25 mg/day; if inadequate response, may increase dose once every 4 weeks to 2.5 mg/day and then to 5 mg/day if needed. Consider adding another antihypertensive and decreasing the dose if response is not adequate.",
"     <b>",
"      Note:",
"     </b>",
"     Canadian labeling recommends a maximum dose of 2.5 mg/day.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F182448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15897627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15897628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F182422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 1.25 mg, 2.5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F182408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F803136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals (Caruso, 1983); however, administration with food or milk may decrease GI adverse effects.  Administer early in day to avoid nocturia.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F182425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of mild-to-moderate hypertension; treatment of edema in heart failure",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F13364970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nephrotic syndrome (Tanaka, 2005)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F182491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Indapamide may be confused with Iopidine&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Pretanix [Hungary] may be confused with Protonix brand name for pantoprazole [U.S., Canada]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F182482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &ge;5%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, dizziness, fatigue, headache, irritability, lethargy, malaise, nervousness (dose dependent), pain, tension, tiredness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia (&lt;3.5 mEq/L: 20% to 72%, dose dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, muscle cramps/spasm, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &ge;1% to &lt;5%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, chest pain, flushing, orthostatic hypotension, palpitation, peripheral edema, PVC, vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Depression, drowsiness, insomnia, lightheadedness, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Hives, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia, hyperuricemia, hypochloremia, hyponatremia, libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, constipation, cramping, diarrhea, dyspepsia, gastric irritation, nausea, vomiting, weight loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Nocturia, polyuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Hypertonia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision, conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: BUN increased, creatinine increased, glycosuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough, pharyngitis, rhinorrhea, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agranulocytosis, anaphylactic reaction, aplastic anemia, bullous eruptions,  erythema multiforme, fever, hepatitis, hypercalcemia, jaundice (cholestatic  jaundice), leukopenia, liver function test abnormality, pancreatitis, photosensitivity, pneumonitis, purpura, Stevens-Johnson syndrome, thrombocytopenia, torsade de pointes",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F182428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to indapamide or any component of the formulation or sulfonamide-derived drugs; anuria",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Severe renal failure (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute); hepatic encephalopathy; severe hepatic impairment; hypokalemia; concomitant use with nonantiarrhythmic agents causing torsade de pointes; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F182412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte disturbances: Severe hyponatremia with hypokalemia has been reported at recommended doses (particularly in elderly women); risk may be dose dependent, therefore, use lowest dose possible. Hypochloremic alkalosis, hypomagnesemia, or hypercalcemia can also occur; monitor electrolytes periodically during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Photosensitization may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic dysfunction; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy. Canadian labeling contraindicates use in severe hepatic impairment or hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations; thiazide diuretics have been shown to increase cholesterol concentrations; however, indapamide (a thiazide-like diuretic) has not been shown to adversely affected lipids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Use with caution in patients with hypokalemia; correct before initiating therapy. Canadian labeling contraindicates use in hypokalemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in severe renal disease. Canadian labeling contraindicates use in severe renal failure (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic lupus erythematosus (SLE): Can cause SLE exacerbation or activation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage forms specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactose: Formulation may contain lactose; Canadian labeling recommends avoiding use in patients with hereditary conditions of galactose intolerance, glucose-galactose malabsorption, or lactase deficiency.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F182417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F182440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid herbs with",
"     <i>",
"      hypertensive",
"     </i>",
"     properties (bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng [American], kola, licorice); may diminish the antihypertensive effect of indapamide. Avoid herbs with",
"     <i>",
"      hypotensive",
"     </i>",
"     properties (black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, shepherd's purse); may enhance the hypotensive effect of indapamide.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F182418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13364971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Diuretics cross the placenta and are found in cord blood. Maternal use may cause may cause fetal or neonatal jaundice, thrombocytopenia, or other adverse events observed in adults. Use of diuretics during normal pregnancies is not appropriate; use may be considered when edema is due to pathologic causes (as in the nonpregnant patient); monitor.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F182452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F182430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals (Caruso, 1983); however, administration with food or milk may  to decrease GI adverse effects.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F182429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Indapamide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.25 mg (100): $67.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (100): $85.28",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F182420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure (both standing and sitting/supine); serum electrolytes, hepatic function, renal function, uric acid; assess weight, I &amp; O reports daily to determine fluid loss",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F182431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aldapres (ID);",
"     </li>",
"     <li>",
"      Amoron (HR);",
"     </li>",
"     <li>",
"      Damide (IT);",
"     </li>",
"     <li>",
"      Dapa (MY);",
"     </li>",
"     <li>",
"      Dapa-tabs (AU);",
"     </li>",
"     <li>",
"      Dapamax (TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Depermide (TW);",
"     </li>",
"     <li>",
"      Dixamid (GR);",
"     </li>",
"     <li>",
"      Extur (ES);",
"     </li>",
"     <li>",
"      Fludex (AT, BE, CH, DK, FR, GR, LU, PT, TR);",
"     </li>",
"     <li>",
"      Fludex SR (KP);",
"     </li>",
"     <li>",
"      Frumeron (SG, TH);",
"     </li>",
"     <li>",
"      Heimdall Diurex (CO);",
"     </li>",
"     <li>",
"      Hemidol (TW);",
"     </li>",
"     <li>",
"      Indahexal (AU);",
"     </li>",
"     <li>",
"      Indalix (HK, MY, ZA);",
"     </li>",
"     <li>",
"      Indap (RU);",
"     </li>",
"     <li>",
"      Indapamide-Eurogenerics (LU);",
"     </li>",
"     <li>",
"      Indapamide-Generics (LU);",
"     </li>",
"     <li>",
"      Indapress (CN);",
"     </li>",
"     <li>",
"      Indicontin Continus (HK);",
"     </li>",
"     <li>",
"      Inpamide (TH);",
"     </li>",
"     <li>",
"      Insig (AU);",
"     </li>",
"     <li>",
"      Intril SR (TH);",
"     </li>",
"     <li>",
"      Ipamix (IT);",
"     </li>",
"     <li>",
"      Lorvas (IN);",
"     </li>",
"     <li>",
"      Magniton-R (GR);",
"     </li>",
"     <li>",
"      Millibar (CL, TW);",
"     </li>",
"     <li>",
"      Napamide (MY, NZ, SG, TH);",
"     </li>",
"     <li>",
"      Natrilix (AE, AR, AU, BF, BH, BJ, BR, CI, CY, DE, EG, ET, FI, GB, GH, GM, GN, HK, ID, IN, IQ, IR, IT, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NZ, OM, PK, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Natrilix Retard (SE);",
"     </li>",
"     <li>",
"      Natrilix SR (AU, BB, BM, BS, BZ, CL, CR, DE, DO, GT, GY, HN, IE, IN, JM, MY, NI, NL, PA, PE, PH, PR, PY, SG, SR, SV, TT, TW, UY);",
"     </li>",
"     <li>",
"      Natrix (KP);",
"     </li>",
"     <li>",
"      Natrix SR (KP);",
"     </li>",
"     <li>",
"      Pamid (IL);",
"     </li>",
"     <li>",
"      Pretanix (HU);",
"     </li>",
"     <li>",
"      Rinalix (SG);",
"     </li>",
"     <li>",
"      Sicco (DE);",
"     </li>",
"     <li>",
"      Tandix (PT);",
"     </li>",
"     <li>",
"      Tertensif (BG, CZ, EE, ES, FI, HR, PL);",
"     </li>",
"     <li>",
"      Vazamide SR (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F182411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diuretic effect is localized at the proximal segment of the distal tubule of the nephron; it does not appear to have significant effect on glomerular filtration rate nor renal blood flow; like other diuretics, it enhances sodium, chloride, and water excretion by interfering with the transport of sodium ions across the renal tubular epithelium",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F182427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 25 L (Grebow, 1982)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: 71% to 79%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 93% (Ernst, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Biphasic: 14 and 25 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~70%; 7% as unchanged drug within 48 hours); feces (23%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Acchiardo SR and Skoutakis VA, &ldquo;Clinical Efficacy, Safety, and Pharmacokinetics of Indapamide in Renal Impairment,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 1983, 106(1 Pt 2):237-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/0/35846/abstract-text/6346847/pubmed\" id=\"6346847\" target=\"_blank\">",
"        6346847",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronow WS, Fleg JL, Pepine CJ, et al, &ldquo;ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(21):2434-506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/0/35846/abstract-text/21518977/pubmed\" id=\"21518977\" target=\"_blank\">",
"        21518977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Beckett NS, Peters R, Fletcher AE, et al, &ldquo;Treatment of Hypertension in Patients 80 Years of Age or Older,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 358(18):1887-98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/0/35846/abstract-text/18378519/pubmed\" id=\"18378519\" target=\"_blank\">",
"        18378519",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Caruso FS, Szabadi RR, and Vukovich RA, &ldquo;Pharmacokinetics and Clinical Pharmacology of Indapamide,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 1983, 106(1 Pt 2):212-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/0/35846/abstract-text/6869203/pubmed\" id=\"6869203\" target=\"_blank\">",
"        6869203",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ernst ME and Moser M, &ldquo;Use of Diuretics in Patients With Hypertension,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 361(22):2153-64; published erratum appears in",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010, 363(19):1877.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/0/35846/abstract-text/19940300/pubmed\" id=\"19940300\" target=\"_blank\">",
"        19940300",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grebow PE, Treitman JA, Barry EP, et al, &ldquo;Pharmacokinetics and Bioavailability of Indapamide -- A New Antihypertensive Drug,&rdquo;",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1982, 22(4):295-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/0/35846/abstract-text/7106164/pubmed\" id=\"7106164\" target=\"_blank\">",
"        7106164",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Letsas KP, Alexanian IP, Pappas LK, et al, &ldquo;QT Interval Prolongation and Torsade de Pointes Associated With Indapamide,&rdquo;",
"      <i>",
"       Int J Cardiol",
"      </i>",
"      , 2006, 112(3):373-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/0/35846/abstract-text/16260053/pubmed\" id=\"16260053\" target=\"_blank\">",
"        16260053",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/0/35846/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tanaka M, Oida E, Nomura K, et al, &ldquo;The Na+-Excreting Efficacy of Indapamide in Combination With Furosemide in Massive Edema,&rdquo;",
"      <i>",
"       Clin Exp Nephrol",
"      </i>",
"      , 2005, 9(2):122-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/0/35846/abstract-text/15980945/pubmed\" id=\"15980945\" target=\"_blank\">",
"        15980945",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8557 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-1E1E8CC54B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_0_35846=[""].join("\n");
var outline_f35_0_35846=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182444\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182484\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182447\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182448\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897627\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897628\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182422\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182408\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F803136\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182425\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13364970\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182491\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182482\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182428\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182412\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299515\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182417\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182440\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182418\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13364971\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182452\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182430\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182429\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182420\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182431\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182411\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182427\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8557\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8557|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?42/36/43588?source=related_link\">",
"      Indapamide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_0_35847="Acute lobular hepatitis high ALT - high power";
var content_f35_0_35847=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute lobular hepatitis in a patient with an unusually high ALT level, 7500 (high power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 292px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEkAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDlfiJFrEvi6DXNC+0vbW6xASjGxeeQc+5r1e68LXVy6Xem6tbyXLRZlti6yRsCOqehzUmteFLxLKB7NYxJdwILm2cZRHAzuRh0IPboa1vCVlBpel2geQPuTG8JjzCckkegrqeJkrNHZVUJwTjuZkTzWOnzyvbmeW2gOxmyjF1GcEdBnpmsf/hPNK8QxWyaqi6TqCAKRKSY3PB+VwMYPviu58QpcXGnXEsEqrPHGTEmAAx7hvUEVwb+CtD1yaV721uTezRiKRmY7EP97AwRiul2nHmZz0ZQjdSPPrrxf4r+H3i+ezub0Xirh2S5QAFGOcoeo49DXXfEnx94msbuI+HLErZ3ESyfayhkCsQNwIHygj3zWzJ8MJbPT449VvhrNhbk/Z47hPni7hMk5Irs9O0Ca1gt5be4ntH2geVAFKqoHQ5FY3SfMbzrQdnymT8Er661vwZd6x4k0iEak8pSK6MG1pkxw3IxgEkZHWvI9Bus+PPEAubi2TSrguJZbtgin6Y5z6AeleoeIvHXhq31GTS9Ql1CcR7Y7iVM+XHnseeR3PFcH8VdKtrTxp9jnkfToodNU6TPbj5ZWOcnPHUkA9xRFuPMnuzahGUp6qyZJoFha2e+bQdQguoy+1poU37cHuGOcVl+Op9S03UEltXjvAUEh8zPzjOCmSeCM5A98VmfCi7k/tqWfMdiiWzQ3UjNuEpHQqf73WutvtDttX0yQu0V6tmy/abZZiZLfdzkN0Y45IH61HPZ6nZy8k77nFXviG6vLrT4oTd2yGXaUblkDD7jHHqDXv8A8NpdWk8J2Uk00YkDukcoyQUzwx9e9cBpOjaPo7RvO0ctjIhmaTPmbx0BPtzivTdJnb+wUuNPjeNzhIoCTsK+gHb8KUm2kjjxdRP3UifU9UurLUTDa2lwXYjdcKwMZ9M8ZHpwKyNe8crYalFaarrejaT5qBmhmk/eDsDnGAMinfE3WLrw/wCG9+kQmS5n/crNIWIgyCdxwCfYfhXzn4d8PJ4hv3l8Ufa4bJJcLdA5ecA52IpHI684wKtK8bpHPTpKUeeTsj1n4ja7r0estDJc6ha6ZCiPbyWzvsnZgMlmTpgdj6Vv/DLUNdOkS3Go3lzc2WB5KXURaVlwdzlgOBnGAecVzK3Nv4f8F2rtp8d1dJfLbWlpfOzKiAAoX6Z4xW/4U+M0H9pNa+KtPtbKO6iUGewkLpG2cbXU8rxSbdrWN3Gc6Xux0XU7LXr2K78Nst98+mPHzJE20g8d/XivIr3xVbQvcm0nlltACZHuSEUAf3f5V6PM1gbm8tbS4aa0MissbDcrZGQR7j29qzNa8P6Prts2lSaabiKVt5WN9mSe4xz+FXFRS8jCnU5NGcF4F8b6JeagYFubiO4+8iGNsy54wCOB1716VomvpfGWwjuYl3EhFCkvGeAO/OMV8+y6ebPxrcWPgzQ7hxby/Z5XlzKWYHBG4cKK+jdC0LRdOeD7fZtBqSwAyR2+55OexUZxUTSi9TSq0lcktrhBLYW5uZZ7qFtkbRx8A9y3fb34qHVdWsNRuJHaWGRkJjz/AA5A5HseOlQ6vcpYWd/Jo1utvPGMXF9KhQQgnGFB6seKxJfFFtotjBDf2c0guWLLJBCGG4Y6nsSffmnGy1sZRpznqi7qt5LbTaR5srXEV0myCOIHcHHQcd8VVk1CIWM3ki6Z1fyBHJw7uPvZ9B71Jaa1bXOn3N3ZW7iyJOJSATby4wGB6jOeR2rn9UvZ0e5vBIYrO3jHnyIN2SCQSfUdPrUm0YNuzKPiHxRo2hwtFdX1xJfyJhreIAmLt85z6dMelSaF4iS+f7NYxSXMdzGdgRQ0i45zz/KvDdd1Pfqk0tupa2uJi6XUqbd/qPYc9K7T4WWV9fahdXVtqhsLa2Cq17EuQGPAUZHJNN22OqdOMafNfU+iEgsdD8NnRbOGaR7vfM24clyMt07jtXm/jmy8fy+IdOvPC+r3MdukccLwgbUjx0Zl5ByOvHUV6P8A2fJP4Zs9Viu5JruKXZuxgFDwcjv2NeR+JrTXdN1jWtc0eK61Ro4hC2C23fwS2wHLBRTgtNDgpu7d9z09pbeCyim1G4jLpGBLNJjaX9QPc5qwfFun6fAksuo2NvGhx+/cZkHsM5FfPHhrTdf8VtHD4gubiwskLSxjy9iknoQo/ma2PEeiSWtpKmmRQ6reT3DWxWZl/coAApPT72QfTrUtLZs6aeHjPd6nvOhaz4lt9WudS16JYNMdgkKJggoQCGPpyTyTVfWLSePxVHfibz47kr5ErD90hc8ggdenB7V5P4T8Y+IvCzLo9/dxajp9nGsMsFyp2qWGdgfqQvIHtiuh0bxnpS2EdjLcyFnINtG3CBt2QE74B9aI3TuZVcPKMtD0/VNY09LC4i1wGzu1XyXtuSMNwCmBlgeoNcnoEy32haZperGf7RFMfIklyrMFzjcCPT9K6Kz0aK/eOS+kmlv5SpeaZySq91ArzxvizPrXxX/4QsaRaDRYrw2Ic7vPLJkeYDnjlemOlNNctkc0E76HF/Eq81PSNYexS4iQo5k+VjmQeuK7f4TS3/jDSxeS3cX2W1fyp1ljId8Yb5W6YzXfeJ/h3pNxdJdXMsqHflmGPmAHTnpVCwi0+0s/Jsp5Hg2kJG67AG7k4AqZTU4rlOl14uFktTB+JmqXV9atp1pdzsJlB8tgChTPI/LNeg6Jf2i6LbnTlt5C6pEAz4HYZI7Dt+VeYReEtTCLLpMguLqdmikWaT7gIPOfT/GsDwf4T8SWOs+bsdDYyZuI3lJTn+JR3/pQ1GSSvsLkjKO50vxb+H1xr2pJf2t/bWsqOBIrgiKQHhcY7jpk9eK3/h5Y2PhXwhLaagrzOCWf5du5sZK49M02PxLo95op0RrdrgDKM9se4Oc5HTHvUmn3cYs5NPlQyXxT92JmyjL/ALR/vAfnTcZSilLoZOrPl9m9iODxIl9NItxDCbWMZjtWjAGD2J6ce/SuU1zxHpdlHPHOoRHBiNtZbmWT1wuAM/T0reOk6Ld3ljbaOqT3kjeZLbiRgyIvVsE4GT+dYXjzStJ8danPZWd7FpWo6YPLxcLtjlzxg9+OzD9aXup7aG1JJsoXHxA07XbKzgsWvbOe3kVLWC5iIDbeo39Mnimw6gde8SXEhv4otUjdFW3Y8FQvPTHpXAa1pmswXF6buCaB4PlSQTb4F2cgxccZPcmuHs55hq0L20khuNw24B3lyenqTmjZaHfGhBr3WfSn2KHU9PM1pqSWt1A29pM8NzjHB6V5D4wt9S1LWLr+07susY24kdiwXsV56V23hvRp9chjW6E9tNAC7orDy5j7/StrStHEt3qFtFbw3E0EYktfM5Lk54z9O3rQpWM4zjSfM9TC+FVk1jLZCeCVoLqQRWqsDkkg73/3QAe1bvxyhi0mexs7i8e2t5AzNIuWIAx27HBrcn1G2sNJTXpklnNpyNo/eAjgqo46c1zkGuaX8SdM1BbhJrfUEn3mS6x93bgBWGR6ce1Sr35jNVHKp7S2h59ZaQvnWk9pdLcWsxJWQfeHy/xL1zSiO6sNZia3lRWzkFBhmz7f0rQsrN7CYWtxA9okbZeaWMqGdTk/hx+tTG50i5X7Vc3LLN5m9RGCW24PUn26VSbOqbUndI3H02z1izt4lQw75MzAybQTjnJ7dDXn3xDht9PtGs9L5WIBriZmBzk8KCPevQdF1pry1jsLJllu7lmTaV+eNcZ3P2OB6Vz3jrwLJaz2jWUoktJhsa4kJGxycHd6A5oWmjMFJxdmzxcSSM5VUHluAePWvffBMrWWhW09zHAbpU8uFlP3QQMe3OP8an0z4RG3vLWXUJLaSwki2u0B3FZMcZI7V2Oq6Fpvh/w7HEzxx4JEaM24seo46n+lTBrZahXrKSsbPiDxTJoTQ20KRXFyATIJpQkapkZJPXv0FY1j4s03WbmMiJbW4YbPLSbeg2nOB6demM1xx+IGheKnhs/EVjqGkTsdtvfRSByOgJJ7jPPQ1DoXwv1Lwfetq8U8WpRm6t4rTfKYkdriZIUdmCtgZkBOFPSj3UrS0ZzThGEfeVme3Xl3ZyWcDrDvmgccrkjJHFZVxqMTyyNbx7ZfKYFIx87g4yMZ61NZ+H/Gtq7EaX4dZCMbTrc/X1/49Kq33hPxnc6rb36aV4ailii8s41ic7/Un/RaunUglZnDLujYkv8A7aFadcW8SjEYyHDEcZ98c0zQ9Qlt31S5vbnzrXaGt12bWBxgLjv0qjJ4e8dSkM9h4eDKMKY9anXH1H2XBrOm8E+OJJlcWnh8DIJzrE+cj0/0XA/KjmpuNrgjyvx94H1LUtTuZtOcfZbuT7S5EoUjt8wPb07120tvYa98PNJ07xDCLxrJPJMrqRKm3gFGHTt9a6WTwh41kG1tO8OeXkkqNYn+b6/6LUGl+B/GFpbSWtxpXhme1ZshF1i4jxx0yLXpWc6nPZt7HZ9Yukn0OfTwtp+j6Gy6UkR09yo2TR7isueufeuat410W51S50GPzr24uR9ptr3iPBGAFOOByT15GK9NbwZ4qZFgbSNCNouMQ/29cYyPf7JUVz4O8b/ZrmPT9M8J2klwNrv/AGlPJx9DbdfelGStqy4YpR3OW8IWMd/fELcGDTLKApMzLlPMZs7F9QOvFej2Nl/ZURzeRyRF8I20g9OwrjdfsNb8M2Ph7T9WtNKsdFmuWt5JLTUpJpXl8mWXe+6CMYPlEHnuK6DS719QijubW7kjjt0Cqrx7VlB54brjpzWi95Xvoc9SfO7om1/7Tc6jBpti2ZLpGdpJBhLZQMbmP949l9q4+HXdRi1my8P+G9Ek1u/hhNz5u6Fd8KOFMpMrKDy6AICDzmu3N5Hp73A1GKczGHzw0UJCLzyofoW9j1rE8BahZ33xctjZ2k9q40a9Z1mTYeZ7TGB+Bok7R2FG8U5WK/jbTPEXiyzaC58Daxa+ZCokMN1YcSqThlP2jIGMf/XrzlfhR4p+0x3E/hrW7mVFP37mwTJxgZKz5PuTzX01aa79o8ZaloP2bb9isre88/fnf5rzLt244x5Oc5Od3QY5wo/if4citLWTUb0xSy2yXj/Z7a5nhihaR41kaTygEXcjDLhcY54wTiqkkrIcMROCtF6HimheEfiDpM9ldWvgie3njud80SajbSRyRHqBunyD7dOBzXoGoJ4nbQ9Qg03wNrNvqNxG0cc/2yxAjyMbgRcZBGSa6/W/iR4f01NTjS4mnu7JLjCLaTGOWWFCzxJKE2M6gHKqSRg5HBqDwl49s7rw1Jea9qES3ttBBc3ix6bc2ogSZmWMbJNzNlkYbh1ADYAIy/aSJnVlN3Z4z8NfCXxH8M2Ulte+Gr6IZVUks7ixZ9m5mbOZ1+YkjB5wK9Phn122sZIbbwHriSNkl/tVhl2Pdj9pya6oePfDxiv5vtV0LWxLLNcmwuBAWWQRFElKbJH3nbtQsScgA4NV7n4g6NaO8t7JNaWMdqbl2urO6hnUCVYh+5eIHbucDOc+gIyQpTcndkSm5O7PMBpnjthdpL4R1VoZ5/NCNeWLADqAQZ+eRTbvR/GrS/6P4P1QQkENDJd2JjYkj5in2jGRj5fSvW7Xx54Ynt/Nl1m2sf8ASDaeXqObKQTAK2zy5grbsMpxjowrkrP4lXVxq2rx7baO3iu7qytIZ7G6hkZoIJJC3mlfLkJMTZQbNq8liSFI6jZpHETjscpoWleM9M0q/wBLbwTqD6deFg6C6sd6qRgkN9o+8eO1YWueEPHOo2MqJ4OvvPJj2eZeWZQqjA7WAuOhxXqnhr4kJNFPJ4h8uH5LEW8dlazTSzST2qzMqxpvZsZY8DhRz61J4p+J+k2ejCbQLg319J9ndFFnPJHGkkwj/fMqgRH7+A5U5HTtQptD+sTvzHzdefCb4oXttsuvDlxI2WIU31oY4wWztVTLwK9M8B+Ddc8PeDZdG1DwZrd09zcfaJljubFY1ORjZ/pOew5wK9u8SeJ9K8OG0Gqy3CyXbskEdvaTXLyFRuICxKx4HPToKzdI+IXhzWIppNMuby5EduLsKmnXO6WEtt3xL5eZRnj5A2O9JyY6mKqVElIw7C91i3tlR/AniHzFORsubDbjptI+1cjFchcwfEDT7yefw94QvSZFZAbyey4B6cC5PI6V6WvxC8OPbRSxXN5I8s0tuttHp1y9zvjAMgMAj8wbQy5JUAbh6inT/EDw5AbkSXdzm2lEEoWwuGKykoBFgJzId64QfMecA7TgU2rmEZOLueDWfhH4jLzeeEZyw7x3dnk898z1c/4QbxJPI0l14L1dJtu0S297ZqxX0J+0DI9q9ouPiP4Yt7a0me8u2+0icxxRadcySjyColDxrGXQpvXIYDrms7RPiVpt54o1TTbqdRbfa7WDTbiG1maOZZ7aKVN8oBjVmaQhQSuRgAE9X7RmzxE27nieqeAfHU8Is7TwdcrZesl3aF8+vFxyfqa5+2+EvxBSeGZvCtwksEgkjdLy0YsQehBn4/CvqKbx/wCHbee+hvbu5spLOBrmUXljcW+YlYIWTzEHmDcyj5M5LDHUUxPiH4ceOQi4v/OjuBatanS7oXPmeWJNogMfmH5CGyFxgg5p+1ki1i6iVjjGu/G9vplv9j8E6o+pABZHlu7FUHuuJySfrWRG91ZeNrG6vfBNnpXiKeGa4jvr0wETKhjWTJhkcq371fmOODXqWn+ONA1K8tbXTbm5vJLmOOVWtrGeVEWTOwyOqFY84P3yvQ1zXxHgmn8eeG1tomkl/srUsYIAH72yGST25pRlbQw5rvU89+JvxIF9ZRmFZLS9smKXMcJEvUcFOzAnHPam+CPFP9pSywagschRFCyRFQCSMlWUdD/9evL/AIpWVz4dvbXU7dnNtcE4z2YE9+4YCs7SfHej3l5aLJpoglyEbaBknOchhg8n1zXRK2kUd8adP2dk9WfQtjq0Wk6zbRyFGtro7MbSdmT1/wDrVe+IN/LaeCNVfTJzG7wyRsqrgx8d/fv+NYtpHNqSxyQiNVZBs3HJGeflxU+rsL3RWjvEPn3MRhmSI8NjgZ/DvRCKclJnFJI8o+Bt/Ld+KtQSK3f7MunBJSueWXGG9BnmvQ9S1dCLNPJuMz3EVsVixlGY4yc/wg4yaq+EdAj8K6XdnR2kmmvyN8pbIHBAB9geK0LPQ7iwkjOqhZwjmWQRxkcBeCB/epte85G1SpGcr2Oi8Dy6dFrlxHLas97asYHmjTJYZ5Y+1eD/ABOa1/4WPqFyl1NHG0+ElTIWVQMlefwFe0WVlrui6hFqzx20iPuQxoduYmOR14LAcGr0UemeJrl4LG1tL29Vm8mO8xtsTj5mKjqfT19RUfA3LoyqFVU5c1jxXwVrWoTWE9pM63unyTAxRSjO5s9Pm4weSPpXqfhLw7o0uoXE6Rlru3JfcYArYPcnHXqOK8+8e69JpOpxaRatZ3EkDld8a7I/MAIIVR06jvVvwPq9/cs7Z2+YVSXLH5j1x9KUoNq+x0zUpR51pc7TSrjRZNQuYdQTy7i1kLrHK5jVlPQ9s4xXXW2raMNOcWwiW/kTMaZ59Bg9h3rwf4iePLO38Xx6RcQqBbpsN6oBMcjL6f3RkV5RN/bGkeIUJnm+2eYNjKxO/J4IPcHPFU4RZzRoOfU+nvEXhWxkt2ij1C+gld/OaJGDI7euD25rC0Xww/heOVtJWC6iYl3ic+W5bjoxqzBY6k0EtwL2RfLtwziVt2GOOAD0OT7VLpmtQ6ZaXMmt3aMVj3GMg5+nsfamrtdyfejocN8WfFTzeHvsiwSxSMCrxyx/MM9cH0FebeFU1KXgI7RhduGHbHGfSveNK17w747sZ4ks3SaPiGVlxhh/T2rKTQnNtDb3GmxLJvIeaA/M49ABjmhq2lrHTRrqm/eOQ8BHxBpmrx3DaedkhCorkHK/zr0HxP8AEjTbbZol1Bi7nbyGAPmKmeMED6ir+lXNthILGzitpLchClw21go4344zXG2/w4s4PFT6hfeI59Su2LyrCLXYgkJ9SSPpS03kjOrUU2dzofhoWumyx3fiHVbeKY4SGDai7R0weTVbU9R+H/hwKBd3OranITuY3HmeXjrvYnAFYXhHXj4h+Idr4ev7KV7WKNlAzjyioxlvUdK434jeDNb8MeMbhB5Ekd9I7xhQFDRg8AqOlPaVpMVOlzytJ2Oj0LwjoHjxy9veXFhfE5ltfkOc9ShOP854r0Lxl4sjsdW8PeC5MQSrqGlGNeD5irewEDPsBnHtXiHxF0Yve6prtgx0zLB1trbOyME4wCPesjwDb2R8XeD7mS/uJ9XbXLHzIbiNlZUNwmGDHgiu+vg6Ti583R2XnY43WqzXvq6PtDxdrOp2uraJo+hfYo77U3lP2i9RpI4Y4lDMdispdjuGBuXuc8Vz3iH4mW3gVo7DxrLa3GpmN7ktp5jgT7OG2q+yeYMWOD8iGRuDjNdn4i8O6Z4igt49Wt3kNtKJ4JYpnhlhcAjckkbKynBI4IrJ/wCFfeHlEZih1CCZN4Nxb6pdRTybjubzJVkDyZPPzE814pBmXfxNsknuIbXSdVlRbmSxhvAkPkS3KwmZYx+8DfMo4YqFz1IqHwl8R5tU0vw2uo6BqaatqumrqOyEQeUYwId8oJmO2PM2QHIbCkEbsBuofwnojsC9luP246l80rnNwUMZc88/KSMdPbNVtJ8DeH9JWNbOzmKR2sljGs93NOEt5Nm6JRI7AJ+6TCjgY4xk5AOLu/ixbayY7PQDNZ6hBqmmQ3AaW1uVaGe6WJ1DQySqDjcCCQwyDxwa7fxP4w03wzcrHq63EUT2lxdrOEBjbyQGaMc58wqcgY5CnnIxVKw+G/hexljkhsbl3i+zCNp7+4mKC3k8yFV3yHCq/IUcdsY4rb8Q+HdJ8RRWcetWUd2lpcpdwByRslTO1uCM9SMHgg4INAHJJ8WvD58VW/h+VLmC/llhtmWWSBWimkQMsbR+b5pI3BSyoyAnG7g1U0v4s2Uul2lxPpuq3S/YbO9u7y3tooooEuWZUZkadmHKnKqXIHc812B8K6UNefWIlvIL2R1kl+z388UUrKAoaSJXEbnAAyynIAz0qpa+AvDVpps1hb6bstJra3s5I/PlOYoCzRLktn5S7c9TnkmgDkv2hJRDpHhWQ9tcUY2hs5tLkYwfXpXL6f4rsLuGC3f/AI+0wPLkwrZHpXW/HnRJ/EWneFdLtLgW1xNrOY5T0DLZ3TjPsSuPxr5717wPregaxfX9/Bd5tASZ4lZ42HtgZH410UkpRtfU7MNGnKLUnqeyeLPtniPTbUafNbxxwsJHguA37wjoCRUnw1s7m3+J1jNeSxSST6NfN+7XHHn2Z/r+lc8La7fwnpN3OLpzcwCRyFOwLkZ5HOcH+dWQ3ijTvEOk3/h77G2oyW01okeo20jRFZGibG4OmGHkL19TRZuPKhVUlCyZ67qPhJrnxPNrljr2raXdT28VrNHarbNHIkbOy5EsLkHMjdCK5RvhNG+pyWx1a9j8NtpEGmSW0bx+bdBJ55GWUmI4QiUDKMpPzA9q8z8d/Gb4l+CtXex1nSvD6cbopfsU+yUYGSp8/Bx061D4I+PXjDxJ4ht9Luh4dsPtB2RTf2fNKu/Gdp/0lcdPespU5R3MVRm1dI9quvhnpdzPcebqOq/YZJbq4jsBJGIIJrhHSWRPk3ZIlkIDMygucCjWPhppupSuw1PVrOOa1trS6itniC3KW7ExF90ZIILH7pUHuK5LxB4s+JOnX9na6cPDeovdfcxps0fHrzcnilXxX8RrfTLmbVn8MwX0OCLW202e4DA/7f2lRkdxz9aFTk1chwaOnufhZpN3qeqahc3+oNdX+CZIkt4DE6ypKkgMUSl3Vo02tLvIAI7nNy/+H9rqZL6vrGrX9wYBbGeXyEYoJ0mHEcSrndGo6dCe/NeZap8U/F2n3stvJqHhZdkQkDS6ZOm4kA7cfaTz1/Kr3grx9478TaUL1p/DloGcqinSp33gcbh/pI/lR7OSV7FOlNK7R69pGiW2lX+sXdu8zSapdLdzByCFcRRxYXAGBtjU855J+lYs/gHS5nRmuL0FL671AYdP9ZcxSROPu/dCysR3yBknoeei1bx+zur6h4aQjkf8Sic5HY/8fVVR4l8cfavIOpeG1bODnR58j/ybpcrJUW9jU1L4ReHdQskt7iS7cxtbtHJIkE2wwwCBfkkjZGyg5DKeeRjAwo+FGlR25trXVNTs7SVYBc29olrDFcmGQujMiwgIcnny9gOOQayNR8SePbNHdbzw7MF7Lo8+TyOAPtXvXI+Hviz43174i6/4X0+Tw06aVHI/2z+zpsTFJUiYBftPTc5wdxzj34Ti1uLlZ7tqOi29/rGk6lM8qz6a8jwqpG1i6FDu4yeDxgjmuSuPhVos2g2mk/bNTSC201NLR1kj3GJZUkBYFCrEmMAgjaQSCvNcP8R/iZ4s8G6ZBNHqHh3UbybpbLo88eMcHJ+1HnJ6AGsi0+KfxQXSrjUta07wzpVnFGWUT2splkbGQqp9oBz9cVSpyauV7OR6Xovwo0vQo4m0TVtV0+9jnnmW6tktUYCZY1kj8vyPKCHyYzgJwRwRWxP4FsZdOu7b7dqCTz6iuqi7RoxLDcKFAZPk2Y+Toykcnj08OHxz8WyWUl5b3PhWSDyo2jH2GcO8rYzGV+0cEevOa2bj4p+OYZniz4eMixiTH9lzjIP/AG80uRlyw9SO6O6vfhpO2saTLY69qNvDFFqH2+83xG7uZLloT3iMYXERB2hSMLt71rWXw30Sxt/Is3vIoBe2V8kauuEa1jijjUZXO0rCuc5JJPI7eW2nxV8cXUjRLP4VWfaCqPYzDcT0H/HxXMH4+ePzeCxh07w++oAhGtTYXAcMTjA/f89jn3pqEmNYaq+n5HqrfBXRbNNQubCe9ub+a1kgjE8kEHJlSVWaZIDIzK8aEO/mEdwaZY/CQ6xbX0/je8+06rcaj9ujlQQXXlgQJDtbzbdYnyEz/qRjjHIydG51Hx4l7bQQax4UdZUy7yaTcJ5b9QpH2o9fXiuM+IPxL8c+Er6C1jn8MXhf78r6fNDGuOoB+1MWI9hSjBy2MowcnZHoUXwy0pNS0S8+2XI/sjZ9niitbOAfKSeWjgVwpJyUVlU+mMis/wCJFxY23j3w0+p7zB/ZepLw5VcmSyxux1HXj6Vynhf4meJvEM6QWes+GTcNgbF0iducZ73Q49Diujt9P1rXPEVvqWuapp0qWVnc2sS2mnSW2TK0TM2XmkzjyQBgDqacY2eoTjKDtI5zUIrXxRbfZde04S6aQ0ESl9hO3kOMDgenNcxovwq0TR5p9TsLOe6kQbooblhuUjrjHH51r+PdRbSzDp1pBdxXW77Uty20KAOCBjiuStPFWpTTh3mEyTnbIkh2soHBYEdq6nFvbRHTClNw5kzek8TFLieSGRrRpIfkixlI5BwBntWjoOt3F+qSatEkZjUONr/e7ZPHINcpp/gyS9uXK3Xl2sj+Yg2Hp3APp9ayfGnjyz8NR3disMk05IWGNeIiMcEnrx7etacsY7EzUX8J6musDTFiuZ4GSNgXwIPM2DopAHPJIpPFXxN/sW3RL2KzMrR/uyAUMeM9uprE+HOu3Y0a1n1uxWznuoFeMOd8RQ52HOTtHfB9a8u+Iq317qkktzGk0AClpt4OWPXb6fSs7KUtUaYejGo/ePSNC8S6xPeTo82LWbFxELqEyqykZOwevtXS/wDHprkV9pptbafhLmRI2jSbI4RQpPzY71yXg26vbXQbNZzJHz+4I4MY6ZHt7HisrXPEqW6vIsFzII3byjGpTLnIJJHX8OlTq29CnRvLliRN4SvrrW9SGnxW7WU90zGe4O9kY8kJnk4z97iuz0fwlpfh2wkW3mmeRgHknlJJJ/DpXk1vqEjXpvBfzwyDncsjOUOO4/pXbwfE2DTla28QWst9E6gm4tRggH+8v61NTmb0N6lOpyqN7mbrvgfQNY16S7miuftQCgqsmElYD7zd/wAq3tM0q2v9UtPtsds8ETKttKE24YD7p9Ki0yfSNam+1WN9K1u/EUbDYxP90k85+tXJbyzhstTsW02QKiI63bttbzz/AAD1x14q1BM5LyWiN2fStH8L3dzJe3C2tkxa7uZGkLbzwAPr7d6xvFd5pviDwrbz6d9kkUn5ZUGCx7cV5xeQ694utby3txK8Uu1A8hwm4Ed6Twb4V8f+FNft7N7TfpryjftkWUBSfmIOcihx5HvqVZJq71Os+HHhZ7CYvcttDElQjZDZroPiVdS6X4VnvLFmSeIEqwYgge3rW9YWqSX0sDW8ltdHPlxbQQRnglugNP13w9dX9m9tPKszD5WXaNuP7p56+9Q5Ny5mQ5Xldnk3wp13xH4h8Qpp9zcLd6bJFvmaWMbosdgfWux8Utc6FeG00a0uL+CzP2u4eM87wCVXOemeoFdZpfgOx0Xzbfw3CbaSFA88M5J3Z5xuHIrLXxB4b021uxrE39nXM77ZIGByQBglT6e9CqXu0rlNqc7wR816d4s1a38WPr8NzKut+dvDk+/KkemOMV7kuq3fjnUJbjxFeWljPbRAlUjyfKxzjnueazrPRfhRBe3Ei3E1/LM+9cM3yE9cngYrnNcGmz3LDS4bq2fb5cDo2d4xyD60R957fgdluZJWs0dp8Q9Ka18Mxt/ZJubbBWZzIQy8jaOPU59s14pF5x17TptLvJbXULK4ja0FyFJidGDJgnKsAQPvD8DXoFx8WvEGna86arZxpYGZ4p7RYwHX5sHg8gj0PBrV8UfDSC8vkuUeawnlw6pNGQjKRlcdx+ftXXfXlmcy/dx5J9Rl38QviJZ6xNZy+L7mRIYw7umn2nUjnH7k8CiX4ifESSR103xReXkY2qJVs7NQWPJGDD0963te0yG50m2tM2760IRAQ+I2nUcHHOc15bqMEFnLfWFtFcxvExkLHO+LgDaR3Ge9d+Gw+HrK/LqjyqrnTdj3nSLrxrqdhHcReMtTUsi5Bt7EjcPv8/Z+nYVz/iPxf4v0e+ET+KdbSInG+Szsio994t8fhXmUnxQ8R+GdGs7G2toBburOJJ4WbzBnGB06dT9a9l8Ea3PrvhSDU3ig8yaHzZoSSCm0kEr1GCOfWvMq04U5tOJ10o8qUpalXw/rvjPUp9f83xjqSwadruoaWrC1sgTHB5Xlk/6Ocsd75PA4GAO+u9/4nYYTxnrcTjqJbaxP6fZh+dUfhjdpaXvjMtdW9tJJ4z1aOJ5SPvnycAA961tXl8TJqDPqSJc26t5ajjAXn5ie3Fc0OW2qJUbq5NCviiSw80+O9UWQH5gbaxwV74At+tIv/CVH7Ru8Za6BFHu3fZbDg47/AOj1NAYLSzAjtIHjQbi5fAQ/0rl/HGs36xoNOnjZQVYyxPnbnoDjqCOtVGMZbFRpuTsYGkXXjnxh4js7G+1i8upNHuTeMJ7WBIs7HRCpjiVjlHfgnHNenpqt5N5uk306xTXAPmuCPusOQoP415xc61rtl4ZkuYVltriWYI8luCrGLGMeuc/pXMap4c8U+MdLhn0fVYrSRJ9knmOY/NXACksMkkENx05q5QW9kkayhfVaHrmt3MEtpbeHNLu57a0tlG12O3KKMBQw9+teb39t4qPx98OztdM9iqxMs1uxaGKFVxIpB4yfmJz1zWVqHiDUfDmtWnhLK3M1jGtuLgqZWuZOCxA7KNxHJzx+Fej+E479tKgOswx21+rltgYfu8McDgkZxjP1pPSNv616g4OCu2ek+PfCmi+J/CtzZ6+pubEjzhJnDxkDIZGHRu3v0r4w8c2tpbXVtYeENP1CG3Rsu1yp8yacEjI+g9OMk19JN4qub7W4NO+0JHpS3DwywtGWd2G7DF84Byh+XHQg1zPjHxnNoGuw6XLJES4BiDnaqqTjp+dOlBqPKwpKVN6bswIfikvg7QNFtokttV1uyjYTt/yyhVsZTdySwPXHFei+BruLxL4Un8RMJbSbUJthg3F0AUYyoPUE55x/KptP8P6A+npbrolhdwZa4JeNWxI2DnBHet2W0hjgRUB07ylVFES7l44A44xU3gvhJqTjLocv/wAIxpt1rQudTsUnue00q/KABgcdOldDbWx02drkMk2npH5L+WQNh7Ee1cr8SpdbtNFd4As9mxEKXKHmJycYYDn2Hua4/wAFa/am1vNE8Sam9nqikkWU6OqgEZG5x90nsK0aco819AVPmjc6/wAb/FDRtMtY9I8KLc3OqMAnnR/cjAznJPevO/DfjHZraPfThblv3v7vMjydSVYe/TIqXxXo13/Ztj/YOLa8diblFypbngA9P/11mad4Vu4pbS+uliZ8gSR+YfMODzz/AIUuWKVkdtOEIwPab/xkmmeENZ8Sw7HsrS2eSESDDxzD5UUg9i7KPxrxi08LX+k3Nzp1rfw6fq6+HLI3N3dziEJNNei4dWc9xjHvtx3rodSsIriXw54Yt5Jri21O+Op3kLscLa2qlimO29+PqlU9f0ebxLrnjO11G7MF2tvo0ck7rwJHheYhh6Egn2Nc6jeVjhdlPTY9T03S7LVr6NbizhviIvtP2pG3pLkYLIw4HfgV4D8TtTT/AISHU9KtXM1mrlY5Bl2BP8Oc8Y6V6d8E7uPwbpNxpXiDUbaSeS5D2ywOzqiHAYE4wCTzisb4/wDhBLDUjqulQ7FvCkatEwwzNkuSPpjnit6aak4y+R0UJRVTujy/wDp0Vhc3V1qY81iuI4JflCE8hyfYA9PWu+0bV7DUda/s6yv5GvJUPzMuxWyPlC59PXvXFeC431LVDotuxMUiMJnAyy8Y/GpdF8Pz6L4ktluLe5E1vcLJ5zRk4AORgd/T8ahx3sdrjDWN9idNIvl8TTJqc5s5k3F1UMWORwce/rXu/gLw5FLbaHqLRWker2lsUW8uYi8skeeBjIzjjk9O1SLbXGp3kur6xbw20sqpBEGXGEXks3+0T+lbcUCz30NyXZVtkEYCDAAyTRL3kcFfEuqrdg8T3WoWep6dYXN1ZTWt6S0kyZRvl5//AFV4/wDGLTL+78Qzy2EbtZxCOCVyvO0ZLFR3zuBJr2ie1S+1JLyeOKQwZjhjK8DPU/WuP8Q3UFvr1ra3oeS2lkxKsYwBx1J7c4qo6Wt2Iw03GVzzf4R6Pqo186h5Bght18sSKuN654LZPavoO+lltLNNlxDJkA7gcfLjsOuc15tb3ttL4yv9MtpZ7S2W3SVTAwKlgcsCT68VgeC/Eup6/wDEjWdOvmnNrGrxRxu4/d4fapHbpU2u+bsaV71m5M9X1HR9P1C3+1XpNxwVKljtU4wcD161gWngyC2Zn0ZQTsyfPI5z056etYXxVvNW0TxjbWdjeT2ujLYiWIo2A8uTuB7E+xrX8F+Mre7ks7O7nWS7mQtlFIRwBwfY+1Pmmo3WxCozVPnT0NDT764t7I2t5beTdMrqxIwvcAqRWP4y+Hela7a6W2u26xW9sPMe4gP72TI+VTxkjPXvXReLrd017TLbz1jhvQSwJ+6yjO4Dt6GrjSGO9tLqO5L3dtGsoAbKMgBBDDoue2ORVXsk49Tm3Mi7g0KXSYdC03Tmut5TzJIW8sW4GAQWPOfasPxp8PJrcte6VGuo2Mqgm0kJDKQcHDDg1zF1NreseJ7nV5Uht7e5m2GPd8u1eAG/XmvRbT4jQabcxadZS219eMCRboMbVA5bPpj88UveptJanR7OcNYHNanqFjY+H/JvLbUbK6gXiO6gJB/2VbvWL4jS18S6nCujvE2nCBQxhJLQnnsOhJrodY8Zapqd5ctb203lRczMcPGq9mI7Z5rg/HPj77I4afSLZ1P7tXjhQBCMYIYc89RzVcml0aUqk4y1RXh8Iatoxv7n7VDPp7yBkEnDyN9DyMZ61xd5dTypcB7k20sr468EDtgda6XwzrUGqam013HM1jKv78xZZh9Sea9i8L6V4Qgtra30ywtb65kfO+TBeM4zu56Un7u6OqWJdN3kjzfwBol9ZaPd6jczkRKu9PNTIl7ABeuSa6weGtc1C8Y3dpHscrKs2SgC919q9DfRDc6haxF38hT5szKBywPyqMDtXQXiXMiywJMzRFByBt+b0OO2Kn21tjz6lVzlzHmmpJpvhTSmliaaCZz/AKmJy0QJPJPtXFp4n1HWbdkuNVsFnibesduf4Om0980348zapZGDSLERyQ3uHZh8uxFPKfTOMmvKtc0CTRoRqiXYhbzFRIOuDjkqwPPTvS0Vr7s7qFDmjzHp58R+JYXsXvb1FsYJVaYrH8wXOOD6Yr0PXfFml6LewwWkH2+ORAWkj58sk8H3JrxBb7z7ZBudm2/MrHgccirGjXszwyFyW2/KCvG0D+gquRPVk1KabsevaD4tlur64e+Ec96W8sWm5huxwMsON2MdeK8/+Of9m61/Zv2CK6s9SikEUtrKvPuQ3Qj3Fchfa4JL5be0ike4hbzWZDjP97B7+tdPpXjKLxTZ2ljf6erS2TbnuJG+ZQPU9R9aEkpXQvZOFp2Oe8I2EM+sfZS6wQn5BJjKt6g+lei2vhCHUYb5/t8CRWmSJOwAHAHrU2g+HtDvdZiv41hWRjveMHMch9627uzsUuZltLaR2CnCwt+6YZ5LfSh3eiFUrqTujrb+30XUvEt9cpolpLqEI3i9kgBJAOM7sdj+NdLbT6X4g0eS0vQkvlAjjIIA/iB7VMVjmP2K6QCeUHmI9VJPtWLbW0tnp91/Z8zzZABlIHyAHBU+/Xmodpa9jzHJ9TyP4u/D2/utCtvEGiXEt3HbqdsSf61BnP3h+Y9K8dstTuNX1FpLlpftsiYO4/NIAADk+vrX2x4WTy5Lmza2AhX5lkA+V8+vvXGeNvhVa3d3Pf6PawbpiWlhVVRycclH7Z9K7MNi/Zz94uU+enySPB9MsNR/sh49a0iz1DTLacGNJpDujBPJUDr9M16/pvijw54fl0i3vPIsLq6jCpaKjMAp4HAHyg4OAa5WHR57K6m0dhLEcho452IKsPX+lRal4VtX1STV59X829dAsTXGVBUHlGx0I+bFbYh06zbejClGUbJu6MiDWrbSfE99HdRQA3PjnWlW6mkAW3x9lycHg5zjPGK6v4gePdS1jw7FH8M7q11G7tbpYLv5QxK7Tt278BgWByR6Vgx+FbHxPbeMVv41b7N4y1hkYPtkBPkDCjnOcc/QVNceGtN0XwdLp2kxG2naeN7gGUsZdpyMk9Dn0wK8+CTimzWNpRSNbXfEBstHWOa2Vbx41jlit13RiQgMwx3HUZ9KXw7c2K6ZA1zskS4BYRrkgLnru9s9O2K8wvxq/ibUGs5La7M+cGOEFcjp8zdBx3r1X4eeHv8AhH7VbXVIBcMSCkStvRTgdM/SrSUUa1YqELX1NuMvqFnJFCqmFdoWXzFzz7fWs7xzpV1ovh6Iy2Tw2cB80SRSD5iMYUHsST3FaXiAau9+9xaaPbQ6dbuC/ltlpY8fMSo44P41538V/GF2NMtrC5a6TTptskVwWZlDBjhVAHUDrk59K1V9GtjClFuaTehUg8TSrcSWKX/m3PluqxTxDaG2kl1k64VtoyevNSeHf+Epg0O4vNSsZYkkfejpjZInUke4Pc9RWT4X0K3vtImuUnM5kuI4TO67icD5QvoPX9a9G8Oag9kw0d/tM1sp2JbzgcjoWB/u5rllU1aR31HCOsUU/D4a71W41G8JYxoMICTt3AKMds9e1WPG3h1dR8Q2lrNKh8l42V5YAS3GQu/H510WhxSpfyWlvapHCpHkJGuRuHK5atO2je6P2bVrIyyyOSXc4KkDj/PpWvvJ3OSVa8ro8m8XeJ9W/tOTSLCSOxsoiVDwkebcN1G0/hVHwj47nGrHT7m5maRgY5PMYlg3Y5PHbmrviLw3cQ6jc6jMY5LlbjbDHsB8zPAHHI2gdawtK8MzR63eJdaXFDdblAYSEoSepz+VDj0R2qdH2VnuevaPi4ae2mEslpcwKgR8kM5JLSfXHb6Vg+IdA8NHxFBqt9FHcalEViaSSQkuFXA3L0JAA5IrhvGGv6toOp6XpMN9cRxBi1xMsWGXAyUA67aggtG1K7+1LczTXbEOCzZBzz0PbHSnGMl1MI0eb3rnoN7dL51raWlv9rkO9lLPkqByfwp9pHb393ZQ/aVNw7fcWH92WHt6+mao20U8N2bmORlD237pk+Vgw6g/jVWPUm8P6XqfiOZw7WFtLco7IEzNwsY9wZHQfjUy0VyNEmJb63b6f4k8ZeJ44RNFZ/8AEg02NT95YB5lwR7GVlOR6mneGPE4s/iJrl1e2UV0us6tptjKh4ClLTGQPRWYYB6g+1DDS/Bfgzw1oup75dVitftU8ecusrsZJCcckhjt57LVWz8TaB4V1bxPqutWslzdjxZdwWEKrn5oUiVj6AKHGPXNYcui01ZmlpG63ue6+JvDWl3FnOklnFGsjgM8ahWz2xiuevfh5a2WiXBW7u7nzUI8mWXPbhQcZ/DpW1pHi2zvbCPUL8yrbkCVPMG3Gfb2qNvFUlzLI0Vjcf2esvySyAIZG7AA/wAPvWkfaWt2Ode6z5p8S6fd+FL5W0awmjt5h+8VFO/d3Ukc8Z9utZ3ga9Tw0b7XvE0GoPbBvJii5HmF85Jyc4A710fin4l67deN5NMe203TI0n8otcw5xyScsemf8mt3SLa08baffaXqMUGUI8yeKInLlmxycbTgDgZrSSt8SPTc5+z1NfUfiZ4QurSzkS8ub0bV80FGAjPbPGD2/KvQtBaDVbG1NjI7W8+CJkOCT/+qvJPFdxovw6m0iwaza5jCjzAhTaik/3DjcTzXr/gOBdO0YSWwSe2dzIiRfejBGdpBxgj0qJ2jFWOKokldKxrTwGCQxxHesbcO/GeK8x+KGhzT2clw6YyxcFCQy+mfXmvWn1BJoXieNlGdwLocsev+TXMeJrq0+yiS+jdncsEiUbmbjrj/GlT5r3Jpz5Xc+fPDFlerrkEUUE++Rtzs3Xjnk9h9a7Hwv4cutB8danrpdVsZSG2seSSwJHPB5r0HwXoF1LCuo3qk3MsZxEVGAuDtyR/WuR8U6vqH9pW+gr9nSJgzzFG+ZOhC8jAPXNafE2l8zolWdSVkc1+0f4/1WPXpNIgtYUs4URklZcu+4ZyD2Hb8K3/AAK+i2/hbTtVFhKuuXkP7u0iBeViOMgH7q8ZJrRvvD9zdWdh/aUFle5j3MFUc4I4Dke/P0rz9vhdqln4+07V4/Fel2MNxceZbJcXDrMkYbIRVA54461MoqMFboSqt0oRPVo7K+1DVvteuXEcKhcoAc7R12+nP9K0dYsn03Try5vfLFrIhmZ7dfncgZC/p7V21s1pp+iyf2gI2VFJxjO/P93NeLfFLXvGNgy2dlpNrFp12pRBIwc7SMHcD0PPHpU05Or5L+tjGCblZHnVh8SrW3e7tr2xM/nufLRDtWPJ755PrWV4DXU7f4gSeVYSyIrFWuNhACsOOemPSqdl4Ws2lj81LwajHIFeArlnwctIrDjGMDFeq6Pqsot5Dllt7fbCoPDAH+gqpat8vU9OcvZq6OpjGnwTtPcrEuUAUs55k5IG0dcGuP1Hw1JqslwmoWkdrFeqXESoeWznjPIPGfxrq/D0Phmd/PvZXi1N022z3GURWPVlLcE4rXvd9vEs017DKyIREQyk5Ax2pw02OGVV3Of+GngJINMV5YFjhYF2CffdT03HoPpXo1x4Y09rNraC1iRnAJlI2Ece3865TwXqlzFpw0+5+U2+B5207Jl9j2IPatjW/EsUSypDNbz3caE+VICpkPOAPrg/lWc3NzepDUpM8csPFPxD8IfEaSC8iur7Q1nZDGU/drH/AHwwHBAr1fUvEcFxYzXGh3kfnTcrzk59Oemat+HrttRht2vlV/tEe8wnkL7A15143l8LaVrF/De3KWd1tMm0Ehc4zjA4NaKKnJuw73drHM+PZmvNLtIJbea51q2cv9qRvMVt2cqwH/1sYry77FIVWOZbuUq25Y0QlQc8kk1674I8TWep+BfEIs7SWHZKiCSVRsfOeB6ev4iuC1HxLrMziCzn8uI/IBGp5I7cdapa/I7qFSdnFLQmi03Wb6EItq9pCfvz3JCceuDz+NalzoGpaSBPGWkhZQCYyCMe3+e9WvA+n69LqIXU441tJF3O1wMkenHU56V6UtnYXU97BqVsHDW5+zQu21VIOTgg5HbFHNbQxqVXGWp806pFLJdtEWFq7sV3SkqQPc1a8L2barr9pbSyCJSSJJgxAIAznjrXpdz4F1TWYVc2nnvCxYRqQWIzwDnrxW7ZeGdT0yO4ktLOwYRxlGkK5kQ9OAO1RJJSumdDxalDlNPwRZqNPIa1EjDbGwTlWOTgg9q2b6/EGl3OnWUCmVYpI1uccq/uPaq/h1HtNJtBd/Z/NxjbC+d2PyrUDSeIUXbaxWmnWQZnuXITBHUt6gcfrRF2d2cE9z2CW2WOPzo13TxKdpxyfaue0sW17aCGTz1W6ZhNGSV5z09q6qORJU3RuGHqDVByDfs+AUgUZ24zk+30rmUtDmsXoIUghSKIYRBgDOeKdI4jjZzkhRnjrTqZOhkhdAQCwI5qRnDeL9G07xda8N9k1JUPkTsMcjsSPyry+TUJdM0S8tbm0RtTtCHZZVJKKABuU9wR0NetWfhGWzMyx3jusoyN3RT/AD71V1fwddato7/bXh/taHi2mUdB6Me4PpXbCrGLte6BN2sfNfi3xFdaDHryWbvG11431lXdJNjbALfIB7ZyOayNLsrrxNrUa6FY3Mr8koZSBuGcl5GOCOldfceGbXxEfFJnCme28Ya20W58D5vs2eO54FavgsWugtbaZf26aZOigPITnz8nI59K2oU+ajdbo6IYr2MVGK1Zq+GdK1PTnk0i9vLaG98vzrh8nbFu4AL9GPTgV00sDaKLd0vIp7e3DGa4ZtojHU9emOayPE+orDqk0U9sZdPeUMxUHKDHynPTrjv0rkfEyDV/Bsmm3949kbsiN3jfzOAwIyg5GcDOa4J1bTV0aeydRc1z1bwv4q0PX7e/j0W7trqWINuijkyr8cZ9Oe9cBq3hq18QC40yRpls9xbYWAImIzyewHbFU/hN4Q07wzZXF5pE0t+8+ElmlAXGCeFA6CuuvYHkuEuIoEZlOSUOQe1dVCVk2jmceWVjC0jwMnh/TUFteTGOAZO9cIuWzyec8+1dCLTTvD8DTI8gnnOPu5+91zmujsP7OlBt7+ZkM67FjJ+UMPSsIROupS6PqTrclmMqyrkYQipSUm2xuTekjnvEmiX1/bxHRfPIjcTII3IDOpBU57dK7HRrTUNZ0cRauJDdyFlZ8gOpxjPHvR4W17w7qqTJpF8JPs3yzfNyuOMc1Vu766e6jisbuWxtYiWLRgb5B7k9FqudzdtrA725WjjPjD4gj8AahoUUwmubuVTICirkKvGcn16Y9qseC/HFl4kstV126jBgso2eW0ddrtIFyNhHBGAferPihptQ8y01+2j1KO3yUa5jjk+XnngccelYWm+JdMt7aHQrTRLa2t5SWIjgJ/4FgckUW51ZFpWjqjz3X/iNo/inX7PVdQ0K2ie2/ds0krszp6Njj2HFeiS+K/BenaFFc2aEXEhDRpHl3cdx7KP6VPY+E9H1ezlsrvwXYzbSZI7uMvZvMOu1cYyfY1Bq3grwLrGl2f8AYDajpl5aKd9rcRMyE91cnBB5POfwocNeppGrSdovQ63wxcaZ400hU0eRra8K/aITsDbMkjDL3BwePxrnPFemNP4g8MeFJooXF3eHVNREGSrWtqMhcHoJHyv1UUfBy20zwPNJLEZ9W1iXdEfK+SKNSeFUE5Jz3xU9hPNrvjXxh4mhsmubb7WuiWwj6LDB+8nKnqQ0pQjHXms3Ft8ncwqNJtR2MLxPp+lal8QLSSzXXrm/uLhWuziNkZc8ICPuqQeefeoND8P2Ovu+q32oW0TR+JNVu4re4IzO0jxruxn/AKZAY9q9U0nw7FdeJLbUbiFoJkkidIy2xXU8ZwDzzXg9n4O1rxD4L8LeItJDSRLLdzNsUu4ZruQbyo7fKB+FVLWaSZaq+0aV7WO/8WWuvR6rIdurzCFQ9jLp2x4V+78rx9AwIbknpXpXhyefUbK1j1SHN3OoDRE/uwQPmNeX+Gb74h6HFtuJI3t5ZfKki1UxxTFsdVJ/h6YJ7V1+peNJ7Lwu6iO0bUnGIngkEgjGcEll9u9Yyk9Fp8jSpFySikaWqeFdChM15qGjxPPDIIZvPQOJgRxtz1xxjNeaQfEOw0O+bTrPRXj0yO8JaYHLhjxn6DJ4z2rS8J/FrS9V/tbRNduhaxxDzIru4bKuwIDAH+X0rlbbSbDX9S1CPwvdfabQuJXUqxy55P06cU+a9+Y0oU+W6qFXxTavfT6nd32mNqMFzKJrO8RW8zyxyAWGduOB06dK9C+Gba3ovhO9yJYDPIzwRSZd4hjrjrj0zVvS9Hm0q301mV7OGPcNp4ZgV6MvfnPTvVzWNcmcRWWnxw6Z5zhBFk+ZcNkZOT0AHWnFupp0FWrXjyJDtK1XxTqUUSWurW9j9iRXnL2xd3UnGcnoD6V0Wl6v4ftLgXOpalFc323LF9oCn0FeY/EbxTqmiWKaJpYjbVJovNvrlSFyoztRT6AVxHgZ9MbUvtGuzPKEgMhhUgnIGScdQMdPWtZwVr7ehnSw7qR5me+eJfjR4Y8OXENuVaXzhnMABH9K5QadpnjDVl8TaDAIVc7trkqJCDycD1rw23u9P8aeIUtdK0m7s9xZYrh5GljyAc5GPlBHucV9G/CO2tNP0JbG4uw3kEqVU4Pvis3KNNXgNwjGPNB6mjqdwLdrdY7XAiwHPmfu1XuTXin7QHg02+r2nia31KFtNlZIPJyYyrgEnYTxtIHXNfQF1rHhCZJkg12yjuo8xlHnXhv7pBrzXxnp1p4k8FPo19cRbmIlgnb5gsgJ+bAPA5x9KuEr2MKd4STaNjw14+tPG/hzT4NOhkSSykVbi3c7mXb0G7uCB19q4v4p+INS8USWMd3NLp9gkjbbiOURknoOxOVPJHcAiq/w18P6n4D0+81pVheeWaPfbwvvQxrlS2ezfNnHv+FSeLtTtNd0WfTdTllz9qEiRWi4WQbtxB79+fcUoR5XotDqioqbaOX8D3+paPa6ub+0uXsYsf2fcXyFZGyTjPQkHrz0ra0yeK9u431WWRBMQZGjTO7IxgCsafzZ9QiaYOzx4McUrmTIHPzE9a6bwFpcmp391eRvcKts4aLy8mPPcYP16UnaKubWdrs7XXr21bw5FavErwW4WMLIitgY4BzXKeH2V0ezs0ZOOSTuGT0AHpiqurXQa9lVroXCw3DSErICCOmc9vp9a2fhpfaZHd3iNEVvZn3Ry7wVVGPGB3q0+WDRzyhyq5S8VXOsJpA0mwSRXtMSyzW5xuGfunnk1xvh8X1jqM2o3kksCAM0ayEl5HYeh7dK9i0+TVL+8u9OtntWuQc/vYwGMeeTjjJ49a8ruPHEV142fT7fTgyO3kW1xdP5YiIyCduMcnNNPRqw4VG00kdv8MNU1bVdXQmSS40+EtmOIDDHk5NW/iBpvhq9F9Pq2jfbL7ePL3OUBBHcjJH4Va8HaBdaTBBBp9/d2tyoLSmGBGT5jnhjj3rqNE8PeG5LhtS1W4lnu/MZWju5TuGOnyDv+dReMW5fkYTneV0eD+PtLjudP0608GWd1/ZEG7fAqMu6Q9Tk8tzxzWt8OvAuq6HFLd3lq8dwwJEEuCQuOor1vxVc6i9oY9O2WwRRtcRgbR6gnvXmelw+JF8Ste3efsspKh/MJ+YjknPfoe1JyfLY3pzcoOJ1qkJb2ryWohkxh8sNznsPTjtVTVYre0j+0RR7ZJchiBuLe59K8ytbfxkPGXlGaae0ZjJhuEC9yPb6V67ZWqX7QWkyrHNI/MTHdIcdQvtUtcj0ZMopK5yfxP8AGkGgW/hzTWN1bSz2omuWtAASGP4enSmxXln4g0Xfpd9M6yKSHPyMzYwVPp71qfFH4eDxrcWk1pcNZatYxeXiQDDxA/Xgg5/OuF07VPDfgbTDps9yLu/WQvKscm/c3vjgf/WprZWCDi46bmh8O47mLT7qa9eQRRq2Cz4xjjA966L4g6dq194F0+Czmd7W5CzOkfBZOwz3OeTWP4f/ALV8WRyf2dAItJ+0bTIUEeFHPXPPbpVzxF45fwNfQaQmppfIieabYQAxx8dyTkE88CrSlzablSk3O6Wp9BD7Tpw2oiJCwHGMgHuakgjMl20xbdJkHngYqSKddStluradXgkAIRl6DHIPvVC4cwXs2QFBVVVt3X1GBXLucJ0QdTgAg56Yp1c3EnksGjLo+dxJ4GB2Fb9vMs8auncZxSasMe7hAC2cE44FOIyOtFcR8Z9V1rQ/htrOp+GblYNVsohcIzRrICisDJwwI+5uP4UgPN/AHhyTxFaePkt9sdzB4z1R4ps8ox8rgfXH6V4z8XhrejeLYNTWe4gnh/c4aTOx16gj+6c56Yra/Zk8ceLtW+JbaRHfRjTdSvLnWNUUW6Zd2X5iDjKgsEGBgDNfRvxA+HsHia8GpWsy22opF5YJjDLIAcgMD/OuzDYjl9yTshxfK7nkvgLxRpHiXR9Ms/FVnIl6CFQgtCSh6MCOuDxV7xjdeEPDGvRQ3NveGGQ+WJBKp3Z/ug/e6+vFcD8RfCHiSz8Q/aNUmkN0oCoR93Z2ZccfgOaq6lcT+JvDtpa31m73unNuiuQd2QeCCp9ePyrsngozSqQehVKolLXY928DSaQLSa50mVZdPkjYxtt+6c4KkHoR3zUulrFd2rW9uiFMnYyjA49K5n4dQ2Xh3wz5M+SruZMzsQZZW6gfTgfhWs2ry2U0bSw+T5zOuD/F8vy8++K44xauOSTk0hNUaXQNOjFpCJ72eRovMkI/d5HG3riqehXn9tWerWsLBNbtLdrbeHD4JHfHTmunmtodR0+0k8pXSVQ+CclG/wARyKms9OtdLSZtPtoLeaYbpWChWf3J7mq5lbzE5K1ranjfwr+H914dabUdYZlu3/dxwgFQp/vHP3q9fksLYae+nfZvOunhyx9Ac8k+lQeIEuZ7O2lh2SxAhpAx4APGQaozX0FnDujYzXUKbGfPROuCe9KWvvBKTqO5f0K8tbN7+J7IvP8AKvmqoO4KBgZPalklOh6Lr+tW9lDJqVvaSTww7Q3zAEhRjtXOxXHn3Ie4ZEiAyuOd+exxXkfir4n61b61LbeHrb7DGkhQvhmLkHBLDoAfSs1FSkzaNGU/hOt+C3jnxN4/1DUdI8SSfa7NlWVZAgjaHDZ+Uj/9degeOdJuTo095p0tpFaMjKw27mUYwJUbpkHqK5j4Tpcf2NFrfiMJp8t84eCVYwqup67sDgnrz2rqdHMWqXLi+lI0cTeZBEH2xHPQ9OeecdMmtFu5R2MajUZ3R5DpGlx+EtD1HxNc3ySz6TFJcw7VPzTMAsWST3kZM8etei+DLCTwv4Q0vQ4ZYv7StrdPOhYncJ5Pnkd/YM5Gf9kVS8c6XYar478NeGNFsFiivbw6zqMaPnzILYfID2Cu5ZcDuAa19fvNSsLi6aaLCSHLBcbk/wB7jnPpTj+8qNhUqOo7kHiWfV9Av9EFugn3zA3d3GpYxxJ8/T+EE9KpfCDVx4T+D2i3N1K6eZabbWFE3ku00rk4HY78kk+3tWeniBLO38QxxAo82mXk0jKCd+y3d93P3SNvQVzt7POPBPgy1i8tEstLtXWMMS7PKiPux34cY/HpUVotySYU43aizsNfu/8AhI9ZguLKWS8khdpXtdux92MAkHqM8YGaxfFtvotvoEcfjTWTpySMHliiH76dQfu7BzjIHIwKwfF+mazbrcanazzWs2jtE6xQZWS4LvgN6cZ68jqKqHw5N8QbmbXPE8k0dxBtt5olUIZVVQQc/wAJ55x3rnUW3zPQ7lFRimnojnfFOh+FvFMkJ8CG9toYcR3DXUW1OnDdcjoa7v4c+GH8E27yQai8mo3cQxLb8xspGQBn+I4qDWZPBWgWqaXbzSl2j3yQ2iCQou3O9if4hnoTXe+FIo/EtjEPDtu50uwtgFmn43kLwB6H1qlGTtfbzIqTSVzHa4vL1YjNNsmuJSrT3RLGGL2HrWffwQ21y1xLPc3s8cuVk8kNGFHQg9Qa6fxFa6dBeW+nXMko22xl8uHkhjxgt2FcPa+LYLBI7PEt5Or/ADpboWVedvX+ldXwrQilepsjWtX0HUtVhu/EMRuYo1ZVUZ65GEbvjrVzT/hv4cg1VvEYw4DNJBbR8IHPIBHce1chc36XtzJdWsVubeGTc6Ku11U45I6Eda7rVtY0Gx0m2hN3/Z7kgI+0mNW29N3rUSd3ZXHKE4vQ8613xPqmizzQW5gtFgYsIlg/1inrhRjGPwo06PUfEN3J4l0fU5LWN08l7J5CEDAAEAj165x1rY1C2g124VLp4NQgyXScLtwfqOQareLr638IaBCul2YhuOAmwnC+59aNHpHc1c00klZnGax8NbvU9beLQXd5zh5opG6EjLFT3ArQs/EVh4Otv7NvbifVLyP5R5J2omP4cmtH4M+INQ1Lx3bPfBplUMGmCnAGOh/OuEn1v7P49vZNY0KC6iNzIsls0bBl+YgNj1HX3pXabuEkk+WR7B4I1+bVJbp9RuLIaPNCY5Tjakcp+5Ejn/WMOCxAwOKytTs1WWGaJ3hlM8iiR03SDAAxn/vqtXxNplneaM0100VrpttGj25aMrLlRnbGBwuSQSO/4VuXOhXtv4IW4MAEnlGd0lXdJ13ZA67sU09L9zO8U7rQ8b8Y3ElvqR02zuWkR28x5V4Yjj16c1jJrc+iGKTT9VvluTLhwshAGM5JweTnFbvjvT4Yb8SRrOsEkYSZ2OSucNu9cZrjxPNBqguLeKNY4l3AAhlYf5/Gspto9iioyp+Z6Xp2vyaqhu5LW0V1zFOEB3NIRkOV77h3+tdXJqFrDZ2MlnEq3EUgcup4Zf7ua8t0G7eLULi/to1ZxDGD8vyu+cnHvjvXXNqcJuYhJIgd1KqAANnGTmrhqzhxNO3wnqmjm21jU7W6sI2aZHBZCCCvrmuYPgODw38T59V1CLz9GfM1vGuMoScspycDB6exp/gnUr7TdTGrzW0620v7supHzDP3sV3Hxk8QeDk8JW1t4j81orpv3LwKHIcdQT9OtN3UuVbNHAm4ysup0za5pGr2kdxdSR2YCYCzkbVX+VcxPot/q3iW3uNJmhbTY4zIWjbk7j0J9scVT8C2Gk6f4aN4pi1LTon+0RBWUjDKOCBxnIyRjH41r6RP4i1qKWXQZINEsGcycwD8gCP1qY+6nyvTzMpWjJpGr4vsr9PDsy2UTz3CqE2qM4/xrwCTxLr3hu8WPxBHcJYElU3qQBz1+te82V54sNshuZLJpVyJfK++Gx3FeWfELXrTxDcpZ+I72CDyMqyd8juKqmtOVpNG2Hlumr3L1r4906a0VLa7jlmC7+W2k4/z0oPiSw06JNRvbgxTOzcSSBZWz2jbsOlZvg/wX4ZKvfaVdm5tEYK2fvZOM4pnxT8FW1zbRXy3jyW0Chlt9nK89m/pShGF+UqXKpWZva1NY+JdHjsbW4kje+XdLI74Kr2wTyM9M+9cDN8GYNJhFzq97HDalsbnYMM+9dFLZRadp1ja2sUk94QJ5XLlXETZO3HfHqKIb3Q2vLiXVtDuGWABY4TKZcsDncPQkdfpV37bDjCSTcdjY8ITRpp8ttoenarqdvENoeFFSJcdSjEiqXibw1fazJHdXXhy+ciFcvK8bySLyBwp+vFWJviG1pYTCzmt/IaMkBCsfkKeFGB15qL4efE0TXtrp2sxzxyfZxHGGi2K+P4ge+AKi8ldpDVKa95Ht1lPayBhaxLGWfEgTgE/SmzxODMsMbOUHUD8qyLd/JuIp7aTAaXGWOE3c8/T1rdjnugtw+ozpA5HEaDI2+uTWL0ehwmfD8qLM5cSFvnDt3/yKvwXDW8iyRj2ZOcEVUk8yeOKKNss4+UsOAM9z+fNWkBEmwANtGd4PBpuwHQQyrNGroeGGaqazY22pabc2V6oa3uInhkHqrqVI/ImsqLzonBhdl9B1Hv9atG5mI/eiMMOTz/Oo5QufPH7IHhOXRNa8Z3+opi4sp/7HVscb0YtKPzEdfS9lc/aFbKhWU4IH6GsGwsLbTvtTWKCKO9ne8uQpzunYAN/6CKdcQ3OnO08M37s43gjJGfSmopiuX/E+jWmt6TcWl5GrKy8PtBZD6r6GvlbX9AbTNdv5NHvbj+0VIBhbG1+u7j24/Ovq2SZpdKkeddpYHbnj6V4N4m0C4s9QGrWkwaKZt0iPksxJ6DHTpXpZdV5OaLZnNc2wpll0zRG1TW0Y3Me1UtpOV3fT681hQ+Nb25keC7tojbPIMCVvn3DsO4+tb8usWmoWsa30XkzRKAol53A8Fl7GqcCaDdSTwr4htLK1GTNMFRpWJHAjJ5Bp1JpatHZQiuquzsvCmt6XqOmR2cF2ttfJHuVJOdoJwDjvz1rl7u2aw8RQ3GrTSajZAMJXdy7MeSDwOAOwHGK2vCXh62Zbeey1WO8mVt8aBAgBwevJ65rttR02yurVF1WGGK4EbSYij2uw9MjnPFcsakU7dAlJU5O3U5i0mkFsr2QzYyDlA2Rt9s/yrhPGXirQNA1htPuzfW99IVLD7NmJ0I42tu5HYnFdzrOjw6XZ7mvJwsittJkKggjPB9R0zXnmsXul+CLnQrm00VtTS/YxrPcyCU2YU5PVTx8xbPXAPNatKS06k05Lc6OzhcXjX+n3kYh3Ltj3BgeMHH4+lU9Y8PaF4ou5ftNvcCZuJntv4yOcHGM/WmeCvHOm+NNfv7XTiT9nXzhHJCIYpIxgM4wcgdOPeungvdTj1a1ullttO0y2LSyRogLzcfKuf5j0qVaO241KV77HIeBPFWpQotteojWLYt7ZHQny1IwEHbGBjPWurhUeILSWyvLcWIs5GhitYFLEgYK9ePSsrTb7SLbVNQ1C8XT7DNwZ5Wzl1HXO3oB/U1b1bxtp9r4P1/xRok8Ei2UUhEsf3nuXHlxZXt8zLwewq5SVO7sRU97VLQ4WHxeui+L9Z1jT7M3txeXI8O6TDE3WG2CmVlx2eVkYH/e/D2H7RfGFBPeRW0RYNKvkBpJDjJTcScAH+Vc14J8G6Ro2g6GivA/iHTbI25Ytv8AKndjJMCP4SGdhnrgAe1buqm9ubGEAKsqHfvJB56HcPpnHPBrjlKUUrIuCjLQ5r4hXIi8Ba5KI4Ud9MvA0giwxDRsnHpksPzNcTpXiu38MeJtMh1Cy86KO0srSEyLuCOttEvGeCF24z685rovipJDafDHxP5FxI22yAbfzt33ES4B7jDgfjVbXPBltH4ivD/aLRSMf3kTwiUxoMRlUORznjvWaqL7R0UYU3NqW1h3xfn1jVvCsGoeD7yTVLia5Cy2sdth1Vc5wg64YDNP8BRa7L4VibVLWTT70SEzWcluS7gHBYhvXiug8CW0ekRLZ2ME6waa/wDo80h6oQSWI7nkg1bl1Vr27munlQs4MkTQMRtAHGQe3HJFbU6jktdkYyg4txWx554k8B6D4X0291zVZdV1K3MgmNnbsqEE/wB4kZ6n8K2fhT8VD4kgl0Gy0QaXbRR+Vb+S5x/wI9z3962odM1TX9VuLGUJBGsxlHmfOk6kDGAPcE807wp4dutMv729NpaWkVjJ5O2Js/aHJz5g9ODjFdM4Qau3dmTrOS5Z6mH4j8vRrDV4ZZ3a9WE7Z35ck9yR7GuasvDNpY+HVuLy+t5AkbGL7IXQsr8Asemeep6V6J430eG8me5KoYtvltGGzvyOdvqfavH/ABH4euLbULC2j1O4+wagRaypM/l7UXBCnPvj8qyk+dXTPSwlSK06sopPpdneWWk2OoPLbIjtcSKN6oWJO3cANwxjntXcjRl1rSUFqiS3aRYbecqyZ+V09GGME/SuW8R+HNT0nxDfQ2iWtpoiwxNDJuDQTkAHhjzknOfoa774SW9w0dyJEjjgb5oplbIDHkgf7HFZKWnMjbFNRSmmcv4e8J6voviJrpppDb7fMZTIHVtw+6R65PNdtcR6DrttcW155S/Z0zMepRQOa6jVPDwmlv7J9Qjs5LqEOjkjCtjhlFcl4D+FM/h77c+s6mt+NRTawBPze2fXmm5RfvN6nBKrzayJfhvrngiSMQ+FYQmoQNxE6487B6n2q54817QtP1a3N3G0c9w+7MCg7Omd/tz2rF8CfDP+xvEFxPa24jXzNqvOSwVfwxXReINHsdQ1JZWFvJqtvIYGmCciPpjB6/WrgocztqZz5VO4/UkjuorWSK0S6sLO5jnEUzAtIB1C9jjqM1veJJjcI0kDSKzKTy2wqo5+grkdaEqWaTQwvPa2txtuHXgBcc7h2FaErnUdFe4tJlzt2I78A85Kn14qnHaxnFW1OT1yzbVVLRaTHJvBEjlgoweoB9TnIrkvD/gSPV45pl08RxQsY5BMGSQFR27HI/WvaNL0hZfLuYNhWXG/GSAo54B47VuXJtIDNNK5EY+9kcZHfH9aycr6I6I4hw0ieN6X4KvNZeCFY/JhhlaJT5YQeXtxkr39Pxqz/wAKmlhdpbm+hEO5V2xx7cgEjHJ4GKmvvjRp9pqNxaWtkLmBh5cRjJV1I612XhjVD4sihu12xWkS8RlsbmB6c8mrtOGr0QTqVN2bNnptqujwQRwCSK2A2A4OMDoK4Pxr4Xt/GmmXESIY0aTd8iZ8txwCPSu18cyraeFhG91JazySgRMkZYIM/ebHasLSdcXTYW0y3na6vWUMibuJFPcnHFXTTUbo5Xfc5/4d+FbzwvoBsdTmRrWWX98wJX5OoyfTIH516p/wlGlaZp32PTZo7+5lwkcEDbjnHT2x6k4rHtZTbSNJJALT91taIneGz3+tZUFnb2i3StbRreOpJeEBFUdRj0NRKMXqytZvU5jW/jBFpms3VrfQvpzDKNGW3s7Dgknt6Z9q4j/hFbjxTrh1qC4jm+1MHiSbOD3wGHGfaqPjPwxaeMtcuLrShKtxgK3zYDNnBJ/H867X4W+JNG0TT4/DWp39u17BL5cQLEjcOuOx5pyly/CjsinSXNHcsJ428P8AhmNPC6XQjvU+admhwu7PKk9c1qXGu2N2x+3x+VZlRDBdBco6t7+mfWud8U+CPDmu+L5728Mtve7908a8K3ofbPWt6+sIPDGgoLOV7qYSr9mtEXJkAPJJ6DHqaS5U7Ldmbanq92aOrWN1c2AgtI44b+3hMRJXkDqBn+6e1efaubq1s57czO8wBEk0a8HkZyR7Z5rsrTW7zVJfN1D7TZs+5VYuO33gHHceh44rmZNV8L3hmskvZpb0SEC4hbaZD6N2b/61C0NKcpR0kcN4rsLGa3itbWxuI754/OkMbBoWUEkgN3bH4Vo2k/8Aa0+hafoCojRPD/pE2TKmCRtLYHA9K7n/AIRSF/KksdYtURss0E5IGRyDj+dQjTls7lZIZLSXU1Y4ltf3arkfNx0YdKS1eh0vFRUWrHvJnsrV3juyj2aMoIcZEfORirF7qNjMmEilLISOVPA9fp0qnLbLdL5cisjYJUjAyfr6VDJKWLNeW8su6MxI4I+VvU+vTrWVkeKy5GRLCGikRcsEO05J4ztAqaNRb7XaZ1EuV2+uOxrn7SaC0160uLjztpHkiQqdgPUkfyrSu3F5NdSQTOpgciNCMA+nHU5pta2A1NjPKDFOfLVQQqHkfn/Km75CBFOEVGb5wPvH2Peqdjbiy3EZnZm3SFztJPp+FaUkYmZZkgYMobAAycn3qdgIdNsEhnZrR2wzFm3nIX6VtSW0U0YWZA4HOD0zWVYtN5aA5V0JO04yRV+a6eMY2jd9eal3bBaFLVMRQeTEWk2j7rN1J7V5X8ZVubfwLeJZs67mjaUopDpEXAfBHPQ/kTXpckmSz9cd89T6VyvxOlbT/CN1qcjlp0jKANzjdj06+tdVD44pBF8slJniXw60E6vLq9xAY7Wwj+S2jcnrgbiM9ATn+dPsfhFqt4ohSREkaRnSSRCCyH+6Rwa6zwjqE+i6PLMumLezXc6qsuPm5yCwB4AGO9d/omuJrFuLGV540iGxbm2VQCeRkdeQQRWtec4uy2R1QrVEnUj1PLNcmtvhzZwaXZ2Mt1q/BluJCSVboNoHU9eK7GLxmfD/AIcOq+MLWaC3MflRXLH55X6gBeoPrisLXNZt/DOtR2em6O/2zfn+0NTLTO47uhxgEZ6UzXrTQ9e8LwQeL7q8u9RWVrhLZ5QsiA8D7vAGO3vWMrOyaLlT5knLqavh34j2XjqzvY3hjVoDiJRGC7ehPauV8TePIdG0BPtOlm703VJZtNvZBJteJMY+QDv97H0rO8O6rYaVb6pbeE9Hms7gphZHGd+O2T+P5VvXujeH9f8AAVrY30Vy8Fu3mTSWy/v1dQWOF7k9PxrVR91pIzqU1Tkk0U7Pwz4d+Hljc6hYSXVzLJEENxO3zbW5CKB2zj3rX07UX8RaBfTSo1oqboDxlkwNzYHqR3rn/EurWvirw415o1neW8di4UxXPGQoA/HgjPpWj8MbeQeE573UGSRZrtnYRDbtCp90D3x+NJPkjd7lypJw5nvc4HTfDumarq73eq6pYabYXDhfs1zdESzRE5LJxz0/Ou11rRtBh1jwv4a8NQqukyXD6/fjDHzI7YFIw2eSHl3L9cGuLt9M0HxT41tI7SzlsXuJzCI45AAwPqDkAn2rs9PuXuNU8W+IdNQMHuU0XTdoyDBahd5HtJIUbJ9GpVHKpJRfUMSnGy/A9CsLqG1lPzyy38pDTyycxtjnOQMZ5NYnxK1xtI8Fai2jx+deysEMjPlcN1x7+1alq1tdXWmSTzxR3n2ViIgMovru/HgGo7y1sdW0E3N4bWZydxsIwNxXpj1/EVryq6uccZWldnlF/ql1rPwgvLa+lWWe7ktLUxbArH/SozgntnbX0NdW8GsLeD7MUj81iHbBV2zzx+deKa/4dNjpejugiNrqviXTbS3RXJZlMkjEN2Gdo9+K67S/FNp4g1J0XUbYQQv5kI8wKJTn0PUk1yeyUpPsjWcuZ80UdVHrOlRarJpVvKypH/o8jbQqu2Ox7gf1rzr4yTR2+iCLw1aTW9zdPskmiyfNj77ewGeDW3peladfau6nUWmmmd7qJGXYBnBBx3wfT0q7a21jqlzLFrNwWWxZrYW5babgthgTnkVdJKEvJFaQakLpE9/Y6LYPr5u2me3SIi3AxF7se2a53R0vbTWTdau9zHo0sxTyAc4ZvusMfrVrxBqnyNa2t7LFJbKzTRQuzpAvI2knrx3ryW+8a31xctbBCtm7YRZHYTMo6Nx8v4YrshT5Y69TOFOdaTcEami6l4m8JfEnULaytbi/0i9uybmGWFpI5oi+VkGRhSAcZ4rX0HxZpHxC8Qt4dvbH+xpZJGW2mZ/MRXUE4IOCnTqDWh4c19tM0mbTnieVpCZPNbkgN/ePb6H0rpYx4avNds9VgazstZt4gEdwrByDzkjrnnntXNUg7uSXzN1U11Wxi/8ACs7i21RE8TXt1JaDaLbaGeCQZ4yF6f8AAvWvUvDWiafpWkSy8xW65LySLtCDpxntxXTT+J9Ht7BbvUby2twqhhvkHX0HrXmmuandeNNbYCTb4btgGfy+XmyMlQO/QVlGMqivLRIznWlPRnkvxbttU8T+J7i60qaW+sI4xFAyPjCKOePrXb/DDxJer4ebStfS/jURgKTbszBOxVhXKeIfj1bWOsJa6L4VtoIbd1Um8UI7r3zjofcmve7nxZ4Yg0e0uru4isjcxiRA3ocdD3HpWlSTdouJcqrcOVo8c+IniXxdoNtCdJtGWzjQPLO4AlceuO3b8a83t/ifr17dR3Ed7LZuGICrEHGT3YkZNfUPildO8TadZta3sDRwMJl2txICPuuv93BrxyX4cW9h4rudY0l0KxyKI7UodobAJwD1H5042cdFYqjVgviVzobrVNeuvC4TWNPFpC0QLNAcblPG9gepyc1yUnxBh8B6q9vNE+o2jeXJAo+UFSPmPscj8RXsssO/T1g1dYpJGC4C8qMjoQa8z8aaXoB1u3Z7OS+eMHIdgI0QDOSTk+vQURacbNaE0uWbatubfhf4iaf4p1hjYaHd2liAWdUcJvY9GAz+ldTqVwdU3LY6e7W+wq8l9ciNiO+FUE47c1xPga/0O88PT3VnZrY38UphaJm8wxY75HBz2pl5rEtrHNeXJluYERgqodqsf6gZ5pKKvpoKUG5WSsYmq/D7S9Bgk8Q3NtBcRId62cTttxnpnqTVAfF7UI5bW1sPDcCTbQlvAFx8o6D/AOtR4K8ay6xq0drraLdWrMUSKIfcY8LnPUZx+dXvEvh9P7cnkihurKKTAlkIIa2kHU8cjI6dsGqnK7tPVnVTo62qHTWvxJuLm3OleOtKhsTcQNJHJMqvGUxnAdTwfrXnl5qq6p4Tu5/h9JcG6gYSXMO3Myxc4IHORn0rG1mxvbjTJdPsrgXMXlrFwCoXB3Hdu/iPt1ql8Ib7/hHNcu0tFlTW/uxAn5RtPKsO+azXur3SqlBQd47HrP7N/iTXfFV3rGja+JLi2SASCeWMAwsCBtPHf09jXRX2o2Oj3NzYy7p4pIvKZghwWBI4/D0qeX4oStpkssWmwafqUmEllBBBI9QcH8+lcgIDez215Y6hDLIrfvYEb7ozk5P50Ri7NzON+/PTQz4Uex1yGOyjY2rsSr4+6PQ/jXnvxC8GTWfiyC/0qIrAXEsjIchWz1A+vavoO0eyktW89RHcD7q4/h9TUOm2tvPCVjaG6K4lWOdMjHQ5/PioU7vVG8p336HB+K/D2p69o6GC8jtr1oRKu7cjTED+8eprpPA+gQx+D4Gvr95dejHynduKg4yrLnBHvXQTvEX1GG+ja/s2ZDDCMNsyMHnr+VY0PiA2Ym060sVuLlBiOSPGIjnH7wjkYrW0pRt2MVN20KuteGobXw9c6ZFNqUN68JMRnj3KNzE5G319a8z034WaiLXUnspA2qW0SvAPuhyTyQc8YHrXsjXmqymB9Su7SUxR7dynZIM46H/GtPwtpeiXs1yst+66gm4gSuF3DHr0P4UuayKVWcUfPl1D458Nabapq8pkspGO1JCJmXAzz3A5r120j05vC6TZaK+az3GJ48YfGc89v6VfuNXm+wzz6pbLdRpIbe2mhiD5JBwWx27ZpFu306GO51WwjeZmOxwuyNVA79sU3dDcuZWaPUYEdTIXdnR3zhh6+h9Kr+as3mLA/kwxsQRt561BFfyTRRxrIiFeST9KuuWFv5rhCuMggYyR1rG1tzj3IBidJIhEzW4UqrNwc9iKk027isrsnVmKkYWGRhyV68+pzV6zlhk2mFUYMgw4B4PuKS2svPSP7X5cnksX+fvzwRSb7jLEs1xfIHtYYymMHccMvpxSafdfZsxzIxU/d2jP4VopPbi3aYFArcEqepqhfrHbxh1344Cjd0qFroAFcu8ke9I+3tUMu2NXY8/7VTrBcqhbCbsbiC2aoXhBUlVG/wDz2q46iI5pivMb4wMjuPxrzj4vavJc+FhY3Ss1u0uJmUgMp/hx6etdpK054BRB0IYfMa8u+I1mmpm9sWkEFqUAklZc7T2I9xXdhYr2ib6EO7J/CIbxHpd1anehsGjjgmbhXK87vfpW1FJa+CPDeoXdywuntnLstsCqlic7FHpk9a5X4Saha2GiSWUkqNfW85RF3HeY+xYGu31C7s7x73TZ7MTi9ix8hIwSuMn+dGLjy1WmtDooNuKi9jya5+Ktz4g12K2ltm06PooR8hT3JIGTW7daXExaVFhknZQRJnqcY71zUHw3m07X3N+8gtBHhWPBK+x+tbFrazRTGK5ubdrNWCxOykkg/d46ZrFtP4TvnGMbcgC31ldXijuRa+RvSMSEENtAzz6d6l8W6rcw+XqPhIvbiBmS4iaLAnOAA2D3469a5PUfGz6BdS2tsqXjROY5Jp5TtYnso7Vb8L+Ll8Ragmn6hbQJPKw2kAlHI6Yx3qopwd2OcZSSk1oj0Sw8Qajq+jFtdtowDbMqW1ugyzk44xzggck+taHh+C50vw3a6dJbw26zhpIgxBIHO3d/KpdRvU0/RdZltrBkbS4PMkWQ7VOF3AA9TXgWg+J9cvNd/wCEo1eeS5CN9ntbdjtEhwTtRemF4z9aIRUo2Ry8vOzqNO0Y+C7PW/FWoSKl7p9vI1jEnzM1xJ+7SQnv8zggDsCe1dXaavonhfwz4b8E3dzFbalaAKylSWlncnzOegHmM4yeoFYl/qkmv6j4dt7wf6IJZNfuI2wB5FtlIFI/uvMXU/gfokXw9sdTvFu7vV47nX7dnktjCd4mkOWTeD0we1SmlNylrYU06rcpu1juri1i0vS9Rvrq3aZzGU2MMKCBxk+mTWZ8UvFFxongGwee3s3v2kWFo9uFiUjORg59B+NeRy6d4svvELQXov3uEfM7KxOc/eHXGK9b8deFNH1fQtOs9Y1SS2Zf30ZaVd2e5bPbHQVvdaX1ZMqKpSTvdHJWeo2uqDwhNYXGIW8Q2crR84hkgjmZjz6bwff3xUXhXwN4ZvIY57HxRbyMq4lRlO5DjBIx15qxp/h+ytNY8G6b4enM8d3falNHNM4Ys8Vkp3NjgBS3TuPWuZ1Pwr4o8Hzl7eFvtMiFI47ePzFYH0x9c1yWfO9bHVQak5crseuyeKvC2iW+k+HdQuzPJZqkjTBSDgHAII5zz+lZsviXS1vrya2eW6tHm/cSSJ88nu3fHYH0FeW2+l6haX1ubq3livrlCCl3bNv3Y+Zsnr/SvU/DmgWuk+ELa9hiS5FywVvMzuRuST9Pb2rpgoqz7mNenCmrKV2Xri7l1WaKHV4IbG0BEyxxyBhI3TMjDr/umr118PtE8QfbrzS7eCK8tkLR7WGJGIyHI7c9qTSrbTb3VbYa0Rb2DqHhBwFkZTyR9OOtd+G0rSxJHBbI0wClXi5Lj3xUVm9FH/gHNCo4bOx4fDpFtPbx2lvI1vcqUtwmCJ5Xc4II7Kpy27vz2rDl+F/iG58WLfpfWjWsc5XzA+CqD/Zx3r6Lv9OimikvRLaWtwBtyigOwHYk1xENvc6nPLb6M8SQ7izyuTksD0A9/wAqUJPlbTsbPEtvQv6L4P0S5SOfxRc2ZlwB5XmL82DxXJfEvWb/AE/xra2fhKOGLTbcL5vljIlfGApPoM9q8x8XaB4kOrXt5IjXUocuzo4+6DgFe2B04r2H4QaXc3HhhpdZ8qe6SYgxkDfEuARn+dE3ye83ctU1TXO2n5Gvpnwz0bxTtu9ftIDKyhvKMYLDnP3j71y37QlhpsJ0y3luREIAY4YWxl0xz7fT6V7SdQi0+0VGYNOFIjK9cY9K8e8deFJfFt9bvLfmOSCcx/aWgEuzfgcKMDjnB+tZUE7ucnsYxmvaK+xwvhT4k+GdPsEtLrTbo73ZJLl23Mo42kfl07V6l4ZVfEeqIIp+IbYTRS5BYqTx04rw74c2E3/CzLjwhqOm/atONxJFdyzwYkRE3bXDfwg8cD1r1/T/AAlb+D/FEj6VqTxabKOYI23tk87QeuPX61fNq4x3Na6pPVaM6Z7a4sp7i8nRrg58tGk52nOOnp71yvinwvfapPaaomk3MbRM6LNEisoiYfMCjYwcjIPSul8WWlxf3WjSQ3j2ltG/71A2DIOueOvStXU9UguLOe31W8CaeiqQjtsMjehPHy8fjS5npYxjNxfNHc8b1jQbXwtpOpTaWbqUXIQzi5Tad+cD7uAAM5rg7p90QNpPcXEiXDW0ykkfPj+FehB5FfRNxdnVro2UK2rWyweazJiVSh6dP1rjX8NaTorNqxEj2yuS0ZX5UOfvDJ4/Wq5mlbqduHxCV+damZpHw3u4J4LqG3Q2cqEsiPiRGGDzWf4i0x1NzPPPcRXhO1dsp3cccnOa6hfiVpep38Wnadcrp4QlVnn3Pv45UKv9Tmr+qWGl6pGDfapuM3yRGG2MXPuST/KoUZx+MTrvmvNHiK2d1NepbWsIlvch/myzDB7E8V6fqvhi2g8Mahr32KO38SiEBsS/e9So6ZrY8P8Aw1gDfa4XuQHkINy0pPI7j09KoTeCr6DVri4fU3eF3MflM5OU3f5NGkpXvsVUxMZ6LQ8I02y1jxDA9v8AaWVvMwEcnc5z0r1Pwfotn4G0CDUtT1yytlu2ZSLgn5mHYAc8d/Su9bRPD2nWsdmlrHcOMu8YXcWPcnHP51wXjm38Palrtlp/iezljisV4EdysSqjc4P6e9W5Sn6Gcnzq0TAsrTW/FutXv/CO3cV+gY7HS5wAPQjt+NdN4Q0LxjBeyW1281jCG2ys77uR2BHODTvBF/4J0nUnXwtetF5R3yRqp5xkElmPNdfo/wARNMzebNUa7mllLLG8a4A6AAqTmpbm72QOtLl5bGRd3lzpE3lQtby33mbVWIny0Ax82etcJeeOLnR9R1W5srWAX0ylc9i3d/c127faLZ/9JFtFNPcSSQqxG5kyT8o6nHSvI9est/iC8uyHaORtxyPu84q3JNF4ekpO0jFk8Wa7f3f27UryaZ84IxhfpgV6R8Ndc/tHU7iz1aBJbSeLESNyAe349q4n+xlUxt5mIWbIVucHHpXV+GYBb3CrYwmS8dtiRocAN656Y6Vnd2szqqQpqFkdFZm8treeO1e0+zpIWmiJKEgEYGc8/lUPxU1afW9KhOmRXMUNouHU5w3TJC9/rVzw94Ku7jVdRHiEtbTdSpk+UsfT2rN1i4uLBrq3jtvsscJEJld92cHsMc007yujFcnMrHtnhu4h1OyhuYnMZIJOOQSOCa6aKDdCk25z5JHyj371494K1yFtXdbK6jnsCBhE4CrngkY6scmvbIpkGnW5n2gNztU8n0pV4uE7I8jbRkAcS+ei58xiASeBjsfaprPyiiJckhIwMf7R9apyT7VbyDh8k5I5Oe1NjnYxNGY8gnO8jkev4VlZhcvS20Ky+bFK2zjjbwGH8X1puZC8e52cR4YK3O7nv+dNeRRF5S46ccd/Q1antAGtZEOYv4ypyff8KVxiGRwJGBy2MYzx+FUr0SRDzDjdxlCMhMd61LkxrJNvZUKYCLjA6d6oTvvDMq5hXGWPc+3qKcWJmJcsYy8m3BJ3Zb/CvNfiDqD3kVza74woGfkGW3Y64r07U5AsEm8AsTxXh3jLV9MXxSbf7VDG6ozSKpJdD79q9LBx5pXtsRc5f4eTNB4W8Ta/d3Li/R2VGIwZOOgz+Fdp8GtQ1G/0OefWZcKX3ROyHcw78+lcY2k3mq+H4DBptykdzOFSVOVKA/fC9s0vjnXdc0n7Pplg81nYQx7VMf3mboSSOlPGN1JtX/pHpYaknTSXU9u8T69beG/DR1HVoVvLeQBYYxJzI56AD8K8y0n4ieGvEMj2V/ob6eXceXLBdHcCOmRj9a1PAVpN4o8Fra6/KZWkuMGK6UqIlA+VlPUN3yK4XxV4f0bw5r040157gWjolxOG8wx7xww46DjPeuFJarqb0qcdYvf8CTxx4DvJ5DqltbC9sywZ/LwGbjAY47mtj4ZeEroatHqt9BHbW9qpEUCDJ3etd98NUubvTs3rIHtpmgA+7vUqrBiO3BrsbyDRdN0S6M15DdyHKmO3fG0EjPAOSfepu27WIqV5Ri6Z5D4p8NWVz8SLK91HXfJml2lrR8kyBc/KBnGD0/Ot9vCTy38FvpmnRS2cTbmUrhSXzwpH3fwq3a6BoM91NrWnNEYrcNLd39xkhIwOVXOenfFcj8S/jHqPhjStEXwZDbx2F/Bdo73CFncrIYxICCCGBDEc4z2rapVcVp00ORtrVGx4N0u21rUPE+rxRQnTpb2PRrFG4BtbXAZl9Q8hD/VTXpWo+F9PaC3trQulyGxHHbnbtyPvbv8APeuA+AnjzSofhhp9vNp82mwWDizjllIkju5jl5GUgAjBbJGMDeoya5vxz8TNY/tC8XRJktI7aQruUgO3P3hkfKv+NZUeaWuw6VKpVfunqq+ErS0MyW9zPtt5lhleUksWIBL5HOMnFeKeOPhrfHxDf3VtqpuHV9zmVD36KG6e1eqeGtZ1K90K1S2u5pZ9SijaeaRQdjtjJHpxUuun7Bqw0eC4a6m81JyjjcEOMZyB0GO/rXRRk5SauTzzoNnm/g7QG0vxH4L065wxW21e7cKx+XzYI4c5Pc4x+VeoJaxwAOsswvEQG33tuc4PCknp+NcMZJ7b4gWZuUM0tn4aubllIChd175RJ7Y4x9BmsDUviXZQhoY7i7ZxukHloGUeik5zjjrRShzOTfciSnUlornX/FHxnJ4agtZdWhXUbiQsqqeFiBH8yO9UdT8T6KnhGCYs0BeLftRxtUkd/wD61W7DWvDPjyws4Nege5M8OQykkqVAyG9DSeKfBnh++0FdP+0iKa3R3jiILOePlxjgAd60Vo2jYqDimk9zH+Gmjf24VupbwzXHmsUguTuhSNv9k+o9Paux07wzN/aOp7rho1RwqG1LAqVHTaSR+PauF8D397Zg216XtrNQArKQxJHUZ6j1r1PTxZPFbGJ7ma2iiPzLKQNzNnkDk+9S5TTeoYlWkeTzX3iy68VtpthpM8miyHa3nfMWI6ncTxzXrVjo+mWlnaowmjnbKSOu5CmRyD61a1ONLHY1yAUVBIoiI+Zs/d/KsWy13TdPspW1HzypuC0FuW8x1B5Ck/qKzq1JzX+QoKMl7qOQ8Oa1rUmqeJtOvBbwLpPy20ssG4CPOUUqOoPqOldRq2rx3dnoN2tjjVrpTBOts2ZBgdx3XPfqKdd6zpsvipL/AEyR4Lx7by54JF2bh1B/+vWfrt7baL4a1XX9Mtyt7ZWbbZtoLrIxIVsHqAWqYO802jarFNaI2fEGvX1k1wsboLIOkZOAWC4+Yb+xyMc9M1zvgu5u4davo7k3v2JVMjRXEu4xzFsgKR1wOoya4f4eG+8H+CH/ALfuE2ahJ9pFvcnIUMO/uw5I+neul13xsbLTFn02CBVhjDFQn7skrntTgnLRbDatHltqzvIdS0+0c3ofzcSkskhJ2sRyc/lioprmxsHvfFOrtKumRLhNq8sxH9cAZ968v+HHxDfxNqM1rcaTbyTBDKqLxyP7o7+4rp/i0kWoaLoUNgZYrKZnM6YKjdjKhvfIIx70WV+XuZxpe+ovqVT45ttQ0+bWr13tLeNlSKJTyz9gM9gOTXn3xCvNV8aeKrB9Gmm1GKS1jESqpURvk7h6en4V1mgfDmXXPB7t/aL2k0UrXERkjDA8YwQetHjG1/4QH4fLpWmS775o3kuZ4SEaOSTAG3HIGM8Uc6btDc6UoU5e7qzO0/T9Y8CeHZbq71izO+Ty5IoZPMZPVWA7Z610b64PFWnpBa6vo07MgRrfJjd29ge9edfDAN4dUa1eAyyyA+VGYy+FwSWweOcVuReK/Cvi3xRY6fqPh6CTz5BG13bqIyCenIxmsvba2te3XQqpRfNzdfI0NA+GlrYXy6nrt1e2Z8zeivDmEMTgMX6c54r0G2mg0xoNQ0myF9bW7HfcXQZET/d3DBPuK0NDvovEVsdF0+3dbO1YRRlzvLKvfn8K5T45f8JBqGmnRbC1l/s21KveJCp8yRQMgj1Xv+FOL5naX9Iw1qStJnTaN4ruJ/taaZBHdRzFpIyjgqhIyeh7UpkuW00GURxlm3ZbLbH7+n1rwb4catJpt9OdLknjhZAmCn3z7+n1r3TxTq//AAjGjaLPq88JNyVU+YOhI5+lEnaVl1LqYdUpJLW5wnjDx3H4W12PTZLCQ20oBnunIZpQe6ntXOeKdF0bxJdw6hbLOYZxv354z3z6/wD1q6rXPDmk+Kme5sJVlQJnYWyG9lOe1V1fR7HTWtIZIE+zAvKgOCcdfw+lPmX2TZWitDh9Z8CW2m6HcT2vmwbMG4neQcZOAFHGQa5VvBdsl1EtrrIud+DshUhwT2r1XWrnSPEuitN4cuvtjWyjzbaUENGRnDAYGVPPPasO902O6n0y60m8jtmg5lhiiwWAxgMc5Jznio7XNo8s1qtSew0meys/tkBn1Gaw8vELsWfCtnj6c9PU1ma3rekXTSy2tq9rdTj5rfJyrE9B7V2Fla6Ra6oLvUDetKSp8i3l2c9+vvXb+H7vwVEkusHwk8bxtlZbkiViRznGTg0c9ujZyynNO55R4esVi1Bo/EOln7LMoCPPmPyiehyeBXST3ekRNbWegXqi5ebZ5KYwxHQbu3I61R+KN8mrjVLy3WQvcRgiIn5olHU4HBGK8Zge6gaG9sJZGntmDblHTBqtGrvc2hTlUjdnoV94x1mLVpz4ka4nmUNCbSSQxhCOnT655616O3h7wxqXw603XfDE4F4ir9oAkJ/eH7wdT3z0rNNnp/jPT0k13Tbq01qe2SYTWEJk89do2hj2P1ror3UdN8P+HYtK0rQI7S/dFV1fa8hxg72wcKfrS1k1bf8AAzqTirKOjOP8KaFI+gHURfm21ZYxtgXBEyA5GQOx9favZPBWpT6lprC4CGa32j5Wz8jDINeKeEPiTqfg+f8AsnxFpo8lvlY7QHjTHBX+8tejfDTVLGbW5WtnEcN5DsG37rlWJXj6V6GLw86cHdadGeU6rqycnueieaisAykknHrT1m+dc4GOlWLPTnu3bY3lohxux3ovdOuLVd0m2SLvIvBH1rzLxvYEmIp346f0qazuJIN0YPyNzjuDWepaNgQfk9OtW42LHdncKGh30HG4tzcEupkkY7hvySM0FfkCurkcnDcKakTaCdqrzjJ606QswLInX7249qED7mHqbnYSy8vxwO3tXkvjbwxpxuH1WG1RrxgyGJesgIIyT2r0Px7De3WiXkWmFo5n4GDyQOoB7ZFfMk/iLVPDusS3FkZY5+Y5Uc5L8cjBz69fyr0MM3HVM2pUHUi2nsdV4f8AHc3hwQ2M8CvDEgQASH5PUA16nolrpvj2xkuLGKKC2jI378F93oR2B9a8U1nRbvxNqNrbxvGgu4Rc4iXAhXHPPc1g6XL4v8D63cnSnupI2G1m2ny3XsSO1ehWwtKtHmg7TOeFWpGVj3LWtdmi1gaFpGi6jdrDiB54mCQo/csxHQA9qi07RdP1bUr+9mE8EsB8m8EMgwJEIzuPQ8EciuC0PxZfy3F1Pc2S3M1zt3gSkFMdQilgMk9c16tpz2d5pEmnaDLNsJL3MzvucytgkEjj2/DFeXWw06Ts1ZHoKtDl/dvUx4dVjs7+w0rRtNWz015TI1wZC0hUnl2J5JJz19q9IttJ0h0+x2Vu1y06/vpJMAAHI9OtYUXh6MxxzXcpSWFVU+RgGTJ6Z9h3qe71+Kx1iDT9NtprPYgbczbjJ75PeuZvm0iRJc3wmxq2nf2Z4U1GxstJF01rb74raJgDOGyPL54xxznPFfNvxS8Oah4z8c+BtBtLKGwml0jzZdkeyO2i+0z7mKjoFVc/7RPHJFezr43u49bS2uVIR32SFmLOSeh/+tVrxXdafo+oHULSFX1W8tI7aWQkHCISyxj0G5st64HpUTTty9yVCb919Saz0rTND0TT9KtII7ayswsNsJVBY9ckn+8zEsT6ntWLLpPh+41GWa6s7Oa6UEEug3EDHOD1x61w2meJNZtdagh1SSGQhiohXDN83fj39a9LltNBn02LWb4u+sWIfBI2Bxg/J9D7UowlexvUj7LRuwzU57VdOhk00KFikB8yPAGUw3P5Vl2v9oan4jm1ScPBbSW7N+6wZJlCllCg4GCRgVXtLAa3bQ3t7cCG2bLbVTZCox0C/eY/pXK32p3EvjrTIfDv2m4mtLiGUAShQVVwWLe2BjHQV2U4+zTSepz8ntX5GHpfxd8J3XxHm1G90rV59NuNFXRorfyY5HZjceady7wCpJ9Sfavd5Pgp4Fu32/2LPbgEk+VcyKCe4xuPFfNnww8FRRftE3VhdqF0zw9fTXcjHpsikxD9cu0XHoa+p9V8ZSW2stFp9nJOrR72KnO05xgj+tcdNVJ3syI1JU/hZLZ/D7w1o+im30rSIIwDy7Zd8jvvbJrH1LS47O0Zg4Mcaszqi7mIA6L6msSH4hahr89ylvqtnp6W7lZIIVE8jsOMEjoPoDUdhqGqQGFrmWOSBpCQWjO5x/TpXVClOC1ZMpNu8iKLSbJJob2KGU28jeakEkJV92Oh+gz+NdH4eijuL2W1soRhGxMG4UbucZ9ax/EV5PJOwWGcssZlIj9B1wPyH4102g3mjTeG7eHTdSiN3IwlKBsOzHG5T7j+lXNOMb9WS5ObuzP1zRLi4hvbaH/RrqyIktpEkOWPUH6dq47UNPk1mNDbZtrnYT5ipyj4wQwPU55BrvNYv4dHs7jypZBnczXMnJIH8I/+vXG6P4k0h3vFDyLdxfOUu0K5zzkHp1rNuTjc6KCa96JzcHhbU7e8S41O5cQQRrsyoV/9piRwD146VleKvE2k3djLpWy5ntZpEErRDujZCjsRkc16R4i1OO4tbVLbyVa9DRo04ygOOhHueleJ2ug3Oow37zwONOF00MW5tj7gQpO3pt3HHXilF2V5HZC9V3mR+O9QTxPpLmOORZTJ+6JIy2DjG3tXXfDrRotP8KRt4u0+RracG32k4KkkEMe9Q6NomiaDBby6vcoLxS0UqkBwpyOgz6fzr17VZdKn8O6Ybr/SI7VRICGGAuMAHHfBFTzXaitia3LFLkR5XF8M5NC8WWuq+GJnaCE5UTsEG49Ae5Br0rxLbzWvga0udaayW+8wO63Pyxgk5PPU47UkHibRnuoonVfMALwlG3KxB4PsR71xPxktdV8daNYXPh8TXBs3d5rUjEgJ4BHrj096EnzLmMOaVWaUtCxb+PbO5vI4tPRTacRh4/mBkzzgdh7GvNPjjZRP4tg1LSJLyHUr9BI687ZQMDd+n04rY8DabL4R8IalPr9sy3E8oEUTp/F0HNa/hzxRZ6tpE9pd2tuk20Is8g/1a7sld3YH0pqSV7LTY19jaXMtjkrjSr27hxbSI09zbbUAJVlYjBJPp7Ck8HeEb7RbqK9urf8A00Mot4Ad+D0LsR0A7D1rvbHwwlrqDyyWubB3DoiybwnAyQfr0FdzF4esLspNFI4eMhg6OMjjv6isUoplzxDinEwtB8baJ4O1m10uWe0gmji3XTyNtAJ5xnpXUW3jjw345m1C3sWMt5ZR5aaEnG09MHvzXIeIfhHaeIre4uoQkksJBJHLsSOcnuPauO8DWun+FL/UEhu5YJ8iKdZcB8Kegx71o4ResdzJKE1e+pD8TfEEuiSfZ/DUFsvklTKWjG727CuH1Hxfrfi+Aab4quDh13WxZdgVu3tg9M16P8U/Cr+KIbbUfD45Ub7yFWwzjsR24rzqOz1GfUbexSzDwoVEaSLuHHUlh3pJp2cTupU4yjd7o1Phza6joMmoQ6pDK8AhJERb5Sx7j/61RWEn9o3T2FzaFFMZxtHzHPUGvZls7az0ma5uoI7u5W3J8hSSd2MBfx/pXijf8JFo2qtLPGYriPLIgGRg84Ipwd02TTkpNpI39D+Hk2h3b3gvZRdPG0dvAFwWDDoT+VZF/qh0vVrmLV9LmNzINkh3lTgd8gfjmvVfh/4hudXwNStXhuAMbHIA6dV9RXR3t21tbXUkVsJ44o2Z9qhlOBwNuORSTadmjBVnCT0PFrTxOosbeUWhd5f3biVt8jHP94dq0HmuhYStbxyzW8jMZET5d+BkKPT6+1dRb+GU1HVbe8t7OJPs2Lj7OjZVw4yOP7uc4re8S6hPomi6i9lDDJIZ1CW5QHqB0Iob1tEt1I2TseUaRBYalZ3ButRl0q4hVcwXA2jdnkHjkYPb0qja3y6Lqkc1jb28l2sqYLLlJST/AHfSr+vSrfWDW0oKall5JYyPu4GcD3P1rN8B6PNrl0/lo4m05TcSStxj2x68dKqys2zoU1JXvY9Gn1jWNJjljbT5llum89pIQTGyngKMdMdMGse6RdSuLSbV9VurG4imEwhhi2GXGDhmPHFYf/CW69qV/cafFCDbwMVkDYycdT9aSC/udVZpJZX8pFJWOXPr1HvxVJ2Vjl+rte8z0f42eBRe6Xe3Vo7mTTozcwSZHMZIzGfxyRVf4Q6Fd6emnO0q4cCdVJJ2E8FcVNr1t4qvfANvZCNklutrzGN8jaP4GzyO1Zfg/wAWtojaXpuoW7JKg8t3KncCTng+nFehFzqYbkTueNJcsz6b09BHCFGM4yfrVsjIwelcZoviaO5IDSk9AoUA4roZNVSIDckkrHoIl3E14kqcouzNlJFTUdNMO+W3GYjyUx936VQjO1htY4NaKeIInkWJrWdHb+FwBxVBiHkdkGFzkLWiva0iW10LGADkdD61GRPN5oMX7tFJ8zOOfTHpip0JC+9Y95JCqyfabmQjkLAuevbp69804xvsDHSwpcWxeRcoAcKOcV5R468M2l/N9rtUh89WASYpztAztPrXeatr81hpohiRRKQE3DsTXDtezvFIJGkf+HAGMn09Mmu2hBrViTcdUedRw6pdajdyTytFJHgCG1Q/Mp9MdBW/feJo4Vs/s8ci2m7yrsXCA4B4I4rb8U2ZihjvYoorKZEaJkicDzWONo9z9KwYvDOsX3hWRYooY75ZvP3yyEMfRfQ/SvTUoTScjNO0jN8UeGbA6XLrGk35MEZ3PCvT2xR8H9buP7Uns1ZxHMgJCDOSOg/XrW54C0S91DWZbK7nhtJok3PZNHkMSCC/PFbvhnRJtGlvjFZyJcxFZPMeMIcnOV9CvAOR0zXPiMQoU5Upas6IQ5pc0WdboEmqx3lzP4hkjdLQApsOA7EHahGOMDk1gQ+KPNurmK4eAapKd4Zxt2L6KSMe1O8VatbQW8TXlz9j0WBlneQkhp5GY5z6qegx7Vx7a9pfiLxXDp+jSy3M7uFfzYinyqS2O3OO1fPtuzZ6FOnfVo7HR9JjfVUutQlWPDF44ARI7ZJ6n2/rVfxTp9zdJenT1jkURFSsbAgHgbcdq4/4waVrt1qOkReFPtCwMhSYW8vl4kB4LEEcYxj8a6r4beDLTwNaTXdy817qV0gEqNJxvPb6ZraEG0nfUic+T3rlXwt4UsNFtBJcRk63If3LknjjOQB1AzzWzeeGluLW2bVtRmlC7iInGVkc98dsY4+tbtysGnT29xcyrDfXTFI1Ubyc9VUdu3PtWf4ilIuoo5ZFUW74kjEhBJPJO4j0HautytrexyRk5SucbrFlfzXTaeuoSW1ukY86d35x2RB2963/AAjb6bpOnXVtpMUVzdTMFmlunBUvtJGScfl0rh9ba6XXpZdLcmK6mQurZIJz0XPoOMY71P4j8cafputxaPdRmOAjbMYwuUOOvuP161nUnde5qdvspSSTe56VpehafoOp614hv5xHc66LUnyvm2eREqNg/wC1JuJ9cCq/il7q98MXaaDexNLqYaFp42yYV5xk/wCetY5+22fijStOtppLvSZ40jAznI3FiR6fePP1rA+N+pW+iWi6H4Qt7oy3527o9xPuAOufSs6E23ZepzuhaaRn/Dn4dal4Vubm+vriBpihSJ43yp55JNepfZp7GxtHXFy7f8ttxPzY6GvO7Ww1ey8JaCl/elb2PdGttImHVwP4iT+lMh+Ls2kFbLW9IeZo9wWRSYsqccuhHJBPUV0KTeu4TpTqO61O0sI7+C8+0T28s+98MwOGCAcjntnBx7V0pk0a2RLeOeCS8+VvsxRUeVj2+tc3onxD8N6lewW4u7otMFiJZiI1Y9jxkH3q14r8HpPrMwtb7cfL86HcQmxj1+cDJ6cVHtOZ+9oZ+zSdpaF7xbp1++jfYoQls9wf3czneYmXlQ3rzivMDbarLrFjZzXMltYIHa76v58z8FQT0XknHavbtSv7PWEsUcokkL5mjyMFtvAz3rhf7c8P22slbq5SBzKfLhRs5PpnoM+lKLbjtqa0qjjeKLE9hpFraW2kzPEgkwbc8l0dQMMv045rzXxX4fvNT8QrYaPLcXsMEYk+0CXbF7Y/EV0/xF8L6lqt3b6to8mGxsTc2AR7eldPonh2/k0C2FvIp1a1BaQKNqSZ6qfXjp70r8qTTNoVFSSkmfNvjXQNQ0bVY7fVPkmEYcH7wXJz1FbfhG7e48P3AuFbygPL9FkI5zn6cV63q9tHHbwPq+kTyE3CoDInmeYo6fN0GatX2g6NpV9Dc2UezT7llaSz8rEds3TIHT6/Wm2+pu8TGUUrHmfhTQ7q3iSTT2MjXLMYI26Ivv7VvyeI59BvphtkS9vLcxI0Y3bJSvBx0zmu28UalZ6VYmz8NTxyzFdjyhC3lr3wehPasDR9Zsf7ThuryCNViXcenGOg+pNNXkrtXMJ1FUfM1ocD4W8K+LF12Oz8baxJbabcRvcSW9xcb2kAHBC87ecHPFdTH4Hg0Nvt1xdv/ZMfzhT3/wB49x6CqXinxrb6DqNxquohrzWLtw6QADbBCw4G7txVnV9cXxL8OrmTU/O0OykkRba4nwQ7LyAP7w+lJwae4oTml2RF4o8Tadqmi6jp2iXN3DryoBFDIhTP0PTOPpUPwhn+IDIqTxJFpEGXlkvVw7KDggdz+NZHhzwZNq7HUba9hjiYFlkT5/tDdCc/0r0Lw06aR4bm0y7vHbBPnXUr4VUJ5GTS/uxKqqnFWjqzqI/Es+j2jJYWzXk0xKrBG2CSe4HcCvBfi/pGpW1kdReDdbTzGTPRoZD97d7k+pr2W+Wxhhtb/SNZhkiMOBJFKCwYdPY15V4i8ca9p3jM6fE41PTJ4lRo3jDBi4w2DjqCaSm/soiimnp1Mr4Ya7eW+lXjtczukERKRdRwM10+l+OoLnwxDqQtMXEd4sZhIG2TOSTXH3PiNPCdpdafLo0cdxOSUfAU7TkEHHUd/XmqGgXtkmjhL3T757KRgTPFgBGz1H0zSsr3Z2qHM2key2ut6n9mutZvYllhK4WJThFHUde45ryHVPEUmp6kt0Li7+03Emf9kJz1x6ele1eELi0Gi3OlXLPd6W1r5sdyQPnU/wBQa53wR4F0zUNbeyv7x7cHdJCqEL5o6kAnocYNF0otszp1IU5vmRD4Z1SfVFsmhsiXtVMrzxfdBQkH8x2r1qbxPpWneH47mwe3mjvCF35A2ZHqa8t+MHi+00TRV8N+CLaCC33GG91GL7qn/nmGH8WOpry/w1rI0prOxmvJbnR5XJZdmcn2U1KSdm1byF7F1veWiPV/Eut22o3bT2kEkE9oBEtxHKACPdV6j2qCyu71hGscrzwZZ5t0Zy3HA3fw4PtUXgbTG1XxfZhbOaPS4OGnZAvy4BHI+veq2uDTJNR1m4mvb9Gsr1lULJ5TspPGB/EoGf61d09ELk5fcPPfGkmoaf4inLPumch/MH3uRwAa9M8Ea5FD4MllvdISaPz42upohslZAeS2OpBH5Vweq6npeoXnk3JuLnzCY47hjyRngcAe3Ne2fCfwVEkGqWVwnlSwLsRGbfnKgg+h4NKbVveLrtQppPc8H16xvrbxbfjTFfZO/wBohfnDK3OfetuLWdL0mGKGVFn1NfvlWGMkcg4rsfFdvdpbXNjBHFBewfJBJIgZwmSCFI9ua8+0v4YeIIrT+0LuycRK/wA27ryeuKtpX1CFXnilLY+lNS0vQLONrnUXWIQplp5ZDGq49s4/CuIu7/wnqCzzrax3UMEW8Twy5OTngDt2NeO+LpJ5bm1aNrm7uiuWhuZGlEjY5kBJx/hWl4Uif+1I0CLA8cLzXEXJSJccZz36cc0oz5dmweX8sXKbOktodX06/wB+halFd2dz/q4nkMbRjuT+tW9P8ba/oXiJ7PU55v7Mdxn592weobGfwra0EJb2MWo2ttBKGJjYTLk7P72O3tS/EbS5pfCcmqQ2rRskYZiB8u0d/wBa7aNeNaajUW+h5daioJ8p7Laa5ouoWUc0NzFMVUbnQ9TikTWrQkhdvHcmvljw3r76beCJIJRLOiCJYjne7dTj0HWtrVPF19NZAaTBOLliNxY9gcYA7ZPareVyjKyehy+1PoS71uFQcMCx7elVGuBPtijKtLIfuN6da8WtvETXi41Itp1tKMT+eMOyjP8AqwOvNV9J8V3aeI444dRZYQTGCygnb2Jz7UfUWk2hc5c+IfjvTdO8RyadpkbMLd2E2TjDeh+lUtK8Uf2mHaJxBGVLKC2MsO59/auW8T+FprnxFe3sE0jwTuWZlXJkfufaux8JeD7e502VVea3uhtxHwCT3Jz0olT5Y6HoqVGNrnDaPrNzc+JFXUJroBpDMqsS/wA3QsQa9quNJs5NCi1DUJXu1gIbzYpWTaR6qOv0rK8F+F7K18RzahqoRkAMULTMOQvJYY61dsfFelQW1zFcqLeC5ut1uc8FQeGK+/NaS55P3Fsc1WdNyXY5vxL4qtNL160vkilmMSFEMlwEaTcOhwO3oa6Xw78UdN1CI2uqWV9bIiGNXK+Ym4jpuFRXPhbwxq+q/agivdyf6sunyox77D/WpZvBM8Fx9jcKWlUOzIgjBA6n0A+grjnaekzo5qH2IlTVNNtdQ1TT10xoNUvrd/PFpcNs39AvXgY6jPoKj0fTktfEDX2vSWFjLAkskdvagFnZwytJI44J28YGfrV/F/ZIbC7toXt5ZGxMCPMOOnz569K2rO2hv9Fu4Li1P7sFVnMYZmbj7pqPYRCWKqRjyGRpOu+HvDlgt7IlzO0wYRSytkhQOAQOnWpPCsEevtc6te3FypuGC2fyERLg5y1Y3xEshPpdvHJN9nVBiVAoJI+gHNcq1xrdt4dFhaHGloFSMSN5crA8nC1vGEV8OlyXTdSPNfU9W1VPt+rQyWcBDQpt87OVVu+Pbjk1AfC1w83nLeQRhsGVpWYmSMEnHt1qz4dWWDRdORlcbWX7ylsIPvD8a626ka3lZ7QF4JwFlilgBQcdRzkE1y1tbIzhNw0RzfhrwUDKrwyksm5/Pcgu5J/hH+PpXk/xP0I6v4rMP9hytcROBuJIaVR1IC9RXvzWNxbWirbzSRup+XcmFwemfasnWNTk07wrqE9jNEviF7aRFcoFZHwSu3PvSp6O61NIV2pa7nk1r47PhpTGdHuvtlqGaP7RkKBjqOM5x2qxZ/Fnw9fXWn3Er3VtfK/A8j7rHg9+etZnwbsfFFprU2o+KWuZbO9iIC3TiZjKWB3gc4wM8e9ep6x8NvDPib7Vf3ds8LqigTW6GKXcBy3Hb6U5+zi7JfM0vDm/eGR4l1C11ywbWL28i+xQvtbK4MeQASwHQ46Gsq2s4fE1is9ncWU1vnYguEVnKj29/XtXP6/4s8M+FXuPCpu7jVHMggmuhCpjj6fK3I3YBwcCvSfB/wAN7PSUWXTbgJDgvmaPKc9e/TFZyjGKs9H0G2oR0+Rz+m+G7OCxOnyR2kZt8zKsaY2lvmwT1PauG8b64JtTay0+3VgrolwxL+ZKQoIRP7vXAI6k17brWmm4nLXLWp3MIkkib29uTmuY1PwwdOu4NSGn7YbiQAtC5cLIBw209OB1relZK3UyjVXPzz1MXw9pL6LokBurRt75aZ3BDIBkbCf4j0ya8fu9O8Q3/jG3s76B4oI5/NYldqhM5JGOv4etfSsWpNb2BsLsxzWe393MeCuRwDnrzWZoGn2kV/Nd3cwkCkCOWRt2U7jPbnihuSi77lQrtNtE6yanBpS2+m2wuRboDwwJPHT0rNf4rW/h4SWNzpc0eqOoDQ+YC3TJJ25Arqbrxnomk6ddmwjR7+PO5ETIBI43eoNfOGuayuneI7o6ibqSW/uXkuHs1UKQ4w0fIyMZ4wayjFcr54l0KPtpPmPeIvHmkeL/AA5cGSyu7e180bby3TzkR1GQSByO/asaTw7401h5rjwj4n0Y6cWDRiDBLezhlOPcVh/BTUrTTYb+60mwufsJVIo4HcEuw3FiRnGTnAr0RbfRtYtLzV/Cok0jWrAkuQuwGTGfLdehBqFK14pW/EKtP2MmkVNa0vUjocCakYo9Qa32yQoMIr4PAI7V4z4T0u71jxPHDFmGxtI2lmLAkKx6D3Oa9+t/E+n69BIl9bPBqYGzy2U4Yev0zWZ4Y0qKx0DUYAIftC3TFi64HBzg+taKThBprUzhVsnFnB6l4HsNY8daRPdXED2wGyeB1xllPH1BrI/aXGmXE2nafayzJPaxgRRrgW0aZ5/4EcdhU3g/4h63feO00uDS4ZrATv5m+3G7aGJLbuwHYeld141j8OeIbzNzbTI7x7klhQb1wf4T3HtjvUu8anvdEb3lFx59jy/wB4R1ix0y3jF/DNbTsZo0jc7FB64qXxZpup3kU+l2snyo6S4lX7+3Pyt6jmvSdG8C2Fjc2+q6XfTh4hlVLfuz6grj3rlviJJ/YNxfawx3XToI47UKWyTxkmrpSb0Icrz90x7HSrjTvDUaXC2P2ueVpGjtPuQDAHBHAJxnHaqUni7RoFNq4je5RyDITjA9ee9cfpviPxFoNhdT3lgWt3bIWVdpXPcDvXZfD7TPDHjiOS41mxFtcMSZSDtGMdVI757VM0l8R1K6u2a+jaJpWvWb3jwJdXLI6xSMFynfqeveuRPhTVBaW9lawT27Rq6FwCYnDHlie3TsK3LyTS9BS4sdNnlb7F93Y3PJwD/jVKTxhqGj3cX228Rw0vlbAG3MOvy5HT8qXK0XTnJJuJd8R6JfL4Rms9IgMVwLUW7hG4kxjp7nHXrXBWl9rnhLw6tlq9uxkvPmjWY5aEL0YdweSMele4aPe203lSWarcrJG0jyTHKjuMVzWqadp3igSx6xNcsVIS3KyAKW7nkcfSnF3WpzKfv80keVHWp9eVLf7A25HAdLRSN7dAxUdx61reHtIsY9QuU1ScrPH+8hA+8oz0I4wehr1XxB8OrCD4U6fq3heT7Nf6f++eVcBpB/EGJPY8ivI4AXuzKf9IuZx5s0u4AsB2+tTF8yujup1VODUeh6KniC/hsJ00u98u6m+UswyXA9B9K5nX9RuNQhltdUgikuTjMyKNz498fhW54Qga5YJ9klQXDYUdGbHTr0BrH1/R7zSpNQmvI5o7qEFowTnOD2I601ZaI54v3tTn/C+jHV9TijkiEESDOZRtQAdz617f4IttEnuDPc679lghuGcSRStCzDaBtLdhkV4L4U119M1vS9SnlkldblWlimXdlN3Pt619VaJaN4vsptXto1sdPlZmjgCjM3P3n446dKmcrPXRBjebS5538QNY8M6NqolW2urjSrgMIrhJWbfIAAWQ9cD1zySa5Wx+JWp6nbGw+2P5SLtQug3kZ43eprq/iHodpq+l2LRXX2a3tY3lXKgpASdvUc8kdK8d03w/eQaixR0uyXKBom5+pz0q/da13JoUoyjqba6BZI1vb6rcOLS0Tyo5bYMd5J+8Tjse1bunW8Wl30CWELzRFQtywcO0jYJDkk8cdq9h0HwbqF3pcdjeWlrHpwXJCkhmPqanPwy0SwhS2Zp4t+eYGwcHNXzUtmc88XUejPOdCNxf3l3G0D28NwQu6YYBjHPB+npXoWs/Z9Q8Nz6RLMMTRFOhXFS6V8NlOqLcLruoiBUx5JkVmx2wcfL26Vr6r4N0y0jQrdahvc7Y91wzYPXJP+NJTpqa5Wc85uR8p61oN3pPieN9EkuDIJSkTyADGOuPb0reee2tb5bsWl9Neuw3oDhQ/c12fxD1WG01q20++sftSzAj7SjD5McDgd6vWGhRNpMd7HJc3MP341fKLEenzZHPrXtLGqSXP/AMOc08PKPvdzyjX2vPEuuWelWaRWyw/KozuK55YZ71lePoJ/D9k2muhbU5ZEbzxwQuM8fWvRbXwVfWnimO6mbDM/mGROEJPOFNc14htxf/Eu3Osx8Rv8yHk7c4XNbSqqS5YPRIKMEneRufCjUtOudIa31yYxXaKrySzNtC9s89+Kkn8dR6YLm00fVLSe8uJwscpjznB6n2qv41+G9nb3NvO1/N9m1Z90ZixsWQ87G7/Ss7QfhWwmupJY3LR4WKVW2g57j1NZwdDl55PciUZN6bFnxtdXuhaRpIn1OEXV2WlLiL53LnnnoF6dqwbP4feI0sX13ULqO00yNWZJC3ms7YzhVHXpXqkvh/woun2tn4ov5Zb6EmOOQNkovXAHQfjXLfF+XxVcXem6R4IhnXw9DCpWGF1zvPUufpj2rGeNdKKUdO7t+RdOgpvXYzPhV4mMPiBptFsNW1M4Cz3FyPlVfYDvXsi32o6xqtzehY44Ej8qOViQqJnLFs4rpPBFlDZeE7K2v4Lc6ikamYRoOuBzx755rx/4qWer/EDxYmkaRqdtYeH7VdzpHLmWR88hlB5I7DoK81Yn2rc5r5m6pK9oncXdqmo3FrayqLxU3SEx8DGMEgd+tWIIprC1WbTYGXSYSyPu+XJHcH61lOZfC9zomnaTNHZW9paiVo5sEzJnDAt1ySV6eteC6j4x8Z6z4xu7Nb27O678v+z7ZT5ZAYgKE9BSjW5vQ1WGctT6KtWhv5JVeDJVtzjbvBPbmp76yt1sop5GMygZyUG5SG+6PpSxSS6dazuIUZo1RZySAwYgZPvg1S8Qa1pulWLXN9KywgDIVcs7HoAKptyaZEE9kb1rq1lDY3F6Z5PI3+XFC6lACeu4elQ2etG08PSXQkjuluJCUCtgLg4A+p7CvOtB8b6b4kN7YsJ7E3GI4nZ1csfQ4+6a0/Gk97ongf7ZpoiWRHA2LHu28/eI7n+Vc84tOyNlSs+WW512m+Jxqlx9ihklaCVdv73OAwGdozzW5qWg2er2yJcwfNt2uWXByOwIrwL4V+M7ka4V1hWkmJKxu4AG48DGO9fSVxqaWtnbiW5CGSLdtIG4H1x6VlecJWFXo8krIyINN/1dtCXCJHmOMjCAZ6Z61Jo8+t242FILplLbQnGVz0yfSuTuNQub7XCLHVdtnE2HTgk55GPSuq8HaIbe/NxJfXDqpHlqWAB9c4pzmloyHSSjds80u/h54V1vxcdQvtC1awMtw0rJPMqRTMTk8cnBOe46167f3sMsX9mQhVVx5e3kbxjkA98CtTULGz1e0MtxbiRkU7M9iK8e8QeLbkavPptuLR4LYI0apLtkk5+cr3JQdcelWrVPe7AlOp7t9jpdfNxeTwW2l29vDFZyCR5iMOxAwEHbPvmtHXdUNv4WniMTvdsyJEg43v1wPwrOuIVtX892b7M6edDIvzqp9Pz7+9fPUmveJda+IGlyXd7dtMJtsKnKiMlsEqB6CtkrpS6IqlQ9tfU9e8T6eg8JXEabI7zyhLz8rr2z+FS/Cq3gvNJMN5cC6t1JzIQQSpGeR9a6e2Q3d3KLqHzDIuxAxCk9sZNU1FpBcSW2gyW1vdwnbJDGy4wOT7GpdTnjb5k81o8qR5r8Q9D8TG+1W6tbqZorRxNDEqhVEDcDDAZO0jJHPBrh9N0PxJrGnLe3kFtNDHO53cp5pK9cdMA55r32+8VtpM8Ftr+n3EVtMdnmKodWc/wY65xVLT7eUae40CFNb0ZiR9lb91PBg8ryOcds4NEptpXOmjXlT1SscN4Xt7bQvDsVqsw+1STGaV1BKKAMBVHpV7x/e3mneDoINKcwf2pKsE7RNtk2clm+uBj1qdLJbG6ukmguNPikbzI4pMPhc8jI6cetVtXu4bm8hjuLdJbO2dmVWxtcE5Gf0qLWdzTm558z1Kvw7fz7+80oyzmWO33RTSHcyyZxgdeeN3NekwXMR091u4m+3KxaTK7S23uB3zXCaFdWWmXqNosZhmYM8pXA2huDgevTrXU2nhxrvToJftkpuYw3lTlvmBJyMg9R2Ip3V/eMsRaUuZKxwU6at4atNYvPDS+ULi5JzNHlpgTgr0yBySMcd64jWPFfiHTfEqwwsBLbgQ4YZ3k44xXvMMlwkYTVIFSWP93LGPmD+4NZl5omiHUBdLb7rjO4PjKHjrn1qr23Q4Vl9tXLVnqWj+JtATSEvjBfC3BkEbFSsncj15rlNM0S6t5Ly5vNVS5j06QB3klDeXx8uV5OfQVX1S2h0c3OpWlrNEy5fAwS/fateP8AhnVtQuNR1K2ieVIrxxc3O0YKsrHBYnp94/nQlyRdnoKnT5+p6nf6s/iKa9s5IZLzyQreXLCpIQ8/z6Yq9fWwXQ2tdPsobJWQMzQxANnqK4/wzpmq6ZP9rvr4Q6dyokB2s3HHPpjNdzqurXd3pwn0u4R4+CkqEHjoQfypJpy0LnF0/di9DGHh/T7e3Or6pMyyToFkRmwAwPXA5rNeM3U5s7SW11C3MgK3bxlmgHTcwPTrjrWte6Rq+tRo97cRtsAPK/zrZ1G1/wCEV8FXurReVNJ5XkyJwo5wPm9f50Nq9r3Zcajtq9ThfE/2rw3Zx6Pp5MlvIh3ysvNL4J1lUsyb9G8uIEhUOWZh35o0Txdb6vcLZa0jkSYjDIMjp+dJ4muU8PW4iS2InlfZHIRhVTHTHejX4WbW+y1qzv4b6LVfC8f2K9bYWO+IglST2II5riY/A175k96JFSNFaRUTGfy/Kn/C7Vbi11oaZqRdYvvow5JB55FelLNfaTrs96kAvbA7mwnzOin16Ag1N2rpGEuahJxR5bZxatp11Jef2hLBPFAHU7Mq5wcr6L7HOavmW51qxhv76cmQxnfvbGw9wB3qT4gSSzXnlW6zxWzMc2rMFIUkHA9s81BYeFtfOlyeRbebblPOWJ2B3bWBz7im1ZXZreNRKWxHpehW0btcQWoN1FKCguFDROOp3Y6GovFPj/XdDtnFnfPpdlKfK+z25BDZ+8RnpW9oKXjLBDOw86VhJMYkOwFTnGTyOOK808e+H7i98VB7a2kuopETeiDb5JPTjsMd6SWoTabtudE3iFfE3hS0sLKO6uzabpLq1hch5Yue/fBOTXNWcVlaa5bRaJPcCQsElinbp6//AK69E8FaK/hq0guYoGgvIXBJX5uPcdwao+IrhL7XtR1v+yyWG3ew+UJgY49TSTuzSElG8Uj60ubsWdpG8cJdSwUgcYz/APXrP1hpZdDu7wQmC6SJ9meTwDj8zWjcXMMKmEKdwGcYzx61lXZe+iErOxtyxURH+Ie/vWMNLM8Nk2hQSRaPbO8yNdSRqzFugyPasy8a8u76SynaCRIiJgwBUlR1AJ6kGk8T+INN8GeFrjWNU3LbRACOID53YnAUD3rynwn8Z38X+L7DTrnSDHbSFlRYgWYcfeY+nFaRjJpzS0LVGUouS2R6HrfgSw1O4sNUsApa3JYRsSwk9vY5qDxPr4t9Ekt7fTnIfFrKHXARj/gOaueKtcsfDlmXt7v7Jbxo007KuQFHp+Nc1Fr+ja34q0u3ttYin0+2ia5uImbiVnA2tn25/OrhfSUtUhPmkvIu3fg2JPDhCG7lvoiT5zyFNwzkfIT0rnrzQ9O1PxJpF1q7R/bY0SJ4oiAvOfvH0rpvG3iG5a1lstJtzPLcvsjeU8RqMc8c4/GuH8VeF7/TrG1+16lHLq9+wVW2iMIe5UDJOK6qLla85WbuQ/5UYXjO2tra51WXUbpW0zTNwsrWOQ7jJke/ArlLb42/YNMuLC2sjEigbBnPbrz6GvUr3QfDGl6BeJqdsZILSENc3BfLyu3GBz1JrktP0L4WyXdvbRNcveToJMykHy88BSMYqauIvok7LyOqlThyXa1Mn4T3EnjPUdQfUSjWyKHKE5Zn7VzGvWPiDT/E9sPs94r+eziZ1OCM4wB6YHSvaLnw5pPh243acIbG0SLJKnG49z9aZo/iOLxLK1tqERdLfcsM7pgtnjj0zWXPKbc90bQny3cUdDpniNvEURtltHs5xZnJZQpLYIAB78814FpugeKfDHimWWx066u77eWjkKZTBGSxBOCfrxXvfhzytP1LYL2S+vbgrGIwoUADoBx/KrHj7V9J0SbTrbWpZrW9vpTHAkYwHAHVm7LyBjvmiLt7kVozKnUcG0lueF30PjXxVdnz45UuoQRLPLIgjXHJ6dAPT6V6d8L9A0jTLCHWopXu9W6T3d0PuZ6gD2z+tWFLWNvI0DRx2sg2FIQWkDHPRexPesG5guYdJOn6Qty8kxctCIzvCZ+/u9eMVUKLqaN2RdbE80OVKxc1HWbM+IWS51KK5srx9xUDEjNuAUYH6V2+r6ZZalpyWsKrIuwSiJh8w+vHH0rg/DHhzw19l07V9SvZlutPuFNyJxzhWyCPxA5rqdW8SafdXTXWnSypasoX7QBtTAPHPvWtVOUuWGyOSL5LST1PG3+G9+3jiW6SC3stOhkWUKWKrIVOdvHuOa9sjvLA2y2VhcwSkoZJrdvmUknJ4qOxtprsxC6uorrblo9o4APT6/WvM5NG1uH4oebZWs0Vs+FboF4HO0+hrP2am7N7HS5ur7z3R1reEdGn8RW99oNwlujKXuIlQFFcd+enPHFdFqmjz67rVt5zhytuBHjGF7MMjoeal0HT9P1qwu31UfZ47XJ8xpNrADrk9hmuj0bTfDGu6ck2m363Dqf9fHMchvoeKyk4x+Rl7apLXseTaL4Sv7XW7uwnu7aGCVmCJv3GTjAc/wBB7V1U2tf8K/sLaxuLltVu3O/y4UyVzzgntWtq+kWGna3pxW5tXv0LLCuQkkmBknbnnHfFY1rYw3urTCaNEudvmSGXn5OclR35pypxm+Z7DdfmfvI1fBvxAuNclSxnsG093kLHexyFIzg5Awag1fwJpupeJBNpZlt71iWEo5VVY5dkzwN3Q/WuL+IWi6zrEtofDKTusX7sLG4iaQkctn0xxivT/hXoGtWMS3niGV/OWFYY4CciMcZ+vSonH2aunbyLbUbVKbt5HQazYWttYrHc7fsqIsarjoOB1rzTWLlPClrqL+TFMIR5tuQAWIY8L0r2e/s4b62aC5TfE3UZxXnl1YJdXVxAI5EO4hHHJUehH1ooSVrM5tnc+ebe48ceL/HWj6jcSpaWFvKksQb5EAU8kJ1Jxmp/idF4l8K+LbeLT5pJYLhGltbhMbJFHJGfUd69sn8N3Fw5v7Fs3UK7ViUAbv8AClhmvLbT5dNi0e7t98u8TzJ5xQnqRkEfgMVcpNSvHY64V0nscrpuna3rfw9fUvEnlwtFALu3ViTLGQDgsO2V6Z55rE+FXiK5tNavNjjZsSQkk7QAfm3E+2K6C40XWNWstTE/261MwEUjynb5jYxuAyc8AVj6Po66Rqd29woimk2xxonzqVx3HfNRb3WmaRnFxkmcXr2s63qH7RU8U8kkltNcrAYBkxNakDt3G3n613OoeHb6XW9QsYkDJbOP9LJ5ZSvAB+hwfpXdQ3dh4YWwbWHs/t85C22UBl9dv/1qw9C8X6TqWralFLPNY3DuXP2q32xx4GASSQMYxUxlKV5JaEczVuVFax0G7BiigtIIgmGMo++7D+mK9B020axhbzVSR5VAdtuMt25rx7xZ8Z38P6nYxQR6dqke3LNbkhQM4GTnrjnFdl4e+IS+KLA3a2LW5Y52Mdp2juM8USjPqiZqcldo2PE8sGj2b3t+FEMMElwVQFiu0ZOPyryjUvHukX0H2iO5W1spI+C6EMHB5BX/AAr03X9f0SwZZrtluknj8tbcsDvDDnjPIOcV5f4o+FEP2dpvD1l9lmBZ/s0kpkOHA456Y7VtFLlVxUXC9puxx2o3aTST32kzyxB4gYIrdyd0m7kkHORjPFej6Olppukxy6mkQ1u8iDTkqAz7j9xgB2BBNcv4B0DVfCqalq16LcSWttJKsHIBwORkjrxXY+Br7TPHWnz6vcOlrewyG1nULkEYDKwB6cHr7VlVvbXY66lSNrR2XUp/E3QrjxJpUtjpd1JHHEiksQfKkbGQBjnv19aj8A+E5fC/hZYtVuLeaSTcxiWT7mcfLk9T3rsNf8Rw6NEfLtzJYxLhnk+Uufb1rz3xl4q0qfTYtWhhuFktXP2i0cfeyP3ZHoCQRThF2SZz3lJabDtW8RappmsC2MFithwYGumZPNXHUOOM+3tW9f6jout/DDVvtN8sdzfAhbbcC6yAjbj1GRnPpXnvi7xDrWp+GbCDU7CKzE0SyxKqnJQk4znuRXJ6Xpkg1eCdXkiTOFXByAetaON0m9DeEFON9rHofgH4UeJY9QtL6SS2jt43SQuzbywIJGB+Hetn/hCdW1PX7z+3WR9OkYtuLAcr0wOx96itdY1zStMuYtKujunHlmOUligxjIPrW7Z+MLKbShp1/E0F4qgBmO7e/GRn3NZPn3Y3Wm9Uc1pHhm38OeLEn1KRgLjP2eXl3HbG0ckdK9pjso7rSUt9J1GCeB42R5QuT1wV9sV53rUD3OvWlzNAq3sludnluQ0S5ABBHTr+NbkOoal4csbCSeGRoTIUZ1IY9OuPek05NNPU56t5Wd9Tc8U6LZXNrAL5ra2hhAEsrAY2juSelcYl9oEsMdrpnia1dxuRERzGGGeAGPH9KqeOPEGm+IYp9L1G3nV5UzGAQjLnnIPp7GvILnw9Fa3kdlfa79lgJO1WhV9gPPODwapRstWOlTclrf7j6G8LagovJdOtbKUNBhXN0g+buSGzzXEfEbTL6w8VLqd3GiWNwRCklsuAg7D6+5rT0X7Ro+kobK6g1mzMQUyRt86EDr6g1zuseKPM1Bopr1HaVBIsEjbs46URWvMhRbUiSz8TCJVTS/KSWCPyzPO2Wl/vAH1rk7y/tbq6aR5biVQWac7WKITxuJH/AOqur1G0s7LSJIIpQq3QMvKjIBHUGvMJNTuLi8K2CmH7NGUVGY7CBnJYU1bdHdRp+0ufbGhatpt62bW/t7y4K4k2MGI+lfPOifFfxpP8W59Lis8wm5lh/swwD9wi5w4br0GSTwc8dq5n4UCW28QxvbalEbothwobAI6ZPf6cV9KTXGoRW/2qCO2juWi8t5AoBXuDnrjParnQdJuMle55TcIyajqcr4g8SS+IPDdzDqmloLgDY8cy5HvgVY+Fvg/TfLkurO8jd4jsKwKAoJHQjrkdK8/0Xwx458X+Iby6ub822kpOQZ3+WOXHHyjqRx9K1fE3xt0nwBqV5oekaQ99e2rpBNcMwRZHGOeOTU1E4rkgaypJLli7s9R8ceEZde0LUNOFwkP2m2MZkKAqo7/yrwLw74JbwbqJd5EvL9x5arEvyBepxk5JPFfQ134jt9W8DRahCZbf7fa+Yq7cshI6fnXluieF9VOrQ32qXqpFB+9WELkkEcF2/DpWuGd4NyehgpygnFdTQ0OfVHu4Zm055VRzJtLBTycc5/P8K0Davrviya+uVISxVY4IzwdxGS309/aljvoNL0S41OV2ltlV5Mj5dxycAVxFx8TDFZXF89lE93dy7VSJyAF/hXIB52g1Tb1cV5BClKexjeO/A2s23iRL688SWi6beS+f5FwzKyjOB8oBBAzgHiuS8U+CNV0D4hWV6T5+kXdypjlibAI6lD6HrVP4n69Jq9xptxa3E13YXahhHuIaMp/A3pjJ/PNfSlksb+DLZYbdb2S1tIZQjkDawA557jPWueVRqyZ3T9xJnP3SxJC5feiCUYjY+YDk456461k6xaylbtNFMdtNHaSOQg+VzjhT688Vox280t5bJcK8ULStLK2QAEUljn1wAefSofCHim4vtVvrj7NAdIgJt4VYAsN7ZyfwAP40qT5fMxcW1dHP+EdUTXPFlraS3s63i2iXEKNH5YZjkSMvp2A78Gtn4p+Ev+E3sy93eXUd3ayBUOzeIh06DnkAE1P4b8Ow2/iG71XS7Rp5HLJFJLhY4iTljnrj2rurqwsvtkuo3VzLC8Fuzl43KK74+bjocAdTW3Moy0IqVE5qUTyj4L+F/EOi6pevrl8p020TdGxlALOTxnPsc/iK7jxv4v8AD3hqFmudXUzXZ8sbV3FAOew4HPQ1DpWrafrngvxDqml3FtPc/ZiFxhAkgU4dh27cnjivlnW9H1220qO8vCL3TbgF2mtnE4Vj2cqTsP1qEk5Nt7aF8kZyu9D6BtxZ6vp7W9ldpdaVeDcRwC2eo/A1znj3SNQ8QaTb6F4Wuo4tPsFYzRlsFyo4UEdRT/gb4MksNBj1HVdYiisNTg3QWjfK6vuPIz7DPvmt3xZqmieF7Oa2a3uLqK3wsl5byxKyu2AFx94nn2HFdCrKUbdTKMJKeiueZeDviP4l/trS9AlW2ihhkWE7oBG6gdmPWvpC+1vRI7N0N0tzqDnd8g3HjjjHQCvJLHwnpUjS67pl5HcQsCJprlAJYGGCVYk4HUc967HwhZaNe6bLqtnIztaIVe6ddqHHpzyOvNZNU0+a46ybeiLd7ZE+C9V0+EztJqMZDqi7icj37d6zPhJpGneDNQdtRvJb2cjaxSJjHEOo47VonXrOS/TTNP12xFxNHlVYE9R90NjG7pwa8dsviF4o8D+Nrqx8SYaxeVkkiZAQFPCyI3fFVJ80GhQjNR5T2jx94bfWfiXoWvaTNGktvEyYEi/fDEq+G9c9q7W70Q6tJFNBK8M8WHNwuBz/ABYHpntXk/ifVW07wvNd28NrcvcNHJEtyxHnA4IC9/yrlfDvxpvIrs2RMWkJuCncrSxn175H61nKLsnF7aDVOpOKSWx7nbaDrdjcx3NrfRzOshLJcrhZATnqv3T6cVv6X4mll1e306/tkhlmRiro+csvUYxxxXCaf8Wrae2MccUN7t58y2JO7H+yRnrVGy1lNX8TSXqrcWElzGQkUqkkgHkr6dalU3NNzRi4yi7WPS/FnjLTPDVnPLdmSSWPGIo1JZif6DuazNB1geIZ2vobOe0t9uSzgEMT0KnuCK8v1rSda8QXbS6tqNvFp7Zh8uVt7lOg2rxjnFd14axpNpFEqM6Kixoitk4HGfSsZcsFZbm8qcVC/Ui+OF7q+neBvN8JT/Z7mSVY55IkJdIm+8y+hBx+deM6MnxD0/4bXmoQX2ryfarzypMF5JRCoyXH8QBPy8dq+lvEtxpekaBeaxqZ2WVrCZ5SoycDngdyelcZ8IPiNYfEE6j9jt7q0NgQ3lOQ3mIc4II6fd6U41LQXu3CnPlj8J5r8G9T8T3OtX1vLJqM2gGNpM3u99kvAAVnAJzk8dsV2XjCbUdJs3n0XTY77ULhG2Sy9IiBgY7cdea9N8Q3MA06W51GZrSxVQ28kKQOua5nTprW8urZobyOa0uvlSQclSAcD2Bz1qlJX57CnV55c1rHzd8P/A3izxh4hhuvEr3cVlbSljNM/Rs8hRXq/i7wx4divvJ1CW/vFmTDKsvDAcDOK9B8WtHoumm2tYEhQIduzu3U9K8RupI7O0nvbq5uJbhUaXEh3HGc4BPatE3L3tl0NqUpSNm38PeCNKkeGbQIzJCwH76R3I465yR+FbhsNI8T6HcWFlaCKyCbTBDIQz98lupXOMjjpXicN5qmqma+1WZorJ081ctgMCegHViK6b4XeLIh4ik0iO8nlsXjcqGXaysOevUg1m20731R1VcLKMOe56Zomh2Ntox1Kw0sz29tCsaRv8xV0/iUH3HH0rH8I/EaTxh4ivdLs9IuIJbWHc17IMFyCAVYfw9eOecV3Wg+JNJ8OfDKw1DWbr7NGJGj5G5nbcflA71ZHiDw1qXgu+1PSZklDqyh0Xa7OOgPofrRz8zd11tc81ppNtHEvrMetNeaHqKboBvjaUDaeQVI/WvPfB3hC+8IeN5bvWbqM6YkTH+LdKoHykKBjPTvxzWrdGa3EGqXieU8uAUBJx9fp+tddp8lr4uEMF8kIhjXG2QndH6c+ntV1HyXXQ6Yq0brZnkumax4k8deL54bG2uJbES5HlDasag8EseBxXqlv4dg8LwXWp3ttNNGke1zO6SKqgggtjrg1gafqUmm399p1jNb29i7CN5YWUOrDj9cU/xxrcttpkVhcalBawzdPMcAuB9eoqmru3QluT92OiN3VrTT/FulG5eeAzLbpmQ/L8wOeB6VyNmljcwqllLCZD8pPXnv9KseBFWexuV1EpJArNIGVs78r0yOCM14rb3N5Z6ncokrxFXd2jzjbg96Vt0nsa0ableB71fWilIraXAYJkMvr+FZ0+hSvJDt2uJ4/lyOWbOcj3rm/C99eX1nFcK7tuU8lu9ek+Ew5ZftDIMpuDKuTGR6H6VOqRLi4HjOoyeIZbgSSXF6k1tI/nKzERwRqeMHPX+dey2WsnXdF04yLJJezWyTfK/HIwTtPFcz8Sr3w/qOmXF3pUN1Jqa5jkPzIsmOpbs3TFRfCS3fW9GkutSs50beUiuY3KlWHTHsOmOlVKN1zWsXVmpRTtsUo/CN42rzzXl35lwDvjRW+ZQegPpXI614WlOsXsk5l3I+5n++B+XavXNTm1Dw1pt0ZIF1FpT5nnRrtYAZ+VvX8K8W17xxe6rqBma0ijgX5WjUEEj3ND5jahOUndHoXwViaLWbiCZy0hA2ruwGXp/kVw/xG8B31/41uJvDkbbBJiRC23yWzyVJ/h9MV6z8K7qe/trS7jtoXgYPES331CjPWsD4keMp9DlutL0ezcB5RJLNIxz0zge1QrybVjGrFzqHKa9JqN7pNtpu1mv7RzE5j6Mq9x6irkfgy9/4R19RkWKOOYAOsyHn3HvXQeE/Etvr8gvLAW1pqkJCuj9HDH5iM9q9C1WYmwfTtVmiSGJRIkqADOegP40+bZWL9tKnpsZNj4Bs7XU576zVk3XIuFAcfJkcAYroY9S1Oyu5bSMy3KkGV/OiJ69l9hXDXni/UdP8PQWuiW0r63kOGjHnSRoRzhf4mHTBrR8Jf8JNr+hRPrVxfQzRzMjNKPLmdcDAZR0IOa65SlJ3medKi0uZs9SsWaTSoIhOm3YOQ2I1bqCPx7V5aPhfZ6z8R9R8QaoqXNvJcKUtAmUL7QMk/wAWSM496u2Wn6pFNqFlLc3aWNuPk8/GMeuPbNdrol7DZwWL27I9vEuJGjPHT79ZSg4J8rvciE3HRE/jTxH4f8F6ZpdnrsEoMyt5UNqhKxomM8DsMioLnxTp+uaBY3GlQmGK7kEC+ahXeDnPHXAxk1geP7zQ/FNnC+rw3kiwyZjaJdjAA5xn61leE4f7V1GCd57fSrDy2+wWsxxLLjOSqk5I75qI0eWKk9LF+61pudr4rS0sbGytpm+2ochYkTGWx6DtXgdhoUKQ339s2xtbSKd5UZmKBSc42sOcjNel+ItdstHluG+1NqGqbSSznaEX0GOgrzXxUPEXjBdR0fRjZfYLLZNOynZksM7c9yauN+XlbOrD3gnYbolpolxqVpLBE83hzRYn1G8VzkSyudqL752jj0z60/RdQ13xT8SLjVbyKaxsUTaoTKho3QhB7jv9awNYgvPBvhRdAgbzr6+YXN5GoGUjTG3J9M5r0L4U399q+jajdaxaw28M8QCSrjKoi4GAOgGBWd+ppU0i2d5JpTad4b1C51zUkSylhaMDbygK4wvc5rxfztaTw9cf8I9psu+7m8wmNCWIHGfQYGK7OfXdB8TppyXctzeXFj8sishVS3GMjpzxW/4q1O28G/D6fUNQ2BppBFDHF1YnJ2g9gAOce1aJRgrPdswjKUdLGV8O9G1Lwp8O7ubxHeFbzUZleO3mkJZFzz+JrR8e6xq83w6jurSKYON0bxFdzRxkkZ46HHf3rndY8ZDV7i5Fjbfa7SwtIpXdhkIzlTyR/d9O5HtXpPhSMR+GtPkvAzyT2yuTN1KsMjPQZ5rHnaak0Nx5Pekj5P0uO7fxiI/Dgmt7S5k8t4LyXyotnVkdicbRyRmvevhtovhuxt9Ri8PaqjXdyBFdfZmZo/lORtJ9z1pvxE0G08YiC0nSRbewRpvNR/LUA9Se1S+FtN0/wtpO3SQvlwN+/ctnf6MvfmnJ82pU/ejdFWHwd4oibXmj1A3DPp8n2EkBwsmR8uTgq2ARXDfC7wvf69PNJf6SU0ZEbz5rwFW8wDBKtwevbtXuej+IUgnVZlfZOvySKu5BnO0H0PGfxrpvEOqQjRWn8vYIYneQjAz8uOT0A560e1ls0R7WULxS3PF/HXg2DUvh7/ZHha3WK5inF40KTE/aOD6nnqD+VUrjw14j0D4BrYJM8erTagbqS2iYLmIgDZxweQCR71B4K8fjV/HkejZtbfTogxItVLKwA/hcjJ5xz04r3fULW11vSvMkcJFApkLFcbsDqBROXLJJ+oObg7M+YfAmrXGsa3Z6dfXxsYBK81wJMKqsB8nXkYPb3r1S60HQNWubKTW7O11R4cytNKSpkfPAQA4KHqQa4LxXf+HfEHiK0/tPQII4GaOHzTMUnm39HO3GccArzirfiXxx/Yus6b4R8N6TbzmORI8KD6gKEx0Pcmr15rGtfnk07WOp+IdvDr2nrHZXL2k6oQxaMCPYeoDcY6DpyBXkWh6Faar4oiju59NvVUBf3VwQAijB4bknjt3r2j4heHX1rw9Po2kXnlXMrrJIHP3SOoJHqa850DwNZeA4BrXiea3mvLmTybe1iYuIRgkuw7jpTcouFkKjKUY2uet+AvCllpcEUu63azt5HeESxZk2kfd3g8qCSeRntXi3xJ8X+Kr3xvc6f4dluY4LcFIxEhUsp6n1xXsPh28ml0+GSzuLe90+MbriK2TaVzwuCDyvfFdBLceGLTZPcCOK+dcKr/LJnH6VipcrbepN25e9qzzG2a6bwHoNx4jWcX6S/wCvXliuDjP9RXf/AA+e+ubt3n2bZMeUM5G0dK5H7ZD4vv5rK2iuWexCmKBjhGGRuBPrW14a0C7mlisX1swyQyMWt4JirOnXZn1qZRTVpOxdV2hax3Oupa6sdS0jUXe4t2tQJrcNwFJ7471z3hrw9Y+E4ms/Cli9rE7CS4bcWeTHYk+gzx0qRYo7TVJ0TUnjgY4ClcSqTxtJPX2rpbKwu7aCOJAVhRSXk3Asw96t2iuW5w6/I5H4wzW/iPwjdWE2pnT7aIBm5BZtvJB9a4/wBqfhjwn4KjefVbm/FxLsO1NzQn1x/CORj1rvfHfgG78Q+G5k0p7V55lJRmGBz/MV598N/gjeSvqEfiqNBG8ZijMb7grD+IfQ9KSlHktzaJnZT9m6TUnqejtqY1nw88azRyxPHiOeReNpGQfbNeS+OysXhG4sZGS6kMP7qWJSCgVgzBh9OK9s03wrBotk1nK8r2m0bl3fMD32+1eYanZ2UV/LbxSieA7i7sMn/dbtThbWxFCajLQ8+uLW923V9e3MEulWdtHIgVQWgYrgEAAbgMjJqbwNotrfeNtDlsPs8qhWubu7iBCPGOPmX+E54xV228LX975+n6PNGLKZGBhnXzNidCAevf8ASuitYofhZossSRw6lqMsYLPO2yCFQPlyQMknkhRyetRytaI9OriYzg4Q1bE+KPhjU7zQtOGl/vrxHeZYf7qscjAPfGKyvCfh3WNJ8G3N9Mk1ozT7praPqFCAA49zU0ev+LLPWB4h1Fra+tmZWlSMFR5bEKPLzgnGRxXtmv61p+jWD/boY2mlC7YFUbzxz/k1bnJWilc4JynSioSR4H4Y8YpZ3tpJe26SQJIR5cgyG56getV/E2qy63d3Wm6fetEL2UyRGHLCMk8q3Qr9Kt+KLOHUtWeXR7H7CYsyMjMFPrnb0HFZ+i+I/DklwC73kt6zBPtiwBQntx1we9W0k7pGy5bc0E79jL0X4Z+OPCOpxakLaC406QZeXeGjeM9dwPOa62+0ay8SSXNzpVxY6sjIkc1ldHDxBTx5L9u4Ir0NPEUcnhyW2W5Wfenlk4OAMYPHavJtE8G6l4NsbnVbK/t7qWZtvlg42rnrz3qYptX2ZjCV3bZnd6JoMNppwXToTHNKhL2wG1UboAufQiqniX4faf4p0m11a6juNM126QLcGJB5cjDjlfw6ivP/ABD4y13StFjFreTW9xuAjuVKuD1JA69T61pah8VPGWv+ENKgh0+FmilxNNbgq5K8D2Ge+KS57qw3TqRle513g34dX2gXVvBevHc2ysSoQ8tn1Fdn4oS20vTbi1syDqk6GKKFOWyfQDpWXo/jCG/06D7H5kF+sW1nvEKANj9a88k+IlroXiRJfENhNcXhcs8sJ3FF7EZ61SjJ+81quhk3KcjrLi90LwEyW17F/bc8cYluIIguIARnJJ798Hmta6+Ivh+Dwqup2el3NlaIpYLJCF+bnG3HBrm9cPg2/vNO1Se8UWV9t86Zw+2cAfddcfmT6Vyeo6drvxCnlsLH7LB4UtpHW3njASFNvp3Y44qXFNqUn6mkaaqRudJfeOdN1nQ7fVLWeWwVch45FDZ9iBwQeled21ho2ua1IbGZLVJf4S+Dz1HNbmr6JZWmjJplpLFLHEcM6DBJ9eO9YOieGw1yMgSxKdpkTgn/AA/CmrW3OmEVFNp2PdvCcNvZaTb6TpUcsUka8HIOW9T6+9c18WtJ0mXRpr7WNZsJbm1BDLEuHyT93AJ544ziskeLNJ8MrCdKkvJLmMYMmcqD6YPX3pNT0Ww8TafNc6pZi0n1KUSy3lsSWPYZX09cVMVyu5yuMk+ZmL4V8L+Hri2sdV0S8lIBCXCSybdzemP0Fexf2daaLYzXaSM+SJJYt28yqAeOa+W9T0jWfA+tItyjtYSyZiIYMsyg4zwfpXrvjLX3sNNtreNz55AUANyCeufXgAUpczdrmqp+1aVzrLhli8QancQRRwztd+UXiXadvPpXdX1tDpvh+O8s4wlwpVt395s9T6miiqT+E4p9Dz+91a9GvXiee22QYYZ681E91O99FbiRkgVQ3lrwG57/AJUUV6EErmctiXwxbf2w5vr+aZ3hY7Yw2Eyc84rifiwP7P8Ai14Te2JBmtYFbJyMNI6kD0yKKKis/et5F4Zasy78btRvVJOxI5SFBxwqAgHHUEk5r1bw3bQaR8Dl1C2hRrq6s2mlaQZy3IH5ADFFFcVVuy9TtmlyxPnG5L/2AbkyO09xIRI5OSwHQfSvRP2brie91S6gnmcwfZ2TyhgLgn6UUVVXqb4nSGham0yLT5xp1lJNDayyKHVW5bEhwScdaf8AtQbo4PCdkrsLaGzlnVc9XLquT68UUVdT4l8zk3qHUfB/w9YWvww028jWQ3GqhmumZ87sMQAPQACvQfGI8rMa8osCxAHsoGKKK5afx/eRUd2jhtVhQXkKAfupUCNGeUwCDjBp1ku2K/tmIdG+V2ZRl93JJwMZooraRqvgG2ROl6nHBasfIS3jdY3+ZQc4/pXpGtaTDf8AhG/nnknDmF1wj4GCOeKKKmTs1Yzfxo+cfgPodpH4yv7pfM822dgmSMYB78V7B8INevvEtvrT6qySEXTKoVcBVyflHtRRWmI+J/IKiXvHnfjjw1Y6Zrtta2j3C2ouxshaTcsZ3bsrkZHNe5eDfB+g2V+NXh02A6lIxc3DrucHbjgnp+FFFRim0lYK0nyR1MLWreKyljuoFCyzXEjSejZrx341yOPE1iFdgjW2dg+6MnB4ooraH+ZWE1qxNv4FObLRrkQcM84y5OTjHT0xUXxOsIj4wtrkmQyyQI5+bAB56UUVjD+JI2/5iGcvZ39zp8d29rKyNJII3IJ+ZS3NafhK8n0/4sW1pbSEW7+WSh55Zck0UVdtGdFRLlZ9GeJPDmn38LySo6SiIDzI22t/kVzPw0upvtN9pTyNJa2+UQuctg56nvRRWENaTueYvgOoeEaTJPDYM8UIRXCBuAcdh2ql4X8Q3srXySeUQrgj5emfxooptJxuznZPqt3LPrPzEKBGI8L6HBrmvEWl2fl3WIEG2FpOBjkDNFFVHQqmyl4NiWyu7xoOCCrLn+EsvOKyvHenw6zLHcagDJKpC5wMEgcMRj7w9aKKF8Z0RfvFDwR4ftb3xVaTahLc3hS4Xas8m5Vx0wMdq5X4l+KtTtPiNrFvA8SxRTbQCgbIA75/piiiqXxv0N4e9U110O71CCGXwHe3XkxpcPpz5kUc/czivG4YYP7HuLJII44v3EhZAQ5ZgCTn/IoorOD0+Z24TaZ6GE+yDETN0CHPfA6n3rT8W2VvPbLHJGNqxRYxwcnvRRWvVHnT3M7RNKsLq4vNNvLSG4s4QNqSKDngHn861/Cun2i6NetBAkAt7t4IkjyAq5x37+9FFZN+8bVneBzP7RFzLoPhjw7YaU32eGUGSRl++zD1NW/hPp1rq1layapEl20kQDecobgjpRRVXapXOfaldf1uZnxgs4rKC40y1BislUbY1wNuOcD8a474b6td6ZoHiIWsh2RoJArEkbsYz+VFFbSScFc6aH8NkeiX8s9xJLIE3yKWYgdeM4+la63ssng29kwivaXAkiKjGCR3oorJ/EdNVLU5541aePeNwkOGB+mf616T4Yvbm/TTIZ5mCQsSuzCnjgAn0ooq5CqfAa19odj4g066TUot4hu32FTggr0P1459a5H4i2sdtFpN0oMkwllQGTngHiiipjuYUPjP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There are many lipofuscin-filled macrophages that replace necrotic hepatocytes to the right of a central vein. The sinusoids are filled with mononuclear inflammatory cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_0_35847=[""].join("\n");
var outline_f35_0_35847=null;
var title_f35_0_35848="Codeine: Drug information";
var content_f35_0_35848=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Codeine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/44/14021?source=see_link\">",
"    see \"Codeine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32230?source=see_link\">",
"    see \"Codeine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F14854336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Warns of Codeine Use in Children After Tonsillectomy and/or Adenoidectomy",
"     </span>",
"     <span class=\"collapsible-date\">",
"      February 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The FDA has issued a Drug Safety Communication after reviewing reports of children who developed serious adverse effects, including death, after receiving codeine in the usual dosage range for pain relief following tonsillectomy and/or adenoidectomy for obstructive sleep apnea syndrome. Three deaths occurred in children that had evidence of a genetic variation (&ldquo;ultrarapid metabolizers&rdquo;) which results in faster and more complete conversion of codeine to morphine, possibly leading to overdose or death. The estimated incidence of this genetic variation is ~1-7 per 100 people, but may be higher in some ethnic groups.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The product labeling for codeine is being updated with a contraindication and boxed warning regarding its use as an analgesic in children undergoing tonsillectomy and/or adenoidectomy. Healthcare professionals should not prescribe codeine to children for pain after these procedures. Alternative analgesics should be used in this setting. For management of other types of pain in children, codeine should only be used if the benefits are anticipated to outweigh the risks.  Parents and caregivers who observe signs of overdose in a child (eg, unusual sleepiness, confusion, or difficult or noisy breathing) should stop codeine administration and seek medical attention immediately.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm339112.htm\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm339112.htm",
"       </a>",
"       .",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F154177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Codeine Contin&reg;;",
"     </li>",
"     <li>",
"      PMS-Codeine;",
"     </li>",
"     <li>",
"      ratio-Codeine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F154215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Opioid;",
"     </li>",
"     <li>",
"      Antitussive",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F154180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     These are guidelines and do not represent the maximum doses that may be required in all patients. Doses should be titrated to pain relief/prevention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Pain management (analgesic):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Immediate release (tablet, oral solution):",
"      </i>",
"     </b>",
"     Initial: 15-60 mg every 4 hours as needed; maximum total daily dose: 360 mg/day; patients with prior opioid exposure may require higher initial doses.",
"     <b>",
"      Note:",
"     </b>",
"     The American Pain Society recommends an initial dose of 30-60 mg for adults with moderate pain (American Pain Society, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Controlled release:",
"      </i>",
"     </b>",
"     Codeine Contin&reg; (Canadian availability; not available in U.S.):",
"     <b>",
"      Note:",
"     </b>",
"     Titrate at intervals of &ge;48 hours until adequate analgesia has been achieved.  Daily doses &gt;600 mg/day should not be used; patients requiring higher doses should be switched to an opioid approved for use in severe pain. In patients who receive both Codeine Contin&reg; and an immediate release or combination codeine product for breakthrough pain, the rescue dose of immediate release codeine product should be &le;12.5% of the total daily Codeine Contin&reg; dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Opioid-naive patients:",
"     </i>",
"     Initial: 50 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Conversion from immediate release codeine preparations:",
"     </i>",
"     Immediate release codeine preparations contain ~75% codeine base. Therefore, patients who are switching from immediate release codeine preparations may be transferred to a ~25% lower total daily dose of Codeine Contin&reg;, equally divided into 2 daily doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Conversion from a combination codeine product (eg, codeine with acetaminophen",
"      <b>",
"       or",
"      </b>",
"      aspirin):",
"     </i>",
"     See table:",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"200\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Number of 30 mg Codeine Combination Tablets Daily",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Initial Dose of Codeine Contin&reg;",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintenance Dose of Codeine Contin&reg;",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &le;6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50 mg every 12 h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100 mg every 12 h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7-9",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100 mg every 12 h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         150 mg every 12 h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10-12",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         150 mg every 12 h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         200 mg every 12 h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;12",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         200 mg every 12 h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         200-300 every 12 h (maximum: 300 mg every 12 h)",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Conversion from another opioid analgesic:",
"     </i>",
"     Using the patient&rsquo;s current opioid dose, calculate an equivalent daily dose of immediate release codeine. A ~25% lower dose of Codeine Contin&reg; should then be initiated, equally divided into 2 daily doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Discontinuation of therapy:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Gradual dose reduction is recommended if clinically appropriate. Initially reduce the total daily dose by 50% and administer equally divided into 2 daily doses for 2 days followed by a 25% reduction every 2 days thereafter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Treatment of cough (unlabeled use):",
"     </b>",
"     Oral: Reported doses vary; range: 7.5-120 mg/day as a single dose or in divided doses (Bolser, 2006; Smith, 2010);",
"     <b>",
"      Note:",
"     </b>",
"     The American College of Chest Physicians does not recommend the routine use of codeine as an antitussive in patients with upper respiratory infections (Bolser, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F154197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32230?source=see_link\">",
"      see \"Codeine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     These are guidelines and do not represent the maximum doses that may be required in all patients. Doses should be titrated to pain relief/prevention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Pain management (analgesic; unlabeled use):",
"     </b>",
"     Oral: Immediate release (tablet, oral solution): Initial: 0.5-1 mg/kg/dose every 4 hours as needed; maximum: 60 mg/dose (American Pain Society, 2008)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F154181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F154182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Manufacturer&rsquo;s recommendations: Clearance may be reduced; active metabolites may accumulate. Initiate at lower doses or longer dosing intervals followed by careful titration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Alternate recommendations: The following guidelines have been used by some clinicians (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 50% of dose",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F154183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); however, initial lower doses or longer dosing intervals followed by careful titration are recommended.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F154154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for prescription compounding, as phosphate: USP: 100% (10 g, 25 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as phosphate: 30 mg/5 mL (500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as sulfate: 30 mg/5 mL (500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as phosphate: 30 mg [DSC], 60 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as sulfate: 15 mg, 30 mg, 60 mg",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, controlled release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Codeine Contin&reg;: 50 mg, 100 mg, 150 mg, 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F154138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F154217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F14280402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Oral solution:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM302557.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM302557.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F154159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May administer without regard to meals. Take with food or milk to decrease adverse GI effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Controlled release tablets: Codeine Contin&reg; (Canadian availability; not available in U.S.): Tablets should be swallowed whole; do not chew, dissolve, or crush.  All strengths may be halved,",
"     <b>",
"      except",
"     </b>",
"     the 50 mg tablets; half tablets should also be swallowed intact.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F154158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of mild-to-moderately-severe pain",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F13388435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term relief of cough in select patients",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F154226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Codeine may be confused with Cardene&reg;, Cordran&reg;, iodine, Lodine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F154213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, cardiac arrest, circulatory depression, flushing, hyper-/hypotension, palpitation, shock, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal dreams, agitation, anxiety, apprehension, chills,  coordination impaired, depression, disorientation, dizziness, drowsiness, dysphoria, euphoria, faintness, fatigue, hallucinations, headache, insomnia, intracranial pressure increased, lightheadedness, nervousness, sedation, shakiness, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps/pain, anorexia, biliary tract spasm, constipation, diarrhea, nausea, pancreatitis, taste disturbance, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary hesitancy/retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia, rigidity, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, diplopia, miosis, nystagmus, visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm, dyspnea, laryngospasm, respiratory arrest, respiratory depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F154162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to codeine or any component of the formulation; respiratory depression in the absence of resuscitative equipment; acute or severe bronchial asthma or hypercarbia; presence or suspicion of paralytic ileus",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling):  Hypersensitivity to other opioid analgesics; cor pulmonale; acute alcoholism; delirium tremens; severe CNS depression; convulsive disorders; increased cerebrospinal or intracranial pressure; head injury; suspected surgical abdomen; use with or within 14 days of MAO inhibitors.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F154142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Constipation: Use may cause or aggravate constipation; chronic use may result in obstructive bowel disease, particularly in those with underlying intestinal motility disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: May cause hypotension; use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), or drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenanthrene hypersensitivity: Use with caution in patients with hypersensitivity reactions to other phenanthrene-derivative opioid agonists (hydrocodone, hydromorphone, levorphanol, oxycodone, oxymorphone).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory depression: May cause dose-related respiratory depression. The risk is increased in elderly patients, debilitated patients, and patients with conditions associated with hypoxia, hypercapnia, or upper airway obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency, including Addison's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Biliary tract impairment: Use with caution in patients with biliary tract dysfunction; acute pancreatitis may cause constriction of sphincter of Oddi; may increase amylase/lipase levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression/coma: Use with caution in patients with CNS depression or coma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal obstruction: Avoid use in patients with gastrointestinal obstruction, particularly paralytic ileus; chronic use may result in obstructive bowel disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur. May also interfere with pupillary response and consciousness, thereby, affecting neurologic examination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obesity: Use with caution in patients who are morbidly obese.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with pre-existing respiratory compromise (hypoxia and/or hypercapnia), COPD or other obstructive pulmonary disease, and kyphoscoliosis or other skeletal disorder which may alter respiratory function; critical respiratory depression may occur, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: May induce or aggravate seizures; use with caution in patients with seizure disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP2D6 &ldquo;ultrarapid metabolizers&rdquo;: Use caution in patients with two or more copies of the variant CYP2D6*2 allele; may have extensive conversion to morphine and thus increased opioid-mediated effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects. Consider decreasing the initial dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfites: Some preparations contain sulfites which may cause allergic reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abuse/misuse/diversion: Healthcare provider should be alert to the potential for abuse, misuse, and diversion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Concurrent use of agonist/antagonist analgesics may precipitate withdrawal symptoms and/or reduced analgesic efficacy  in patients following prolonged therapy with mu opioid agonists. Abrupt discontinuation following prolonged use may also lead to withdrawal symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F154209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F154147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatostatin Analogs: May decrease the metabolism of Codeine. The formation of two major codeine metabolites (morphine and norcodeine) may be impaired by somatostatin analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F154173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease codeine levels. Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F154149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5182686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. Opioid analgesics cross the placenta. In humans, birth defects (including some heart defects) have been associated with maternal use of opioid analgesics, including codeine, during the first trimester of pregnancy (Broussard, 2011). Use of opioids during pregnancy may produce physical dependence in the neonate. Symptoms of opioid withdrawal may include excessive crying, diarrhea, fever, hyper-reflexia, irritability, respiratory rate increased, sneezing, tremors, vomiting, or yawning; respiratory depression may occur in the newborn if opioids are used prior to delivery.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F154186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5182688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Codeine and its metabolite (morphine) are found in breast milk and can be detected in the serum of nursing infants. The relative dose to a nursing infant has been calculated to be ~1% of the weight-adjusted maternal dose. Higher levels of morphine may be found in the breast milk of lactating mothers who are &ldquo;ultrarapid metabolizers&rdquo; of codeine; patients with two or more copies of the variant CYP2D6*2 allele may have extensive conversion to morphine and thus increased opioid-mediated effects. In one case, excessively high serum concentrations of morphine were reported in a breast-fed infant following maternal use of acetaminophen with codeine. The mother was later found to be an &ldquo;ultrarapid metabolizer&rdquo; of codeine; symptoms in the infant included feeding difficulty and lethargy, followed by death. Caution should be used since most persons are not aware if they have the genotype resulting in &ldquo;ultra-rapid metabolizer&rdquo; status. When codeine is used in breast-feeding women, it is recommended to use the lowest dose for the shortest duration of time and observe the infant for increased sleepiness, difficulty in feeding or breathing, or limpness (FDA, 2007; Koren, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Codeine Phosphate Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg/mL (2 mL): $2.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg/mL (2 mL): $3.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Codeine Sulfate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg/5 mL (500 mL): $128.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Codeine Sulfate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (100): $52.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $56.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (100): $103.48",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F154151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pain relief, respiratory and mental status, blood pressure, heart rate",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F154155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic: Not established",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F154164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Actacode (AU);",
"     </li>",
"     <li>",
"      Antitussivum Burger (DE);",
"     </li>",
"     <li>",
"      Bronchicum (DE);",
"     </li>",
"     <li>",
"      Bronchodine (BE);",
"     </li>",
"     <li>",
"      Cobitussin (TW);",
"     </li>",
"     <li>",
"      Codant (IE);",
"     </li>",
"     <li>",
"      Codedrill sans sucre (FR);",
"     </li>",
"     <li>",
"      Codein (AR, KP);",
"     </li>",
"     <li>",
"      Codeine Linctus (GB);",
"     </li>",
"     <li>",
"      Codeine Phosphate (CY, CZ, NZ);",
"     </li>",
"     <li>",
"      Codeini phosphatis (HR);",
"     </li>",
"     <li>",
"      Codeinsaft von ct (DE);",
"     </li>",
"     <li>",
"      Codeintropfen Ribbeck (DE);",
"     </li>",
"     <li>",
"      Codeintropfen von ct (DE);",
"     </li>",
"     <li>",
"      Codeinum Phosphorcum (PL);",
"     </li>",
"     <li>",
"      Codeinum phosphoricum Berlin-Chemie (DE);",
"     </li>",
"     <li>",
"      Codeinum phosphoricum Compretten (DE);",
"     </li>",
"     <li>",
"      Codeisan (PT);",
"     </li>",
"     <li>",
"      Codenfan (FR);",
"     </li>",
"     <li>",
"      Coderit (MX);",
"     </li>",
"     <li>",
"      Coderpina (GT, HN, SV);",
"     </li>",
"     <li>",
"      codi OPT (DE);",
"     </li>",
"     <li>",
"      Codicaps (DE);",
"     </li>",
"     <li>",
"      Codicompren (DE);",
"     </li>",
"     <li>",
"      Codiforton (DE);",
"     </li>",
"     <li>",
"      Codin Linctus (IN);",
"     </li>",
"     <li>",
"      Codipertussin (DE);",
"     </li>",
"     <li>",
"      Codipront mono (DE, LU);",
"     </li>",
"     <li>",
"      Codipront N (PH);",
"     </li>",
"     <li>",
"      Compretten (DE);",
"     </li>",
"     <li>",
"      Contrapect (DE);",
"     </li>",
"     <li>",
"      Dicton (DE, LU);",
"     </li>",
"     <li>",
"      Galcodine (GB);",
"     </li>",
"     <li>",
"      Glottyl (LU);",
"     </li>",
"     <li>",
"      Histaverin (ES);",
"     </li>",
"     <li>",
"      Kaodene (GB);",
"     </li>",
"     <li>",
"      Kodein (NO);",
"     </li>",
"     <li>",
"      Kodein Recip (SE);",
"     </li>",
"     <li>",
"      Kodein &rdquo;Dak&rdquo; (DK);",
"     </li>",
"     <li>",
"      Lertus CD (MX);",
"     </li>",
"     <li>",
"      Neo-Codion[Sirup] (DE);",
"     </li>",
"     <li>",
"      Optipect (DE);",
"     </li>",
"     <li>",
"      Para-Co (TH);",
"     </li>",
"     <li>",
"      Pectinfant (LU);",
"     </li>",
"     <li>",
"      Pectoral Edulcor (LU);",
"     </li>",
"     <li>",
"      Pulmocodeina (EC);",
"     </li>",
"     <li>",
"      Tricodein (DE);",
"     </li>",
"     <li>",
"      Tricodein Solco (AT, CH);",
"     </li>",
"     <li>",
"      Tryasol (DE);",
"     </li>",
"     <li>",
"      Tussamag-Codeinsaft (DE);",
"     </li>",
"     <li>",
"      Tussipect Codein Tropfen Mono (DE);",
"     </li>",
"     <li>",
"      Tussoret (DE);",
"     </li>",
"     <li>",
"      Tussoretard (DE);",
"     </li>",
"     <li>",
"      Tylex CD (MX);",
"     </li>",
"     <li>",
"      Voltaren Forte (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F154141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to opioid receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; causes cough suppression by direct central action in the medulla; produces generalized CNS depression",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F154161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Oral: Immediate release: 0.5-1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Oral: Immediate release: 1-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Immediate release: 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: ~3-6 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~7% to 25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via UGT2B7 and UGT2B4 to codeine-6-glucuronide, via CYP2D6 to morphine (active), and via CYP3A4 to norcodeine. Morphine is further metabolized via glucuronidation to morphine-3-glucuronide and morphine-6-glucuronide (active).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 53%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Immediate release: 1 hour; Controlled release (Canadian availability; not available in the U.S.): 3.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~90%, ~10% of the total dose as unchanged drug); feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, &ldquo;Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3): 776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/0/35848/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 18, 135.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bolser DC, &ldquo;Cough Suppressant and Pharmacologic Protussive Therapy: ACCP Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2006, 129(1 Suppl):238-48.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/0/35848/abstract-text/16428717/pubmed\" id=\"16428717\" target=\"_blank\">",
"        16428717",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Broussard CS, Rasmussen SA, Reefhuis J, et al, \"National Birth Defects Prevention Study: Maternal Treatment With Opioid Analgesics and Risk for Birth Defects,\"",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2011, 204(4):314.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/0/35848/abstract-text/21345403/pubmed\" id=\"21345403\" target=\"_blank\">",
"        21345403",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cardan E, &ldquo;Fatal Case of Codeine Poisoning,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1981, 1(8233):1313.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Groot AC and Conemans J, &ldquo;Allergic Urticarial Rash From Oral Codeine,&rdquo;",
"      <i>",
"       Contact Dermatitis",
"      </i>",
"      , 1986, 14(4):209-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/0/35848/abstract-text/2941218/pubmed\" id=\"2941218\" target=\"_blank\">",
"        2941218",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Desjardins PJ, Cooper SA, Gallegos TL, et al, &ldquo;The Relative Analgesic Efficacy of Propiram Fumarate, Codeine, Aspirin, and Placebo in Postimpaction Dental Pain,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1984, 24(1):35-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/0/35848/abstract-text/6368614/pubmed\" id=\"6368614\" target=\"_blank\">",
"        6368614",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferrell BA, &ldquo;Pain Management in Elderly People,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1991, 39(1):64-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/0/35848/abstract-text/1670940/pubmed\" id=\"1670940\" target=\"_blank\">",
"        1670940",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Forbes JA, Keller CK, Smith JW, et al, &ldquo;Analgesic Effect of Naproxen Sodium, Codeine, a Naproxen-Codeine Combination and Aspirin on the Postoperative Pain of Oral Surgery,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1986, 6(5):211-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/0/35848/abstract-text/3540871/pubmed\" id=\"3540871\" target=\"_blank\">",
"        3540871",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Irwin RS, Boulet LP, Cloutier MM, et al, &ldquo;Managing Cough as a Defense Mechanism and as a Symptom: A Consensus Panel Report of the American College of Chest Physicians,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 198, 114(2):133-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/0/35848/abstract-text/9725800/pubmed\" id=\"9725800\" target=\"_blank\">",
"        9725800",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ivey HH and Kattwinkel J, &ldquo;Danger of Actifed-C,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1976, 57(1):164-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/0/35848/abstract-text/1246497/pubmed\" id=\"1246497\" target=\"_blank\">",
"        1246497",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobi J, Fraser GL, Coursin DB, et al, &ldquo;Clinical Practice Guidelines for the Sustained Use of Sedatives and Analgesics in the Critically Ill Adult,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2002, 30(1):119-41. Available at file://www.sccm.org/pdf/sedatives.pdf. Accessed August 2, 2003.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/0/35848/abstract-text/11902253/pubmed\" id=\"11902253\" target=\"_blank\">",
"        11902253",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaiko RF, Wallenstein SL, Rogers AG, et al, &ldquo;Narcotics in the Elderly,&rdquo;",
"      <i>",
"       Med Clin North Am",
"      </i>",
"      , 1982, 66(5):1079-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/0/35848/abstract-text/7132470/pubmed\" id=\"7132470\" target=\"_blank\">",
"        7132470",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khan K and Chang J, &ldquo;Neonatal Abstinence Syndrome Due to Codeine,&rdquo;",
"      <i>",
"       Arch Dis Child Fetal Neonatal Ed",
"      </i>",
"      , 1997; 76(1): F59-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/0/35848/abstract-text/9059191/pubmed\" id=\"9059191\" target=\"_blank\">",
"        9059191",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koren G, Caims J, Chitayat D, et al, &ldquo;Pharmacogenetics of Morphine Poisoning in a Breastfed Neonate of a Codeine-Prescribed Mother,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2006, 368(9536):704.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/0/35848/abstract-text/16920476 /pubmed\" id=\"16920476 \" target=\"_blank\">",
"        16920476",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/0/35848/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain,&rdquo; 6th ed, Glenview, IL: American Pain Society, 2008.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reynolds EW, Riel-Romero RM, and Bada HS, &ldquo;Neonatal Abstinence Syndrome and Cerebral Infarction Following Maternal Codeine Use During Pregnancy,&rdquo;",
"      <i>",
"       Clin Pediatr",
"      </i>",
"      , 2007, 46(7):639-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/0/35848/abstract-text/17704497/pubmed\" id=\"17704497\" target=\"_blank\">",
"        17704497",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SM, Schroeder K, and Fahey T, &ldquo;Over-the-Counter (OTC) Medications for Acute Cough in Children and Adults in Ambulatory Settings (Review),&rdquo;",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2010, 9:1-33.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spigset O and Hagg S,  &ldquo;Analgesics and Breast-Feeding: Safety Considerations,&rdquo;",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2000, 2(3):223-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/0/35848/abstract-text/10937472/pubmed\" id=\"10937472\" target=\"_blank\">",
"        10937472",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research, &ldquo;Public Health Advisory: Use of Codeine by Some Breastfeeding Mothers May Lead to Life-Threatening Side Effects in Nursing Babies.&rdquo; Available at",
"      <a href=\"file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm054717.htm\" target=\"_blank\">",
"       file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm054717.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilkins D, Rollins DE, Seaman J, et al, &ldquo;Quantitative Determination of Codeine and Its Major Metabolites in Human Hair by Gas Chromatography - Positive Ion Chemical Ionization Mass Spectrometry: A Clinical Application,&rdquo;",
"      <i>",
"       J Anal Toxicol",
"      </i>",
"      , 1995, 19(5):269-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/0/35848/abstract-text/7500611/pubmed\" id=\"7500611\" target=\"_blank\">",
"        7500611",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zacher JL and Givone DM, &ldquo;False-Positive Urine Opiate Screening Associated With Fluoroquinolone Use,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2004, 38:1525-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/0/35848/abstract-text/15252190/pubmed\" id=\"15252190\" target=\"_blank\">",
"        15252190",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9291 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-EF0CD76C64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_0_35848=[""].join("\n");
var outline_f35_0_35848=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14854336\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154177\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154215\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154180\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154197\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154181\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154182\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154183\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154154\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950033\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154138\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154217\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14280402\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154159\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154158\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13388435\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154226\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154213\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154162\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154142\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154209\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154147\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154173\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154149\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5182686\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154186\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5182688\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323077\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154151\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154155\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154164\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154141\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154161\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9291\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9291|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/44/14021?source=related_link\">",
"      Codeine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32230?source=related_link\">",
"      Codeine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_0_35849="Microscopic findings of PSP";
var content_f35_0_35849=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F66637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F66637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 579px\">",
"   <div class=\"ttl\">",
"    Microscopic neuropathology of progressive supranuclear palsy (PSP)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 559px; height: 577px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient was diagnosed clinicaly with PSP-parkinsonism, a variant of classic PSP. The substantia nigra (A-E) shows neuronal loss and gliosis. Several surviving neurons contain globose neurofibrillary tangles (NFTs) (A, arrows). Tau immunostaining (B) demonstrates the NFTs (arrows) and numerous thread-like processes. The globose NFT expands the cytoplasmic profile of residual neurons (A-C) and its characteristic coiled \"ball of yarn configuration\" is highlighted by routine silver preparations (D) and tau (E). Tau-immunoreactive neuroglial lesions are widespread and include NFTs (arrows), pretangles (arrowhead), tufted astrocytes (thin arrows), and threads in neocortex (F) and striatum (G). Selective anti-4R tau decorates a tufted astrocyte in the subthalamic nucleus (H) and an oligodendroglial coiled body (I) in the internal capsule, as well as numerous thread-like deposits.",
"    <div class=\"footnotes\">",
"     A, C: hematoxylin-eosin; B, E-G: anti-tau; D: Bielschowsky; H, I: anti-4R tau; A, B: original magnification x200; C-E, H, I: original magnification x600; F, G: original magnification x400.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Golbe LI, Boeve BF, Keegan BM, Parisi JE. An 81-year-old man with imbalance and memory impairment. Neurology 2007; 68:1147. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_0_35849=[""].join("\n");
var outline_f35_0_35849=null;
var title_f35_0_35850="Parathyroid exploration for primary hyperparathyroidism";
var content_f35_0_35850=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Parathyroid exploration for primary hyperparathyroidism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/0/35850/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/0/35850/contributors\">",
"     Nancy D Perrier, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/0/35850/contributors\">",
"     Paxton V Dickson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/0/35850/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/0/35850/contributors\">",
"     Sally E Carty, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/0/35850/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/0/35850/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/0/35850/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/0/35850/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H28792026\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary hyperparathyroidism (PHPT) is typically diagnosed when hypercalcemia is detected incidentally on routine biochemical screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/1\">",
"     1",
"    </a>",
"    ]. However, hyperparathyroidism and hypercalcemia can lead to an array of symptoms, as described below. Parathyroidectomy provides definitive therapy for PHPT and is recommended for all patients with symptomatic disease, selected patients with asymptomatic disease, and patients with familial disease.",
"   </p>",
"   <p>",
"    The surgical treatment for PHPT will be reviewed here. The medical management of hyperparathyroidism, surgical anatomy of the parathyroid glands, and the role of preoperative localization are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/23/29045?source=see_link\">",
"     \"Surgical anatomy of the parathyroid glands\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/60/18377?source=see_link\">",
"     \"Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/47/8954?source=see_link\">",
"     \"Management of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10466681\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a diagnosis of primary hyperparathyroidism has been biochemically confirmed, a decision regarding surgical intervention versus observation must be made. The recommendations vary depending on whether the patient is symptomatic, asymptomatic, or has familial hyperparathyroidism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/47/8954?source=see_link\">",
"     \"Management of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10466688\">",
"    <span class=\"h2\">",
"     Symptomatic primary hyperparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical intervention is recommended for patients with biochemically confirmed hyperparathyroidism who present with symptomatic disease. Clinical manifestations include polydipsia and polyuria, nephrolithiasis, osteoporosis, fragility fractures, pancreatitis, peptic ulcer disease, gastroesophageal reflux, and significant neurocognitive dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1338?source=see_link\">",
"     \"Clinical manifestations of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10466695\">",
"    <span class=\"h2\">",
"     Asymptomatic primary hyperparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic primary hyperparathyroidism refers to patients without objective features of disease such as osteoporosis or nephrolithiasis. Although some of these patients may be truly asymptomatic, many have nonspecific and often subtle symptoms such as fatigue, depression, irritability, anxiety, anorexia, and difficulty with concentration or memory impairment. These subjective symptoms are often difficult to quantify and are frequently not fully appreciated until successful surgical intervention unmasks an improvement in these complaints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/3\">",
"     3",
"    </a>",
"    ]. Completely asymptomatic primary hyperparathyroidism is uncommon. Surgical intervention is indicated in asymptomatic patients who are &lt;50 years of age and in patients considered likely to progress to symptomatic disease based upon their serum calcium level (&gt;1",
"    <span class=\"nowrap\">",
"     mg/dl",
"    </span>",
"    above normal), glomerular filtration rate, and bone density (revealing a T score &lt;-2.5) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The management of asymptomatic patients is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/47/8954?source=see_link\">",
"     \"Management of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10466716\">",
"    <span class=\"h2\">",
"     Persistent or recurrent primary hyperparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with persistent (&lt;6 months from initial exploration) or recurrent disease (&gt;6 months from initial exploration) after unsuccessful parathyroidectomy, the diagnosis of primary hyperparathyroidism should be reconfirmed, and the surgical indications should be reevaluated. Reoperative surgery is associated with higher incidences of recurrent laryngeal nerve injury and permanent hypoparathyroidism as well as higher rates of failure to cure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Thus, some surgeons prefer to have two concomitant, concordant imaging studies before performing reoperation. Precise description of gland location using a standardized nomenclature system is particularly useful for reoperative surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/60/18377?source=see_link&amp;anchor=H6#H6\">",
"     \"Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism\", section on 'Reoperation for recurrent or persistent hyperparathyroidism'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/60/18377?source=see_link&amp;anchor=H6958973#H6958973\">",
"     \"Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism\", section on 'Standardized nomenclature for adenoma location'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the majority of reoperations for persistent or recurrent primary hyperparathyroidism, the overactive parathyroid gland is identified in a usual and expected anatomic location, such as the deep tracheoesophageal groove or superior portion of the cervical thymus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Ectopic parathyroid glands, such as undescended glands or those deep within the mediastinum, are uncommon. The rate of successful reoperation may be increased with intraoperative parathyroid hormone monitoring to confirm excision of all hyperfunctioning tissue and in some cases, to guide laterality of dissection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10466879\">",
"     'Intraoperative assessment tools'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H260978\">",
"    <span class=\"h2\">",
"     Familial primary hyperparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary forms of primary hyperparathyroidism may occur as part of a multiple endocrine neoplasia syndrome (MEN) or as isolated familial hyperparathyroidism (FHPT). Patients with multiple endocrine neoplasia type 1 (MEN1) hereditary disease have a more aggressive form of hyperparathyroidism. The disease is multiglandular in MEN1, and in MEN 2 there is also a higher incidence of multiglandular disease, although solitary gland enlargement does occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Bilateral neck exploration with subtotal parathyroidectomy is appropriate in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. However, the potential risks of permanent hypoparathyroidism as a result of overly aggressive surgical treatment must be considered and discussed with the patient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/14/43240?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22794?source=see_link\">",
"     \"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/37/44632?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of hypocalcemia\", section on 'Hypoparathyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H260985\">",
"    <span class=\"h2\">",
"     Parathyroid cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parathyroid cancer is a rare cause of primary hyperparathyroidism. This diagnosis should be considered preoperatively in a patient with a markedly elevated serum calcium or PTH level, hyperparathyroidism with a palpable or painful neck mass, or imaging that shows local soft tissue invasion. The condition may also be diagnosed intraoperatively by the alert surgeon when a firm adherent mass with a white or gray appearance is noted. The surgical management of parathyroid cancer is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/23/13688?source=see_link&amp;anchor=H7#H7\">",
"     \"Parathyroid carcinoma\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H260992\">",
"    <span class=\"h2\">",
"     Parathyroid crisis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parathyroid crisis is characterized by severe hypercalcemia with the serum calcium concentration usually above 14",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.8",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and marked symptoms of hypercalcemia, in particular, central nervous system dysfunction, nausea, and vomiting. Because PHPT disease is progressive, most patients have a slow steady increase in calcium over time and do not have acute spikes in serum calcium levels.",
"   </p>",
"   <p>",
"    Emergency parathyroidectomy is rare, but is indicated in patients with parathyroid crisis. In a report of 43 patients who underwent emergent surgery for parathyroid crisis, 42 were normocalcemic in the immediate postoperative period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/16\">",
"     16",
"    </a>",
"    ]. Ninety-three percent of patients followed long-term remained normocalcemic, while 7 percent had recurrent hypercalcemia requiring further intervention. Emergency parathyroidectomy may require bilateral exploration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1338?source=see_link&amp;anchor=H24#H24\">",
"     \"Clinical manifestations of primary hyperparathyroidism\", section on 'Parathyroid crisis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28793494\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three contraindications to parathyroid surgery include: contralateral recurrent laryngeal nerve injury, symptomatic cervical disc disease, and familial hypocalciuric hypercalcemia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A known contralateral recurrent laryngeal nerve (RLN) injury or vocal cord dysfunction is a relative contraindication to neck exploration for parathyroidectomy, since bilateral RLN injury can be life-threatening. Thus, an evaluation of vocal cord function should be performed preoperatively in any patient who is hoarse, who has a history of prior anterior cervical surgery, or a suspected RLN dysfunction. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/57/31642?source=see_link&amp;anchor=H31#H31\">",
"       \"Initial and reoperative thyroidectomy\", section on 'Recurrent laryngeal nerve injury'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Symptomatic cervical disc disease is a relative contraindication to neck exploration because of the mild neck extension necessary in positioning patients for thyroid and parathyroid surgery. Hyperextension may potentially cause spinal cord injury in patients with cervical disc disease. Thus, if cervical disc disease is present, the disc disease should be evaluated and in some cases corrected prior to parathyroidectomy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/24/1418?source=see_link\">",
"       \"Evaluation of the patient with neck pain and cervical spine disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Familial hypocalciuric hypercalcemia (FHH) is an absolute contraindication to parathyroid surgery. FHH is an autosomal dominant inherited disorder which often leads to unnecessary parathyroid surgery. These patients do not have primary hyperparathyroidism, and surgical intervention does not result in cure. The disease is suspected when persistent, mildly-elevated serum calcium levels and a high-normal or mildly-elevated parathormone level are noted in association with normal renal function and low 24 hour urine calcium excretion (urine",
"      <span class=\"nowrap\">",
"       calcium/creatinine",
"      </span>",
"      ratio &lt;0.01). The low urinary calcium level (&lt;100",
"      <span class=\"nowrap\">",
"       mg/24",
"      </span>",
"      hours) is the mainstay of the diagnosis . FHH results from a higher renal setpoint for calcium excretion. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19258?source=see_link\">",
"       \"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3609736\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to offering parathyroid surgery, the endocrine surgeon must carefully review and confirm the preoperative diagnosis to avoid unnecessary surgery. Error in diagnosis is a major cause of failed initial exploration. Initial evaluation includes a thorough history, review of systems, physical examination, and review of the biochemical diagnosis. The medications that may confound the diagnosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cause hypercalcemia should be reviewed. The diagnosis and differential diagnosis of primary hyperparathyroidism is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/26/5545?source=see_link\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because hyperthyroidism can complicate parathyroid exploration, a preoperative thyroid stimulating hormone (TSH) level and T4 should be obtained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/17\">",
"     17",
"    </a>",
"    ]. Specific inquiry about a history of the conditions, symptoms, comorbidities, and medications associated with primary hyperthyroidism helps to guide treatment and decision making. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26520?source=see_link\">",
"     \"Diagnosis of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A personal or family history of other endocrinopathies may suggest an MEN syndrome or isolated familial hyperparathyroidism. In a case series of 939 patients referred for surgery of apparent sporadic hyperparathyroidism, MEN-1 was identified in 4.5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/14/43240?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22794?source=see_link\">",
"     \"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10466851\">",
"    <span class=\"h1\">",
"     CHOICE OF PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the decision to perform a parathyroid operation is made, the surgeon must decide whether a standard bilateral neck exploration or a more focused minimally invasive parathyroidectomy is appropriate. The goal of parathyroid surgery is durable biochemical cure, defined as eucalcemia at six months postoperatively. Because approximately 15 percent of patients with primary hyperparathyroidism will inevitably have hyperplasia or double adenoma, the surgeon must address the possibility of multiglandular disease. The standard surgical approach has traditionally been bilateral neck exploration under general anesthesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. However, with increased experience and availability, minimally invasive parathyroidectomy techniques combined with intraoperative PTH monitoring have emerged as the procedure of choice and appear to be as effective as bilateral cervical exploration in appropriately selected patients, as described below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10466858\">",
"    <span class=\"h2\">",
"     Bilateral parathyroid exploration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral parathyroid exploration has been well-demonstrated to exclude or identify multiglandular disease with high surgical cure rates (95 to 99 percent). A low threshold to either begin with or proceed to a bilateral neck exploration is warranted in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with negative (non-localizing) preoperative imaging studies or when bilateral foci are detected, this situation precludes a targeted minimally invasive approach.",
"     </li>",
"     <li>",
"      Most forms of hereditary hyperparathyroidism are an indication for bilateral parathyroid exploration due to the predictable involvement of multiple glands. A bilateral parathyroid exploration should be considered for young male patients with apparent sporadic primary hyperparathyroidism because they are at increased risk for MEN-1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/42/8872?source=see_link&amp;anchor=H14#H14\">",
"       \"Approach to therapy in multiple endocrine neoplasia type 2\", section on 'Surgical approach'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/61/38871?source=see_link&amp;anchor=H6#H6\">",
"       \"Multiple endocrine neoplasia type 1: Treatment\", section on 'Surgical approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Concomitant thyroid disease requiring surgical resection, such as biopsy proven papillary thyroid cancer, necessitates bilateral exploration. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/60/18377?source=see_link&amp;anchor=H2#H2\">",
"       \"Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism\", section on 'Imaging modalities'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bilateral neck exploration should be considered in pregnant patients due to the radiation required for some localization studies. However, if ultrasound expertise is available and the results show an apparent single adenoma, a focused approach can be planned. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/47/8954?source=see_link&amp;anchor=H23978864#H23978864\">",
"       \"Management of primary hyperparathyroidism\", section on 'Pregnancy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"      associated hyperparathyroidism has a higher incidence of being associated with multiple gland involvement and may require bilateral exploration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. However, if intraoperative PTH monitoring is available, a focused dissection may be attempted [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10466865\">",
"    <span class=\"h2\">",
"     Focused parathyroid exploration",
"    </span>",
"    &nbsp;&mdash;&nbsp;When combined with use of intraoperative PTH monitoring, minimally invasive parathyroidectomy techniques result in excellent outcomes that are comparable to a traditional bilateral cervical exploration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. Localization results inform the surgeon where to start looking for the adenoma, and intraoperative PTH results suggest to",
"    <span class=\"nowrap\">",
"     her/him",
"    </span>",
"    when to stop looking.",
"   </p>",
"   <p>",
"    The smaller incisions and less extensive dissection lead to reduced postoperative pain and a lower incidence of hypocalcemia from ischemia of other glands. This approach is appropriate for patients with unequivocal imaging suggesting unilateral pathology, no suggestion of concomitant, thyroid disease requiring surgical intervention, and no family history of multiple endocrine neoplasia.",
"   </p>",
"   <p>",
"    The success of a targeted parathyroidectomy is dependent upon preoperative localization studies that permit the surgeon to limit the operative field to the region where a single radiologic focus is identified, combined with intraoperative PTH monitoring which confirms that no other hyperfunctional gland remains in situ. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/60/18377?source=see_link\">",
"     \"Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H10466879\">",
"     'Intraoperative assessment tools'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    When preoperative localization procedures do not identify an adenoma or the adenoma cannot be found during minimally invasive surgery, bilateral neck exploration must be performed. Minimally invasive procedures should be performed by an experienced surgeon in case conversion to a bilateral operation is required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there are few randomized trials comparing minimally invasive parathyroidectomy with the traditional bilateral approach, cure rates appear to be similar when the procedures are performed by experienced endocrine surgeons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/30-36\">",
"     30-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 91 patients with newly diagnosed primary hyperparathyroidism randomly assigned to bilateral neck exploration (no preoperative imaging) or minimally invasive exploration (preoperative sestamibi scan and intraoperative PTH measurement), long-term results were similar. After five years, six patients had persistent or recurrent hyperparathyroidism (four and two patients in the minimally invasive and bilateral groups, respectively). However, 18 of 47 subjects assigned to minimally invasive surgery required bilateral exploration (for negative sestamibi scan or intraoperative PTH measurement that did not decline by &ge;60 percent). Thus, the success of minimally invasive surgery is dependent upon the surgeon's expertise and understanding of when to convert to a bilateral approach.",
"     </li>",
"     <li>",
"      One of the largest published series to date, a retrospective analysis of 656 consecutive parathyroid explorations, compared the results obtained using conventional (n = 401) and minimally invasive surgery (n = 255) surgery with intraoperative PTH monitoring [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/20\">",
"       20",
"      </a>",
"      ]. The overall success rate for the entire group was 98 percent, and there were no significant differences in cure rates between traditional (97 percent) and minimally invasive (99 percent) techniques. The overall complication rates were also similar, but minimally invasive surgery was associated with a 50 percent reduction in operating time, a seven-fold reduction in length of hospital stay, and a mean cost savings of $2693 per case.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27512606\">",
"    <span class=\"h2\">",
"     Endoscopic and video-assisted minimally invasive parathyroidectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Video-assisted or endoscopic minimally invasive approaches for parathyroidectomy have been advocated by some for the management of PHPT (",
"    <a class=\"graphic graphic_figure graphicRef58251 \" href=\"mobipreview.htm?41/30/42465\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Candidates for an endoscopic parathyroidectomy are patients with sporadic PHPT and unequivocal preoperative localization studies. Contraindications include prior extensive neck surgery, hereditary primary hyperparathyroidism, large goiters, multigland disease, obesity, and suspicion of parathyroid carcinoma.",
"   </p>",
"   <p>",
"    Two approaches have been described for video-assisted parathyroidectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/39\">",
"     39",
"    </a>",
"    ]. A randomized trial of 143 patients who underwent open minimally invasive parathyroidectomy (75 patients) or one of the two video-assisted approaches (68 patients) showed no significant difference in conversion rates or outcomes. The open surgery took less time than the video-assisted techniques (60 versus 84 minutes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/40\">",
"     40",
"    </a>",
"    ]. Except for shorter incision length, video-assisted parathyroidectomy does not offer significant advantage over open minimally invasive parathyroidectomy and should only be performed by surgeons who have first mastered the standard open operation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lateral endoscopic approach is performed by placing three working ports for the endoscope (one 10 mm and two 2 to 3 mm) along the anterior border of the sternocleidomastoid.&nbsp;Insufflation with carbon dioxide gas at 8 to 10 mmHg is used to create and maintain the working space [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/37,39\">",
"       37,39",
"      </a>",
"      ].&nbsp;The strap muscles are mobilized laterally and the thyroid anteromedially, allowing visualization of the lateral thyroid, recurrent laryngeal nerve, and ipsilateral parathyroid glands.&nbsp;A parathyroid adenoma can generally be removed through the 10 mm trocar or through the trocar site.&nbsp;Case series report conversion to open operation in 13.4 to 28 percent of cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/37,41\">",
"       37,41",
"      </a>",
"      ]. Conversion was required for a difficult dissection, bleeding, lack of intraoperative localization, and failure of the intraoperative PTH levels to normalize. Morbidity in one series of 339 cases included permanent recurrent laryngeal nerve palsy (one patient), injury to the internal jugular vein (one patient), sternocleidomastoid hematoma (two patients), capsular disruption (six patients), and persistent PHPT (three patients).&nbsp;",
"     </li>",
"     <li>",
"      The central gasless video-assisted technique utilizes a 15 mm transverse incision 2 cm above the sternal notch and development of the subplatysmal space [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/38\">",
"       38",
"      </a>",
"      ].&nbsp;No insufflation is used. The strap muscles are separated in the midline and a series of retractors is used to elevate the strap muscles laterally and the thyroid lobe medially, using a 30&deg; 5 mm endoscope to view the working space. Case series report conversion to open operation in 6 to 18 percent of cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/38,42\">",
"       38,42",
"      </a>",
"      ].&nbsp;Morbidity in one series of 370 patients included permanent recurrent laryngeal nerve palsy (three patients), transient hypocalcemia (10 patients), postoperative bleeding (one patient), and persistent PHPT (six patients). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28793366\">",
"    <span class=\"h1\">",
"     PREOPERATIVE LOCALIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parathyroid localization studies are an integral part of a minimally invasive parathyroid exploration. Localization studies should only be performed to help plan an intended operation when the biochemical diagnosis has been confirmed. The role of the imaging is to suggest where to start the surgical dissection. The expertise of the local radiologist in study selection is important since interpretation of studies is often user dependent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/26/5545?source=see_link\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a bilateral standard cervical exploration is planned, then there is little role for preoperative parathyroid localization studies since all parathyroid glands will be visualized. However, cervical ultrasound is frequently useful in identifying concomitant thyroid abnormalities that may need to be addressed at the same operation. Details of preoperative localization studies are discussed elsewhere in detail. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/60/18377?source=see_link\">",
"     \"Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H262466\">",
"    <span class=\"h1\">",
"     SURGEON'S SAFETY CHECKLIST FOR PARATHYROID EXPLORATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;To avoid surgical complications, the parathyroid surgeon should review and assess the patient&rsquo;s medical status as well as the preoperative laboratory and imaging workup [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. A preoperative checklist is a good way to assure that all safety issues have been addressed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Consent",
"      </strong>",
"      &ndash; The surgical consent should include the possibility of operative failure, transient or permanent paralysis of one or both vocal cords, a change in voice quality and strength, transient or permanent hypoparathyroidism, wound infection, and intraoperative or postoperative bleeding. (See",
"      <a class=\"local\" href=\"#H10466964\">",
"       'Complications'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Medical records",
"      </strong>",
"      &ndash; Prior laboratory reports should be reviewed to confirm the diagnosis, which is made on biochemical parameters. Documentation of preoperative vocal cord evaluation and any prior neck surgery (eg, thyroidectomy, an anterior approach to cervical disc repair or tracheostomy) should be available and reviewed.",
"     </li>",
"     <li>",
"      <strong>",
"       Imaging studies",
"      </strong>",
"      &ndash; Imaging studies should be reviewed, and pertinent images should be immediately available to the surgeon in the operating room suite to confirm laterality and location of the abnormal parathyroid gland or glands.",
"     </li>",
"     <li>",
"      <strong>",
"       Parathyroid hormone (PTH) monitoring",
"      </strong>",
"      &ndash; If intraoperative PTH monitoring is employed, a preincision PTH level should be obtained and used as a baseline value. A relative drop in PTH value of &gt;50 percent and into the normal range is suggestive of adequate removal of hyperfunctional parathyroid tissue. Adequate peripheral access via either peripheral intravenous catheter or arterial line should be established for intraoperative blood draws. Appropriate tubes and arrangements for transport of blood to the lab should be arranged prior to the surgical start. (See",
"      <a class=\"local\" href=\"#H10466887\">",
"       'Intraoperative parathyroid hormone monitoring'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Frozen section",
"      </strong>",
"      &ndash; Expert frozen section pathologic analysis should be available. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/57/31642?source=see_link&amp;anchor=H19#H19\">",
"       \"Initial and reoperative thyroidectomy\", section on 'Intraoperative frozen section'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Nerve monitoring",
"      </strong>",
"      &ndash; The decision to use intraoperative nerve monitoring is at the discretion of the operating surgeon [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/46\">",
"       46",
"      </a>",
"      ]. Intraoperative nerve monitoring necessitates availability of an anesthesiologist familiar with the proper positioning of the monitor. If intraoperative recurrent laryngeal nerve monitoring is to be used, the system should be tested prior to prepping and draping the patient. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/57/31642?source=see_link&amp;anchor=H5#H5\">",
"       \"Initial and reoperative thyroidectomy\", section on 'Intraoperative neuromonitoring'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Antibiotics",
"      </strong>",
"      &ndash; Parathyroid surgery is a clean procedure in a well-vascularized area, thus postoperative infections rates are very low [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/47\">",
"       47",
"      </a>",
"      ]. A perioperative antibiotic, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"       cefazolin",
"      </a>",
"      , is given selectively for patients who are immunocompromised or with other medical comorbidities that increase the risk of infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/48,49\">",
"       48,49",
"      </a>",
"      ]. When employed, antibiotics should be administered after arriving in the operating room and before the incision is made. The efficacy of antibiotic prophylaxis decreases if administered more than one hour before surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/50-52\">",
"       50-52",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link\">",
"       \"Overview of control measures to prevent surgical site infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Anticoagulation",
"      </strong>",
"      &ndash; Most parathyroidectomies are performed in the elective setting. Any bleeding diatheses, thrombocytopenia, and platelet dysfunction should be addressed and corrected prior to operative treatment. The risk of cervical hematoma and subsequent airway compromise from thyroid and parathyroid surgery make it particularly important that all anticoagulants such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , NSAIDS, and vitamin E are discontinued prior to surgical intervention. The appropriate management of anticoagulation in such patients is reviewed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/50/35626?source=see_link\">",
"       \"Management of anticoagulation before and after elective surgery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Deep venous thrombosis prophylaxis",
"      </strong>",
"      &ndash; For patients undergoing general anesthesia, primary prophylaxis for prevention of deep venous thrombosis, such as sequential compression devices, should be employed. Patients should also be encouraged to ambulate the night of surgery. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link\">",
"       \"Prevention of venous thromboembolic disease in surgical patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Surgical time-out",
"      </strong>",
"      &ndash; A surgical timeout should be performed with the entire operating room team (anesthesiologist, surgeon, nurse, scrub technician) to assure correct patient identity, laterality of operative field, intended operation, and the informed consent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10466879\">",
"    <span class=\"h1\">",
"     INTRAOPERATIVE ASSESSMENT TOOLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraoperative parathyroid hormone monitoring provides real-time confirmation of surgical cure. Use of a radioguided surgical probe has been advocated by some to enhance focused dissection and allow ex vivo confirmation that a sestamibi-avid gland has been removed. These techniques may be used in combination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10466887\">",
"    <span class=\"h2\">",
"     Intraoperative parathyroid hormone monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraoperative parathyroid hormone (PTH) monitoring provides a useful tool to indicate when all hyperfunctional parathyroid tissue has been adequately excised. Intraoperative PTH monitoring takes advantage of the short plasma half-life (three to five minutes) of PTH and a rapid assay technique that allows measurements while the patient is still in the operating room [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/27,53,54\">",
"     27,53,54",
"    </a>",
"    ]. A baseline PTH value is obtained at the start of the procedure, prior to skin incision. PTH levels are then measured at following removal of the suspected adenoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. A reduction of at least 50 percent from the baseline following excision of the hyperfunctioning gland is an accepted standard for intraoperative confirmation of success, although a number of centers also require that the PTH level drop into the normal range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/58/21416?source=see_link&amp;anchor=H12#H12\">",
"     \"Parathyroid hormone assays and their clinical use\", section on 'Intraoperative PTH assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intraoperative blood draws may be obtained from an arterial line, a peripheral IV, or from the ipsilateral internal jugular vein. For localization of a missing gland, bilateral jugular venous sampling for PTH levels can be performed at the time of exploration. A unilateral elevation is suspicious for a missing hyperfunctioning gland on that side. Bilateral PTH levels that are equivalent may be suggestive of hyperfunctioning parathyroid disease in the mediastinum. (See",
"    <a class=\"local\" href=\"#H1352796\">",
"     'Missing parathyroid glands'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    False-positive intraoperative PTH findings (defined as a &gt;50 percent decrease) followed by recurrent hyperparathyroidism should raise suspicion for a multiple endocrine neoplasia (MEN) syndrome. In a series of 269 patients, six had intraoperative PTH decreases consistent with cure, but later recurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/60\">",
"     60",
"    </a>",
"    ]. Three of the six had germline mutations in the MEN gene (MEN1), and two had mutations in the RET proto-oncogene (MEN2). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/14/43240?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22794?source=see_link\">",
"     \"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5041991\">",
"    <span class=\"h2\">",
"     Radioguided parathyroidectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of a radioguided probe has been advocated by some to serve as a useful adjunct in parathyroid exploration. The technique involves intravenous administration of technetium-99m labeled sestamibi approximately two hours preoperatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/61-64\">",
"     61-64",
"    </a>",
"    ]. Using sestamibi uptake as an indirect measure of parathyroid gland hyperfunction, the surgeon uses a handheld gamma probe in conjunction with preoperative imaging results to focus the incision over the site of greatest radioactivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Once the suspected offending gland or glands are removed, intraoperative PTH monitoring is utilized to confirm adenoma excision of identify multiglandular disease, and the gamma probe is also used to survey the surgical bed. An ex vivo radioactivity count &gt;20 percent above background is a possible threshold for completion of the exploration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, use of the probe alone may not reliably ensure operative cure because the probe detects sestamibi uptake as a surrogate indicator of hyperfunctioning parathyroid tissue and sestamibi uptake is unreliable for the definitive exclusion of multiglandular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/54,64,68-70\">",
"     54,64,68-70",
"    </a>",
"    ]. Another limitation of the radioguided technique is that thyroid nodules often retain isotope which can potentially lead to false positives and unnecessary resection of healthy tissue. In addition, the timing and dosing requirements for isotope injection can cause delays in the operating room schedule.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28792404\">",
"    <span class=\"h1\">",
"     OPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The challenges of parathyroidectomy include the wide variability in parathyroid gland anatomy between patients, the limitations of localization studies, and the possibility of more than four parathyroid glands (supernumerary glands). Accordingly, judicious dissection informed by thorough knowledge of the wide anatomic and embryologic variations in location is necessary to find an enlarged gland or glands, manage multiglandular disease and deduce the presence of a supernumerary gland. The experienced endocrine surgeon can accurately recognize size and shape differences among parathyroid glands and reliably estimate their weights. In addition, the surgeon must be able to intraoperatively recognize and properly treat parathyroid carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/23/29045?source=see_link\">",
"     \"Surgical anatomy of the parathyroid glands\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/60/18377?source=see_link\">",
"     \"Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following is an outline of general steps and principles to help guide safe and efficient parathyroid surgery:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28792348\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;General endotracheal anesthesia is most commonly employed for parathyroid exploration and should be used in cases where accurate preoperative localization is unavailable, bilateral cervical exploration is planned, and in reoperative cases. Placement of an oral or nasogastric tube, an esophageal stethoscope, or a temperature probe can facilitate digital palpation of a gland deep in the tracheoesophageal groove.",
"   </p>",
"   <p>",
"    For focused parathyroidectomy, cervical block anesthesia with monitored conscious sedation can be used for appropriately selected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. A cervical block with sedation is most appropriate when a single gland has been well-localized and the procedure is expected to have a short duration. Cervical block anesthesia should be avoided in obese patients or those with claustrophobia. Cervical block approaches may reduce postoperative pain, nausea, and vomiting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=see_link\">",
"     \"Overview of anesthesia and anesthetic choices\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Conversion to general anesthesia is sometimes necessary. In a report of 441 patients undergoing minimally invasive parathyroidectomy under cervical block anesthesia, 10 percent required conversion to general anesthesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/73\">",
"     73",
"    </a>",
"    ]. Reasons for conversion included concomitant thyroid disease (34 percent), multiglandular parathyroid hyperplasia (failure of PTH levels to drop, 32 percent), technical considerations (17 percent), patient discomfort (11 percent), intraoperative diagnosis of parathyroid carcinoma (4 percent), and toxic reaction to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    with seizure (2 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10466908\">",
"    <span class=\"h2\">",
"     Positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is positioned on the operating room table with arms tucked bilaterally and placed in the semi-Fowler position with the neck in extension. A roll can be placed transversely under the scapulae for mild extension to facilitate exposure of the region posterior to the tracheoesophageal groove (",
"    <a class=\"graphic graphic_figure graphicRef67508 \" href=\"mobipreview.htm?10/23/10608\">",
"     figure 2",
"    </a>",
"    ). Care should be taken to prevent overextension. Hyperextension of the neck during surgery can lead to vertigo, headache, and postoperative nausea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/74\">",
"     74",
"    </a>",
"    ]. The bed is tilted to an angle of approximately 30 degrees in reverse Trendelenburg position.",
"   </p>",
"   <p>",
"    The safety of neck extension in patients with known significant cervical spine disease should be assessed preoperatively by an orthopedic surgeon or neurosurgeon.",
"   </p>",
"   <p>",
"    The skin preparation should extend from the lower",
"    <span class=\"nowrap\">",
"     lip/angle",
"    </span>",
"    of the mandible onto the anterior chest. Mediastinal surgery should only be performed after preoperative discussion with the patient and operating room staff, but if it is contemplated, the entire chest is included in the operative field.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10466915\">",
"    <span class=\"h2\">",
"     Incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;If PTH monitoring is being used, a pre-excision PTH level is obtained just prior to the incision or just after the dissection begins, but prior to any manipulation of the first enlarged gland. Preemptive analgesia with a local anesthetic is helpful in postoperative management of pain.",
"   </p>",
"   <p>",
"    A 2 cm incision is made on the anterior aspect of the mid neck. This is usually 2 cm above the clavicular head. Efforts should be made to place this incision in a skin crease, if possible. A longer incision may be needed if the patient is obese, the gland is large, or the neck is foreshortened as with kyphoscoliosis (",
"    <a class=\"graphic graphic_figure graphicRef82297 \" href=\"mobipreview.htm?7/46/7906\">",
"     figure 3",
"    </a>",
"    ). If a minimally invasive procedure is planned, the incision may be lateralized to the side of the predicted parathyroid adenoma, as indicated on preoperative imaging.",
"   </p>",
"   <p>",
"    If a bilateral exploration is planned, a 3 to 5 cm transverse incision is made in the midline. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10466929\">",
"    <span class=\"h2\">",
"     Dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The platysma is divided transversely and the median raphe is divided longitudinally. The strap muscles on the side of dissection are elevated off the thyroid lobe ipsilateral to a radiologically identified focus of parathyroid uptake. In planned bilateral exploration, the initial laterality of dissection may be guided by thyroid pathology or surgeon preference.",
"   </p>",
"   <p>",
"    Parathyroid exploration begins after inspection of the ipsilateral thyroid lobe. The lobe is grasped and retracted anteromedially. At all times, the surgeon should be cognizant of the course of the recurrent laryngeal nerve and strive to maintain excellent hemostasis of the surgical field (",
"    <a class=\"graphic graphic_figure graphicRef50925 \" href=\"mobipreview.htm?4/37/4694\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    If imaging predicts a laterally or posteriorly located gland, a \"backdoor\" initial approach may be useful. In this setting, the lateral border of the strap muscles are separated from the medial border of the sternocleidomastoid muscle, exposing the lateral edge of the thyroid gland as the plane where parathyroid exploration begins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10466936\">",
"    <span class=\"h2\">",
"     Identification and confirmation of the parathyroid anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gentle palpation of the lateral, inferior, and posterior surfaces of the thyroid lobe, and in the tracheoesophageal groove is conducted to identify an enlarged hyperfunctional gland (",
"    <a class=\"graphic graphic_picture graphicRef55183 \" href=\"mobipreview.htm?23/21/23890\">",
"     picture 1",
"    </a>",
"    ). Normal and enlarged parathyroid glands are usually brown-pink in color, but can also be red, pale pink, or yellow and can be found nested within a lobule of surrounding yellow adipose or thymic tissue. A single hilar vascular pedicle is frequently a visual clue and must be carefully preserved. A logical and strategic order of inspection of the most common locations of parathyroid adenomas is recommended. Areolar tissue between the thyroid and carotid sheath is gently swept laterally (",
"    <a class=\"graphic graphic_figure graphicRef87045 \" href=\"mobipreview.htm?26/9/26768\">",
"     figure 5",
"    </a>",
"    ). To find an enlarged gland presumed to be a superior parathyroid gland, the undersurface of the superior pole of the thyroid lobe is also inspected. Exploration continues until the first enlarged parathyroid gland is identified, taking note of",
"    <span class=\"nowrap\">",
"     normal/suppressed",
"    </span>",
"    parathyroid gland locations as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20979570\">",
"    <span class=\"h2\">",
"     Standardized nomenclature for adenoma location",
"    </span>",
"    &nbsp;&mdash;&nbsp;While parathyroid adenomas are classically described with respect to their superior, inferior, or supernumerary embryologic origin, a classification scheme which utilizes details of preoperative imaging and intra-operative anatomic findings has recently been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/75\">",
"     75",
"    </a>",
"    ]. This is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/60/18377?source=see_link&amp;anchor=H6958973#H6958973\">",
"     \"Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism\", section on 'Standardized nomenclature for adenoma location'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1850183\">",
"    <span class=\"h2\">",
"     First enlarged parathyroid gland",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first enlarged parathyroid gland is dissected circumferentially and isolated on its vascular pedicle, with great care not to rupture its capsule. Capsular rupture is a cause of parathyromatosis or seeding of hyperfunctioning parathyroid tissue in the soft tissues of the neck",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mediastinum. Overgrowth of this tissue can cause recurrent hyperparathyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is helpful to start dissection and mobilization on the lateral aspect of an adenoma. This helps the surgeon appreciate the full extent and size of an adenoma that presents visually as &ldquo;the tip of an iceberg&rdquo;. Prior to division and ligation of the vascular pedicle, it is imperative to confirm safety of the ipsilateral recurrent laryngeal nerve (",
"    <a class=\"graphic graphic_figure graphicRef74541 \" href=\"mobipreview.htm?23/37/24146\">",
"     figure 6",
"    </a>",
"    ). Enlarged parathyroid glands can also be found wedged between the recurrent laryngeal nerve and the trachea at the ligament of Berry and in this circumstance, the surgeon must take great care to gently dissect the structures free from one another.",
"   </p>",
"   <p>",
"    Upon excision and inspection of the suspected adenoma, frozen section is commonly relied upon to confirm that the specimen is in fact parathyroid tissue. Ectopic thyroid tissue, thyroid nodules, and lymph nodes can easily resemble an enlarged parathyroid gland especially in a reoperative case or when the patient has concomitant thyroiditis. Direct fine needle aspiration of the excised gland parenchyma can be performed when frozen section is delayed or when there is extensive scar tissue or reactive lymph nodes. The aspirate is sent for intraoperative PTH assessment, and if the value is exceedingly high or above the upper limit of the assay, this is highly suggestive of parathyroid tissue. All resected parathyroid tissue must be weighed and the weight recorded. Weighing is accomplished either by a pathologist or by using a scale located in the operating suite.",
"   </p>",
"   <p>",
"    Following resection of the first enlarged gland, 5 and 10 minute blood draws are sent for PTH assay or exploration continues if bilateral exploration is planned. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/58/21416?source=see_link&amp;anchor=H12#H12\">",
"     \"Parathyroid hormone assays and their clinical use\", section on 'Intraoperative PTH assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3610120\">",
"    <span class=\"h2\">",
"     Identification of the ipsilateral normal parathyroid gland",
"    </span>",
"    &nbsp;&mdash;&nbsp;After resection of the first enlarged gland, many surgeons search for the ipsilateral parathyroid gland to support the assessment of a single adenoma versus multiglandular disease and to clarify the anatomic findings. Operative identification of a normal gland can be reported in the dictation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    documented by biopsy. A normal parathyroid gland weighs 35-50 mg. In primary hyperparathyroidism, a &ldquo;suppressed&rdquo; normal gland can be even smaller. Shave or hemi-biopsy of a normal gland is accomplished by gently applying a titanium clip to the distal edge of the gland opposite the vascular pedicle and sharply excising a 5-15 mg fragment, which should then be weighed and assessed by pathology. Care should be taken not to disrupt the vascular pedicle or to devascularize the gland.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3610128\">",
"    <span class=\"h2\">",
"     Identification of multiglandular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the ipsilateral gland is enlarged,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    if the intraoperative PTH level does not decline appropriately, the diagnosis of multiglandular disease is made, and multigland resection should be performed. Rarely, double adenomata occur on the same side. If an appropriate drop in PTH is documented after the resection of two ipsilateral glands, this may lead the surgeon to perform a unilateral exploration. In all other cases, bilateral exploration is required, and subtotal parathyroid gland resection is the procedure of choice. Whether bilateral exploration or the use of intraoperative PTH monitoring is being used to identify and manage multiglandular disease, the exploration continues until all enlarged hyperfunctional glands are identified and addressed.",
"   </p>",
"   <p>",
"    For patients who have multiple enlarged glands, all but a portion of one enlarged gland is removed, leaving a viable parathyroid remnant of 50-100 mg. This is referred to as a subtotal resection. The parathyroid remnant should be marked with a titanium clip in case reoperation is ever required. Viability of the intended remnant is checked before the remaining enlarged glands are resected. Another approach is to remove all four glands and auto-transplant parathyroid tissue into the forearm, where it is more easily accessible in case of recurrent hyperparathyroidism. However, total parathyroidectomy with autotransplantation leads to a higher probability of vitamin D dependence. Some centers cryopreserve parathyroid tissue in the event that the remnant becomes devascularized or dysfunctional and renders the patient aparathyroid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1850510\">",
"    <span class=\"h2\">",
"     Familial disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with familial disease, the amount of parathyroid tissue removed varies with the cause of hyperparathyroidism.",
"   </p>",
"   <p>",
"    For patients with multiple endocrine neoplasia-1 (MEN-1), the initial surgical procedure usually includes resection of three and one-half hyperplastic parathyroid glands (subtotal resection) with a concomitant cervical thymectomy. In patients with MEN-2a, parathyroid hyperplasia is heterogenous. Initial bilateral exploration is performed, but parathyroidectomy is limited to resection of only the enlarged glands. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/14/43240?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22794?source=see_link\">",
"     \"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When a reoperation is required, a more aggressive surgical approach may be employed, which involves complete parathyroidectomy with placement of a small parathyroid autograft out of the cervical region, commonly in the forearm. This is because of the concomitant concerns that the patient may develop medullary thyroid carcinoma and locally metastatic disease. Placing the parathyroid tissue at a distal site eliminates the risk of future devascularization if reoperation is needed. If recurrent hyperparathyroidism develops due to overgrowth of the autograft, it can be treated by graft removal under local anesthesia. However, if the autograft fails to function, the patient may have permanent hypoparathyroidism. The risk of hypothyroidism is higher with autotransplantation than leaving the gland in situ.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3610136\">",
"    <span class=\"h2\">",
"     Identification of parathyroid carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the surgeon recognizes a white, firm, fibrous, hypervascular,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    adherent, enlarged parathyroid gland, this is a parathyroid carcinoma until proven otherwise. The surgeon must recognize this situation to treat it. In general, surgical management includes wide en bloc resection of the tumor and any adherent structures such as the thyroid lobe, with preservation of the recurrent laryngeal nerve unless there is circumferential involvement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/23/13688?source=see_link&amp;anchor=H7#H7\">",
"     \"Parathyroid carcinoma\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3610143\">",
"    <span class=\"h2\">",
"     Parathyroid cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parathyroid cysts are uncommon, but can cause severe hypercalcemia and other symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. If noted before surgery, the cyst fluid should be aspirated for PTH assay. The optimal treatment is surgical resection. Meticulous dissection should be employed to avoid cyst rupture because this can lead to elevated intraoperative PTH levels which may prolong the surgical procedure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40387?source=see_link\">",
"     \"Parathyroid cysts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10466943\">",
"    <span class=\"h2\">",
"     Documentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is useful to have lateralized templates or drawings of cervical structures on which to place an excised gland to show its location at the time of surgery. The excised gland can be photographed on this template, made a permanent part of the medical record, thus available for future reference in the event of persistent or recurrent disease. Alternatively, the surgeon can include a drawing of the operative findings in the written operative note [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10466950\">",
"    <span class=\"h2\">",
"     Closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The strap muscles are reapproximated with interrupted absorbable sutures to cover the trachea. The platysma is then reapproximated with interrupted absorbable suture and the skin typically closed with a running subcuticular absorbable suture. A drain is usually not required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1352796\">",
"    <span class=\"h1\">",
"     MISSING PARATHYROID GLANDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A missed parathyroid adenoma is the most common cause for persistent hyperparathyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/7\">",
"     7",
"    </a>",
"    ]. During exploration for primary hyperparathyroidism, a clear understanding of the embryology and anatomy of the parathyroid glands will help determine which parathyroid gland is missing or whether a supernumerary gland is present (",
"    <a class=\"graphic graphic_figure graphicRef87046 \" href=\"mobipreview.htm?39/49/40735\">",
"     figure 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The surgeon must also recognize that a curative primary operation may not be possible. When an enlarged gland is not found in the normal or ectopic positions, despite a very thorough and systematic dissection, the cervical surgical procedure should be concluded. The diagnosis should be reconfirmed, and additional localization studies can be performed postoperatively if reoperation is contemplated. If necessary, PTH levels can be obtained intraoperatively via bilateral jugular vein sampling, and used as a localization technique to help clarify whether a missing parathyroid gland is on the left or the right by measuring gradients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1687719\">",
"    <span class=\"h2\">",
"     Missing superior gland",
"    </span>",
"    &nbsp;&mdash;&nbsp;For a missing superior gland, the surgeon should explore the middle and posterior neck compartments, particularly the paraesophageal spaces and the tracheoesophageal groove, extending dissection cervically into the middle and posterior mediastinal planes (",
"    <a class=\"graphic graphic_figure graphicRef79942 \" href=\"mobipreview.htm?11/15/11514\">",
"     figure 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The surgeon must confirm that there is not an enlarged gland in the paraesophageal or retroesophageal space, which is the most common place for missed superior glands. Such glands can often descend in the avascular plane to reside in a location inferior to the inferior gland and are posteriorly located along the lateral border of the esophagus. Digital palpation along the lateral border of the esophagus is an excellent way to identify the gland, which can be appreciated as a subtle bulge.",
"   </p>",
"   <p>",
"    The superior thyroid vessels can be followed superiorly to assess for a partially undescended gland, palpating the piriform sinus and angle of the jaw from the cranial to the superior pole of the thyroid. The missing superior gland may also be found in the direct posterior retropharyngeal space. A median sternotomy should be reserved for reoperation after localization studies have identified a mediastinal gland. The majority of mediastinal parathyroid glands (over 90 percent) are accessible via a cervical approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/7,80\">",
"     7,80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1687726\">",
"    <span class=\"h2\">",
"     Missing inferior gland",
"    </span>",
"    &nbsp;&mdash;&nbsp;For a missing inferior gland or supernumerary gland, the surgeon should explore the ipsilateral thymus and upper cervical region, dissecting into the anterior superior mediastinum via a cervical approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/7,80\">",
"     7,80",
"    </a>",
"    ]. Missing inferior glands may sometimes be palpated by sweeping a finger from lateral to medial on the periosteum under the manubrium.",
"   </p>",
"   <p>",
"    Many missing inferior parathyroid glands will be located within the thymus, and most intrathymic enlarged glands can be removed with a cervical approach. A cervical thymectomy may need to be performed. The thyrothymic ligament must be carefully handled in order to prevent retraction of the thymus into the mediastinum. Resected thymus should be evaluated with frozen section because a normal or enlarged parathyroid gland may not be readily visible.",
"   </p>",
"   <p>",
"    If exploration is still negative, the carotid sheath is entered sharply and explored to assess for an undescended parathyroid gland (",
"    <a class=\"graphic graphic_figure graphicRef55184 \" href=\"mobipreview.htm?40/6/41059\">",
"     figure 9",
"    </a>",
"    ). Great care should be taken to avoid damage to the vagus nerve. Exploration of the carotid sheath should extend from the clavicle to the bifurcation of the common carotid. Although rarely indicated, an ipsilateral thyroid lobectomy may be performed if an intrathyroidal parathyroid gland is suspected. About 1 percent of inferior gland adenomas are intrathyroidal. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1687797\">",
"    <span class=\"h2\">",
"     Missing supernumerary gland",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most supernumerary parathyroid glands are within the thymus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. In the search for a missing enlarged gland, a cervical thymectomy should be performed if possible. Supernumerary glands can also be found along the anterior surface of the carotid sheath and near the tubercle of Zuckerlandl. The surgeon should explore the bilateral carotid sheaths and palpate the piriform sinuses. Pre or intraoperative thyroid ultrasound can help to identify an intrathyroidal parathyroid adenoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/62/21482?source=see_link\">",
"     \"Overview of the clinical utility of ultrasonography in thyroid disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1352810\">",
"    <span class=\"h1\">",
"     COMPROMISED PARATHYROID GLANDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The removal of normal parathyroid glands should be avoided, although only one normal parathyroid gland is necessary for normal calcium homeostasis. If a normal parathyroid gland becomes severely ischemic during dissection or is excised accidentally, the surgeon should send a 1 mm sliver of tissue for frozen section analysis and store the remainder of the specimen on ice for expedient autotransplantation.",
"   </p>",
"   <p>",
"    An intraoperative parathyroid hormone (PTH) level can help to determine whether hyperfunctioning parathyroid tissue has been excised as opposed to normal yet enlarged parathyroid tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/83\">",
"     83",
"    </a>",
"    ]. The PTH level should precipitously decrease with excision of the hyperfunctioning gland. (See",
"    <a class=\"local\" href=\"#H10466887\">",
"     'Intraoperative parathyroid hormone monitoring'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If the PTH level does not drop, then the resected gland is not the cause of excess PTH production, and it can be minced and autotransplanted into a single pocket into the sternocleidomastoid or sternohyoid muscle to avoid permanent hypoparathyroidism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/57/31642?source=see_link&amp;anchor=H16#H16\">",
"     \"Initial and reoperative thyroidectomy\", section on 'Parathyroid autotransplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cryopreservation is available in some centers and is useful in some patients to avoid permanent hypoparathyroidism, particularly after reoperative parathyroid surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/84,85\">",
"     84,85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27512297\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surgical dressing can be removed, and patients can shower on the day following the operation. Pain is usually modest, and mild analgesics such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    usually suffice. Oversedation should be avoided as it can potentiate an airway emergency if there is a clinically significant cervical hematoma.",
"   </p>",
"   <p>",
"    An office visit with the surgical team to inspect the wound, review pathology, and obtain a baseline postoperative biochemical profile and thyroid stimulating hormone (TSH) level, is recommended one to two weeks postoperatively.",
"   </p>",
"   <p>",
"    A repeat clinic visit with a concomitant biochemical assessment is performed six months following parathyroidectomy to confirm cure. We also suggest a follow up clinic visit along with a repeat bone mineral density study one year following cure (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42583?source=see_link\">",
"     \"Overview of dual-energy x-ray absorptiometry\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10466964\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications following parathyroidectomy are rare; however, the patient should be counseled preoperatively about potential complications and the surgeon should be aware of how they present and how they are managed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3610215\">",
"    <span class=\"h2\">",
"     Operative failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Failure to achieve durable cure of hypercalcemia is the most common complication of parathyroid surgery (1 to 5 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10466971\">",
"    <span class=\"h2\">",
"     Symptomatic hematoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of symptomatic hematoma following neck exploration is 0.3 to 1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/86\">",
"     86",
"    </a>",
"    ]. Although rare, this complication can result in life-threatening airway compromise. Symptoms include postoperative complaints of anxiety, respiratory distress, dysphagia, fullness, and persistent or increasing pain. On examination, a visible large anterior cervical mass is often present. Cervical hematoma results in venous congestion of airway structures, creating significant laryngeal edema and subsequent airway compromise. In addition, oropharyngeal swelling creates a narrow window for reintubation.",
"   </p>",
"   <p>",
"    Postoperatively all patients must be examined to exclude hematoma prior to hospital discharge. An exam is usually conducted 6 hours after surgery as well. With rare exceptions the presence of hematoma indicates urgent surgical evaluation; a hematoma should never be &ldquo;observed&rdquo;. Early recognition and immediate intervention are crucial to minimize possible mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/86,87\">",
"     86,87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10466978\">",
"    <span class=\"h2\">",
"     Postoperative hypocalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypocalcemia is an important potential complication after parathyroid exploration. The classic calcium nadir occurs within the first 24 to 48 hours after surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27512400\">",
"    <span class=\"h3\">",
"     Mild hypocalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypocalcemia may be transient and mild, due to functional hypoparathyroidism resulting from suppression of the remaining normal parathyroid tissue. Symptoms such as perioral or acral paresthesias and anxiety are exacerbated by hyperventilation. Such symptoms generally respond well to a short course of oral calcium supplementation, and can be treated initially with 1500 to 2000 mg of elemental calcium given as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    &nbsp;or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38628?source=see_link\">",
"     calcium citrate",
"    </a>",
"    &nbsp;daily, in divided doses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/37/44632?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of hypocalcemia\", section on 'Oral calcium'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transient postoperative hypocalcemia is more common in patients with severe preoperative hypercalcemia and in those with chronic vitamin D deficiency (&lt;15",
"    <span class=\"nowrap\">",
"     ng/ml).",
"    </span>",
"    For this reason, preoperative repletion with ergocalciferol (vitamin D2) (1000 IU per day or more depending on level) may be desirable in vitamin D deficient patients if urinary calcium levels are not elevated. If hypercalciuria limits the ability to replete vitamin D preoperatively, it is important to provide adequate calcium and ergocalciferol after surgical correction of primary hyperparathyroidism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of vitamin D deficiency in adults\", section on 'Coexisting primary hyperparathyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27512408\">",
"    <span class=\"h3\">",
"     Severe hypocalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative hypocalcemia can be severe and prolonged. Symptoms of acute hypocalcemia include tetany, papilledema, and seizures. A symptomatic patient may require intravenous and oral calcium supplementation as well as correction of concomitant hypomagnesemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36646?source=see_link\">",
"     \"Clinical manifestations of hypocalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/37/44632?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of hypocalcemia\", section on 'Intravenous calcium'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Appropriate treatment will depend in part on phosphate and PTH levels:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypophosphatemia  If hypocalcemia is prolonged and accompanied by hypo- or euphosphatemia and high PTH levels, hungry bone syndrome is diagnosed (rapid deposition of serum calcium into demineralized bone following a drop in PTH). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/13/3287?source=see_link\">",
"       \"Hungry bone syndrome following parathyroidectomy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperphosphatemia  If hypocalcemia is accompanied by hyperphosphatemia and low PTH levels, hypoparathyroidism is diagnosed, requiring treatment with calcitriol. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/25/24984?source=see_link\">",
"       \"Etiology of hypocalcemia in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/37/44632?source=see_link&amp;anchor=H12#H12\">",
"       \"Treatment of hypocalcemia\", section on 'Hypoparathyroidism'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5041516\">",
"    <span class=\"h3\">",
"     Permanent hypoparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Permanent hypoparathyroidism may occur as a complication of surgical dissection in patients who have had previous neck surgery with resection or devascularization of normal glands. It may also occur following subtotal parathyroidectomy for multiglandular disease if the remnant is not viable. If the calcitriol and calcium cannot be tapered off over several months following surgery, the hypoparathyroidism may be permanent. An undetectable parathyroid hormone concentration when serum calcium is low can confirm the permanent need for treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/37/44632?source=see_link&amp;anchor=H24#H24\">",
"     \"Treatment of hypocalcemia\", section on 'Permanent hypoparathyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3618803\">",
"    <span class=\"h2\">",
"     Wound infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wound infection is a rare complication following parathyroid surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10466992\">",
"    <span class=\"h2\">",
"     Recurrent laryngeal nerve injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent laryngeal nerve (RLN) injury is a rare complication in the hands of experienced parathyroid surgeons and should occur in &lt;1 percent of initial operations. Patients undergoing reoperation are at higher risk for nerve injury due to scarring and distorted anatomy. Preoperative laryngoscopy is recommended in the reoperative setting to assess any preexisting nerve compromise. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/17/44310?source=see_link&amp;anchor=H11#H11\">",
"     \"Surgical anatomy of the thyroid gland\", section on 'Nerve supply'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To reduce the risk of RLN injury, thorough review of the patient&rsquo;s prior operative notes and pathology reports before reexploration is crucial. This provides information regarding the extent of prior dissection. Intraoperative neuromonitoring can be helpful in high risk reoperative cases but does not preclude the need for intraoperative nerve visualization and meticulous technique. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/57/31642?source=see_link&amp;anchor=H5#H5\">",
"     \"Initial and reoperative thyroidectomy\", section on 'Intraoperative neuromonitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3610312\">",
"    <span class=\"h2\">",
"     Hyperthyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperthyroidism following surgery for PHPT is an underappreciated consequence of parathyroidectomy.&nbsp;Biochemical evidence of hyperthyroidism has been found to occur in 31 to 43 percent of patients following parathyroidectomy with symptoms of mild thyrotoxicosis presenting in 15 to 27 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/17,90\">",
"     17,90",
"    </a>",
"    ], and is possibly a consequence of thyroid gland manipulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/17,91\">",
"     17,91",
"    </a>",
"    ]. In general, the hyperthyroidism is transient and self-limited with normalization of thyroid function studies within a few weeks to months following surgery.&nbsp;Patients should be monitored for biochemical or clinical evidence of hyperthyroidism in the early postoperative period. Patients with symptoms can be managed with thionamides and beta-blockade as indicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14279?source=see_link\">",
"     \"Overview of the clinical manifestations of hyperthyroidism in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261995\">",
"    <span class=\"h1\">",
"     ABLATION TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient who needs treatment, but is not a candidate for a surgical procedure or who has a hyperfunctioning gland in the mediastinum, might be considered for angiographic ablation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/92,93\">",
"     92,93",
"    </a>",
"    ] or ablation with ethanol injected with ultrasound guidance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/94,95\">",
"     94,95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Success rates of 66 percent at up to four years have been reported for angiographic ablation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/92\">",
"     92",
"    </a>",
"    ]. In a case series of 22 patients with MEN1 and recurrent hypercalcemia after previous subtotal parathyroidectomy, ethanol ablation was successful in restoring eucalcemia in 82 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/96\">",
"     96",
"    </a>",
"    ]. However, recurrent hypercalcemia requiring repeat treatments was common.",
"   </p>",
"   <p>",
"    The experience with percutaneous parathyroid ablation (angiographic or ethanol) is primarily in patients with failed parathyroidectomy. In centers with expertise in localization and ablation techniques, ablation may be an acceptable treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10466999\">",
"    <span class=\"h1\">",
"     OUTCOMES AND CURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical cure rates for primary hyperparathyroidism (PHPT) should be at or above 95 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/20,25,31,97\">",
"     20,25,31,97",
"    </a>",
"    ]. The overall survival of patients treated successfully for primary hyperparathyroidism is uncertain. Increased mortality due to persistent cardiovascular disease after surgical cure of PHPT has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1338?source=see_link\">",
"     \"Clinical manifestations of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Persistent or recurrent disease may be the result of surgeon inexperience, supernumerary glands, or unrecognized multiglandular disease. Reoperation is technically challenging with increased rates of morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/5-8,100\">",
"     5-8,100",
"    </a>",
"    ], and careful preoperative planning prior to re-exploration is critical. Due to the increased risks of reoperation, operative indications are stricter and should be limited to major manifestations of hypercalcemia such as nephrolithiasis, osteoporosis, a serum calcium &gt;12",
"    <span class=\"nowrap\">",
"     mg/dl,",
"    </span>",
"    hypercalciuria, or a 30 percent drop in creatinine clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although surgical removal of the hyperfunctional parathyroid tissue is definitive therapy, patients who refuse surgery or for whom the gland cannot be found, may be expectantly managed with symptoms tempered by medical therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/0/35850/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/47/8954?source=see_link\">",
"     \"Management of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10467006\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary hyperparathyroidism (PHPT) commonly presents when hypercalcemia is detected by routine biochemical screening. Although some patients are asymptomatic, many have nonspecific and often subtle symptoms. PHPT can lead to an array of disorders including polydipsia and polyuria, nephrolithiasis, osteoporosis, fragility fractures, pancreatitis, peptic ulcer disease, gastroesophageal reflux, fatigue, depression, and significant neurocognitive dysfunction. (See",
"      <a class=\"local\" href=\"#H28792026\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Parathyroidectomy provides definitive therapy for PHPT and is performed for all patients with symptomatic disease, patients with familial disease, and patients with asymptomatic disease who have decreased glomerular filtration rates, osteoporosis, serum calcium &gt;1",
"      <span class=\"nowrap\">",
"       mg/dl",
"      </span>",
"      above normal, or age less than 50 years. Parathyroid exploration is also indicated for patients with PHPT as a result of parathyroid cancer or parathyroid crisis, and for selected patients with persistent or recurrent primary hyperparathyroidism. (See",
"      <a class=\"local\" href=\"#H10466681\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Contralateral recurrent laryngeal nerve injury and symptomatic cervical disc disease are relative contraindications to parathyroidectomy. Patients with familial hypocalciuric hypercalcemia do not have a primary parathyroid disorder and should not undergo parathyroidectomy. (See",
"      <a class=\"local\" href=\"#H28793494\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have unilateral pathology as detected by imaging, without thyroid disease, and with no family history of multiple endocrine neoplasia, we suggest minimally invasive parathyroidectomy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). With increased experience and availability, minimally invasive parathyroidectomy techniques combined with intraoperative PTH monitoring have emerged as the procedure of choice and are as effective as bilateral cervical exploration.",
"     </li>",
"     <li>",
"      Initial bilateral neck exploration is more likely to be required with negative imaging and should be performed when an adenoma cannot be found with a minimally invasive approach, when the preoperative or intraoperative findings suggest multiglandular disease, for most forms of familial disease, and as directed by concomitant thyroid pathology. (See",
"      <a class=\"local\" href=\"#H10466865\">",
"       'Focused parathyroid exploration'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10466851\">",
"       'Choice of procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The success of minimally invasive parathyroidectomy is dependent upon both preoperative localization studies that limit the operative field to the region where a presumed single adenoma has been localized, and the use of intraoperative PTH monitoring to confirm that no other hyperfunctioning gland remains in situ. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/60/18377?source=see_link\">",
"       \"Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H10466879\">",
"       'Intraoperative assessment tools'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A missed parathyroid adenoma is the most common cause for a failed initial parathyroid operation and persistent hyperparathyroidism. During exploration for primary hyperparathyroidism, understanding the embryology and anatomy of the parathyroid glands is essential to achieve surgical cure. (See",
"      <a class=\"local\" href=\"#H1352796\">",
"       'Missing parathyroid glands'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Major complications after parathyroidectomy include failure to achieve durable cure of hypercalcemia, hematoma with airway compromise, hypoparathyroidism, and recurrent laryngeal nerve injury. (See",
"      <a class=\"local\" href=\"#H10466964\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/1\">",
"      Bilezikian JP, Silverberg SJ. Clinical practice. Asymptomatic primary hyperparathyroidism. N Engl J Med 2004; 350:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/2\">",
"      Perrier ND. Asymptomatic hyperparathyroidism: a medical misnomer? Surgery 2005; 137:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/3\">",
"      Udelsman R, Pasieka JL, Sturgeon C, et al. Surgery for asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009; 94:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/4\">",
"      Bilezikian JP, Khan AA, Potts JT Jr, Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 2009; 94:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/5\">",
"      Bartsch DK, Rothmund M. Reoperative surgery for primary hyperparathyroidism. Br J Surg 2009; 96:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/6\">",
"      Patow CA, Norton JA, Brennan MF. Vocal cord paralysis and reoperative parathyroidectomy. A prospective study. Ann Surg 1986; 203:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/7\">",
"      Jaskowiak N, Norton JA, Alexander HR, et al. A prospective trial evaluating a standard approach to reoperation for missed parathyroid adenoma. Ann Surg 1996; 224:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/8\">",
"      Thompson GB, Grant CS, Perrier ND, et al. Reoperative parathyroid surgery in the era of sestamibi scanning and intraoperative parathyroid hormone monitoring. Arch Surg 1999; 134:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/9\">",
"      Silberfein EJ, Bao R, Lopez A, et al. Reoperative parathyroidectomy: location of missed glands based on a contemporary nomenclature system. Arch Surg 2010; 145:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/10\">",
"      Gough I. Reoperative parathyroid surgery: the importance of ectopic location and multigland disease. ANZ J Surg 2006; 76:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/11\">",
"      Yen TW, Wang TS, Doffek KM, et al. Reoperative parathyroidectomy: an algorithm for imaging and monitoring of intraoperative parathyroid hormone levels that results in a successful focused approach. Surgery 2008; 144:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/12\">",
"      Irvin GL 3rd, Molinari AS, Figueroa C, Carneiro DM. Improved success rate in reoperative parathyroidectomy with intraoperative PTH assay. Ann Surg 1999; 229:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/13\">",
"      Akerstr&ouml;m G, St&aring;lberg P. Surgical management of MEN-1 and -2: state of the art. Surg Clin North Am 2009; 89:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/14\">",
"      Sharma J, Weber CJ. Surgical therapy for familial hyperparathyroidism. Am Surg 2009; 75:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/15\">",
"      Lew JI, Solorzano CC. Surgical management of primary hyperparathyroidism: state of the art. Surg Clin North Am 2009; 89:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/16\">",
"      Lew JI, Solorzano CC, Irvin GL 3rd. Long-term results of parathyroidectomy for hypercalcemic crisis. Arch Surg 2006; 141:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/17\">",
"      Stang MT, Yim JH, Challinor SM, et al. Hyperthyroidism after parathyroid exploration. Surgery 2005; 138:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/18\">",
"      Yip L, Ogilvie JB, Challinor SM, et al. Identification of multiple endocrine neoplasia type 1 in patients with apparent sporadic primary hyperparathyroidism. Surgery 2008; 144:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/19\">",
"      Bilezikian JP, Potts JT Jr, Fuleihan Gel-H, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 2002; 87:5353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/20\">",
"      Udelsman R. Six hundred fifty-six consecutive explorations for primary hyperparathyroidism. Ann Surg 2002; 235:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/21\">",
"      J&auml;rhult J, Ander S, Asking B, et al. Long-term results of surgery for lithium-associated hyperparathyroidism. Br J Surg 2010; 97:1680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/22\">",
"      Carchman E, Ogilvie J, Holst J, et al. Appropriate surgical treatment of lithium-associated hyperparathyroidism. World J Surg 2008; 32:2195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/23\">",
"      Sackett WR, Barraclough B, Reeve TS, Delbridge LW. Worldwide trends in the surgical treatment of primary hyperparathyroidism in the era of minimally invasive parathyroidectomy. Arch Surg 2002; 137:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/24\">",
"      Irvin GL 3rd, Solorzano CC, Carneiro DM. Quick intraoperative parathyroid hormone assay: surgical adjunct to allow limited parathyroidectomy, improve success rate, and predict outcome. World J Surg 2004; 28:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/25\">",
"      Grant CS, Thompson G, Farley D, van Heerden J. Primary hyperparathyroidism surgical management since the introduction of minimally invasive parathyroidectomy: Mayo Clinic experience. Arch Surg 2005; 140:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/26\">",
"      Bergenfelz A, Lindblom P, Tibblin S, Westerdahl J. Unilateral versus bilateral neck exploration for primary hyperparathyroidism: a prospective randomized controlled trial. Ann Surg 2002; 236:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/27\">",
"      Delbridge LW, Dolan SJ, Hop TT, et al. Minimally invasive parathyroidectomy: 50 consecutive cases. Med J Aust 2000; 172:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/28\">",
"      Moore FD Jr, Mannting F, Tanasijevic M. Intrinsic limitations to unilateral parathyroid exploration. Ann Surg 1999; 230:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/29\">",
"      Smit PC, Borel Rinkes IH, van Dalen A, van Vroonhoven TJ. Direct, minimally invasive adenomectomy for primary hyperparathyroidism: An alternative to conventional neck exploration? Ann Surg 2000; 231:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/30\">",
"      Schell SR, Dudley NE. Clinical outcomes and fiscal consequences of bilateral neck exploration for primary idiopathic hyperparathyroidism without preoperative radionuclide imaging or minimally invasive techniques. Surgery 2003; 133:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/31\">",
"      Westerdahl J, Bergenfelz A. Unilateral versus bilateral neck exploration for primary hyperparathyroidism: five-year follow-up of a randomized controlled trial. Ann Surg 2007; 246:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/32\">",
"      Russell CF, Dolan SJ, Laird JD. Randomized clinical trial comparing scan-directed unilateral versus bilateral cervical exploration for primary hyperparathyroidism due to solitary adenoma. Br J Surg 2006; 93:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/33\">",
"      Miccoli P, Bendinelli C, Berti P, et al. Video-assisted versus conventional parathyroidectomy in primary hyperparathyroidism: a prospective randomized study. Surgery 1999; 126:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/34\">",
"      Slepavicius A, Beisa V, Janusonis V, Strupas K. Focused versus conventional parathyroidectomy for primary hyperparathyroidism: a prospective, randomized, blinded trial. Langenbecks Arch Surg 2008; 393:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/35\">",
"      Aarum S, Nordenstr&ouml;m J, Reihn&eacute;r E, et al. Operation for primary hyperparathyroidism: the new versus the old order. A randomised controlled trial of preoperative localisation. Scand J Surg 2007; 96:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/36\">",
"      Mihai R, Barczynski M, Iacobone M, Sitges-Serra A. Surgical strategy for sporadic primary hyperparathyroidism an evidence-based approach to surgical strategy, patient selection, surgical access, and reoperations. Langenbecks Arch Surg 2009; 394:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/37\">",
"      Henry JF, Sebag F, Tamagnini P, et al. Endoscopic parathyroid surgery: results of 365 consecutive procedures. World J Surg 2004; 28:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/38\">",
"      Miccoli P, Berti P, Materazzi G, et al. Results of video-assisted parathyroidectomy: single institution's six-year experience. World J Surg 2004; 28:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/39\">",
"      Augustine MM, Bravo PE, Zeiger MA. Surgical treatment of primary hyperparathyroidism. Endocr Pract 2011; 17 Suppl 1:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/40\">",
"      Hessman O, Westerdahl J, Al-Suliman N, et al. Randomized clinical trial comparing open with video-assisted minimally invasive parathyroid surgery for primary hyperparathyroidism. Br J Surg 2010; 97:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/41\">",
"      Fouquet T, Germain A, Zarnegar R, et al. Totally endoscopic lateral parathyroidectomy: prospective evaluation of 200 patients. ESES 2010 Vienna presentation. Langenbecks Arch Surg 2010; 395:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/42\">",
"      Prades JM, Asanau A, Timoshenko AP, et al. Endoscopic parathyroidectomy in primary hyperparathyroidism. Eur Arch Otorhinolaryngol 2011; 268:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/43\">",
"      Khalid AN, Hollenbeak CS, Higginbotham BW, Stack BC Jr. Accuracy and definitive interpretation of preoperative technetium 99m sestamibi imaging based on the discipline of the reader. Head Neck 2009; 31:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/44\">",
"      Melton GB, Somervell H, Friedman KP, et al. Interpretation of 99mTc sestamibi parathyroid SPECT scan is improved when read by the surgeon and nuclear medicine physician together. Nucl Med Commun 2005; 26:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/45\">",
"      Weiser TG, Haynes AB, Dziekan G, et al. Effect of a 19-item surgical safety checklist during urgent operations in a global patient population. Ann Surg 2010; 251:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/46\">",
"      Angelos P. Recurrent laryngeal nerve monitoring: state of the art, ethical and legal issues. Surg Clin North Am 2009; 89:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/47\">",
"      Avenia N, Sanguinetti A, Cirocchi R, et al. Antibiotic prophylaxis in thyroid surgery: a preliminary multicentric Italian experience. Ann Surg Innov Res 2009; 3:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/48\">",
"      Leaper DJ, Melling AG. Antibiotic prophylaxis in clean surgery: clean non-implant wounds. J Chemother 2001; 13 Spec No 1:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/49\">",
"      Gagliardi AR, Fenech D, Eskicioglu C, et al. Factors influencing antibiotic prophylaxis for surgical site infection prevention in general surgery: a review of the literature. Can J Surg 2009; 52:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/50\">",
"      Fry DE. Surgical site infections and the surgical care improvement project (SCIP): evolution of national quality measures. Surg Infect (Larchmt) 2008; 9:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/51\">",
"      Bratzler DW, Houck PM, Surgical Infection Prevention Guidelines Writers Workgroup, et al. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 2004; 38:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/52\">",
"      Braxton CC, Gerstenberger PA, Cox GG. Improving antibiotic stewardship: order set implementation to improve prophylactic antimicrobial prescribing in the outpatient surgical setting. J Ambul Care Manage 2010; 33:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/53\">",
"      Carneiro DM, Irvin GL 3rd. Late parathyroid function after successful parathyroidectomy guided by intraoperative hormone assay (QPTH) compared with the standard bilateral neck exploration. Surgery 2000; 128:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/54\">",
"      Sokoll LJ, Drew H, Udelsman R. Intraoperative parathyroid hormone analysis: A study of 200 consecutive cases. Clin Chem 2000; 46:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/55\">",
"      Irvin GL 3rd, Prudhomme DL, Deriso GT, et al. A new approach to parathyroidectomy. Ann Surg 1994; 219:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/56\">",
"      Carneiro DM, Solorzano CC, Nader MC, et al. Comparison of intraoperative iPTH assay (QPTH) criteria in guiding parathyroidectomy: which criterion is the most accurate? Surgery 2003; 134:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/57\">",
"      Irvin GL 3rd, Dembrow VD, Prudhomme DL. Clinical usefulness of an intraoperative \"quick parathyroid hormone\" assay. Surgery 1993; 114:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/58\">",
"      Garner SC, Leight GS Jr. Initial experience with intraoperative PTH determinations in the surgical management of 130 consecutive cases of primary hyperparathyroidism. Surgery 1999; 126:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/59\">",
"      Chiu B, Sturgeon C, Angelos P. Which intraoperative parathyroid hormone assay criterion best predicts operative success? A study of 352 consecutive patients. Arch Surg 2006; 141:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/60\">",
"      Westerdahl J, Bergenfelz A. Parathyroid surgical failures with sufficient decline of intraoperative parathyroid hormone levels: unobserved multiple endocrine neoplasia as an explanation. Arch Surg 2006; 141:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/61\">",
"      Cayo A, Chen H. Radioguided reoperative parathyroidectomy for persistent primary hyperparathyroidism. Clin Nucl Med 2008; 33:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/62\">",
"      Chen JS, Sambrook PN, March L, et al. Hypovitaminosis D and parathyroid hormone response in the elderly: effects on bone turnover and mortality. Clin Endocrinol (Oxf) 2008; 68:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/63\">",
"      Flynn MB, Bumpous JM, Schill K, McMasters KM. Minimally invasive radioguided parathyroidectomy. J Am Coll Surg 2000; 191:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/64\">",
"      Dackiw AP, Sussman JJ, Fritsche HA Jr, et al. Relative contributions of technetium Tc 99m sestamibi scintigraphy, intraoperative gamma probe detection, and the rapid parathyroid hormone assay to the surgical management of hyperparathyroidism. Arch Surg 2000; 135:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/65\">",
"      Ollila DW, Caudle AS, Cance WG, et al. Successful minimally invasive parathyroidectomy for primary hyperparathyroidism without using intraoperative parathyroid hormone assays. Am J Surg 2006; 191:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/66\">",
"      Hutchinson JR, Yandell DW, Bumpous JM, et al. Three-year financial analysis of minimally invasive radio-guided parathyroidectomy. Am Surg 2004; 70:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/67\">",
"      Murphy C, Norman J. The 20% rule: a simple, instantaneous radioactivity measurement defines cure and allows elimination of frozen sections and hormone assays during parathyroidectomy. Surgery 1999; 126:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/68\">",
"      Palestro CJ, Tomas MB, Tronco GG. Radionuclide imaging of the parathyroid glands. Semin Nucl Med 2005; 35:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/69\">",
"      Chen H, Pruhs Z, Starling JR, Mack E. Intraoperative parathyroid hormone testing improves cure rates in patients undergoing minimally invasive parathyroidectomy. Surgery 2005; 138:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/70\">",
"      Chen H, Mack E, Starling JR. A comprehensive evaluation of perioperative adjuncts during minimally invasive parathyroidectomy: which is most reliable? Ann Surg 2005; 242:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/71\">",
"      Black MJ, Ruscher AE, Lederman J, Chen H. Local/cervical block anesthesia versus general anesthesia for minimally invasive parathyroidectomy: what are the advantages? Ann Surg Oncol 2007; 14:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/72\">",
"      Shindo ML, Rosenthal JM, Lee T. Minimally invasive parathyroidectomy using local anesthesia with intravenous sedation and targeted approaches. Otolaryngol Head Neck Surg 2008; 138:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/73\">",
"      Carling T, Donovan P, Rinder C, Udelsman R. Minimally invasive parathyroidectomy using cervical block: reasons for conversion to general anesthesia. Arch Surg 2006; 141:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/74\">",
"      Rosato L, Avenia N, Bernante P, et al. Complications of thyroid surgery: analysis of a multicentric study on 14,934 patients operated on in Italy over 5 years. World J Surg 2004; 28:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/75\">",
"      Perrier ND, Edeiken B, Nunez R, et al. A novel nomenclature to classify parathyroid adenomas. World J Surg 2009; 33:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/76\">",
"      Tublin ME, Yim JH, Carty SE. Recurrent hyperparathyroidism secondary to parathyromatosis: clinical and imaging findings. J Ultrasound Med 2007; 26:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/77\">",
"      Kollmorgen CF, Aust MR, Ferreiro JA, et al. Parathyromatosis: a rare yet important cause of persistent or recurrent hyperparathyroidism. Surgery 1994; 116:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/78\">",
"      Pinney SP, Daly PA. Parathyroid cyst: an uncommon cause of a palpable neck mass and hypercalcemia. West J Med 1999; 170:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/79\">",
"      McCoy KL, Yim JH, Zuckerbraun BS, et al. Cystic parathyroid lesions: functional and nonfunctional parathyroid cysts. Arch Surg 2009; 144:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/80\">",
"      Shen W, D&uuml;ren M, Morita E, et al. Reoperation for persistent or recurrent primary hyperparathyroidism. Arch Surg 1996; 131:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/81\">",
"      Wang C. The anatomic basis of parathyroid surgery. Ann Surg 1976; 183:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/82\">",
"      Edis AJ, Levitt MD. Supernumerary parathyroid glands: implications for the surgical treatment of secondary hyperparathyroidism. World J Surg 1987; 11:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/83\">",
"      Carneiro-Pla D. Recent findings in the use of intraoperative parathyroid hormone monitoring in parathyroid disease. Curr Opin Oncol 2009; 21:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/84\">",
"      Henry JF. Reoperation for primary hyperparathyroidism: tips and tricks. Langenbecks Arch Surg 2010; 395:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/85\">",
"      Borot S, Lapierre V, Carnaille B, et al. Results of cryopreserved parathyroid autografts: a retrospective multicenter study. Surgery 2010; 147:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/86\">",
"      Burkey SH, van Heerden JA, Thompson GB, et al. Reexploration for symptomatic hematomas after cervical exploration. Surgery 2001; 130:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/87\">",
"      Rosenbaum MA, Haridas M, McHenry CR. Life-threatening neck hematoma complicating thyroid and parathyroid surgery. Am J Surg 2008; 195:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/88\">",
"      Mittendorf EA, Merlino JI, McHenry CR. Post-parathyroidectomy hypocalcemia: incidence, risk factors, and management. Am Surg 2004; 70:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/89\">",
"      Westerdahl J, Lindblom P, Valdemarsson S, et al. Risk factors for postoperative hypocalcemia after surgery for primary hyperparathyroidism. Arch Surg 2000; 135:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/90\">",
"      Lindblom P, Valdemarsson S, Westerdahl J, et al. Hyperthyroidism after surgery for primary hyperparathyroidism. Langenbecks Arch Surg 1999; 384:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/91\">",
"      Rudofsky G Jr, Grafe IA, Metzner C, et al. Transient post-operative thyrotoxicosis after parathyroidectomy. Med Sci Monit 2009; 15:CS41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/92\">",
"      Pallotta JA, Sacks BA, Moller DE, Eisenberg H. Arteriographic ablation of cervical parathyroid adenomas. J Clin Endocrinol Metab 1989; 69:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/93\">",
"      Doppman, JL. Endocrine imaging. Endocrinologist 1997; 7:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/94\">",
"      Karstrup S, Heged&uuml;s L, Holm HH. Ultrasonically guided chemical parathyroidectomy in patients with primary hyperparathyroidism: a follow-up study. Clin Endocrinol (Oxf) 1993; 38:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/95\">",
"      Stratigis S, Stylianou K, Mamalaki E, et al. Percutaneous ethanol injection therapy: a surgery-sparing treatment for primary hyperparathyroidism. Clin Endocrinol (Oxf) 2008; 69:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/96\">",
"      Veldman MW, Reading CC, Farrell MA, et al. Percutaneous parathyroid ethanol ablation in patients with multiple endocrine neoplasia type 1. AJR Am J Roentgenol 2008; 191:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/97\">",
"      Powell AC, Alexander HR, Chang R, et al. Reoperation for parathyroid adenoma: a contemporary experience. Surgery 2009; 146:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/98\">",
"      Wermers RA, Khosla S, Atkinson EJ, et al. Survival after the diagnosis of hyperparathyroidism: a population-based study. Am J Med 1998; 104:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/99\">",
"      V&aacute;zquez-D&iacute;az O, Castillo-Mart&iacute;nez L, Orea-Tejeda A, et al. Reversible changes of electrocardiographic abnormalities after parathyroidectomy in patients with primary hyperparathyroidism. Cardiol J 2009; 16:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/100\">",
"      Doherty GM, Weber B, Norton JA. Cost of unsuccessful surgery for primary hyperparathyroidism. Surgery 1994; 116:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/101\">",
"      Carty SE, Norton JA. Management of patients with persistent or recurrent primary hyperparathyroidism. World J Surg 1991; 15:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/102\">",
"      Strewler GJ. The parathyroid hormone-related protein. Endocrinol Metab Clin North Am 2000; 29:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/0/35850/abstract/103\">",
"      Edwards ME, Rotramel A, Beyer T, et al. Improvement in the health-related quality-of-life symptoms of hyperparathyroidism is durable on long-term follow-up. Surgery 2006; 140:655.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15039 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-194.187.108.93-5353394DC6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_0_35850=[""].join("\n");
var outline_f35_0_35850=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10467006\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28792026\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10466681\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10466688\">",
"      Symptomatic primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10466695\">",
"      Asymptomatic primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10466716\">",
"      Persistent or recurrent primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H260978\">",
"      Familial primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H260985\">",
"      Parathyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H260992\">",
"      Parathyroid crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28793494\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3609736\">",
"      PREOPERATIVE EVALUATION AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10466851\">",
"      CHOICE OF PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10466858\">",
"      Bilateral parathyroid exploration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10466865\">",
"      Focused parathyroid exploration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27512606\">",
"      Endoscopic and video-assisted minimally invasive parathyroidectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28793366\">",
"      PREOPERATIVE LOCALIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H262466\">",
"      SURGEON'S SAFETY CHECKLIST FOR PARATHYROID EXPLORATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10466879\">",
"      INTRAOPERATIVE ASSESSMENT TOOLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10466887\">",
"      Intraoperative parathyroid hormone monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5041991\">",
"      Radioguided parathyroidectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28792404\">",
"      OPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28792348\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10466908\">",
"      Positioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10466915\">",
"      Incision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10466929\">",
"      Dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10466936\">",
"      Identification and confirmation of the parathyroid anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20979570\">",
"      Standardized nomenclature for adenoma location",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1850183\">",
"      First enlarged parathyroid gland",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3610120\">",
"      Identification of the ipsilateral normal parathyroid gland",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3610128\">",
"      Identification of multiglandular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1850510\">",
"      Familial disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3610136\">",
"      Identification of parathyroid carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3610143\">",
"      Parathyroid cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10466943\">",
"      Documentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10466950\">",
"      Closure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1352796\">",
"      MISSING PARATHYROID GLANDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1687719\">",
"      Missing superior gland",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1687726\">",
"      Missing inferior gland",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1687797\">",
"      Missing supernumerary gland",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1352810\">",
"      COMPROMISED PARATHYROID GLANDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27512297\">",
"      POSTOPERATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10466964\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3610215\">",
"      Operative failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10466971\">",
"      Symptomatic hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10466978\">",
"      Postoperative hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27512400\">",
"      - Mild hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27512408\">",
"      - Severe hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5041516\">",
"      - Permanent hypoparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3618803\">",
"      Wound infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10466992\">",
"      Recurrent laryngeal nerve injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3610312\">",
"      Hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H261995\">",
"      ABLATION TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10466999\">",
"      OUTCOMES AND CURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10467006\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15039\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15039|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/30/42465\" title=\"figure 1\">",
"      Endoscopic parathyroid exploration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/23/10608\" title=\"figure 2\">",
"      Patient positioning for thyroid and parathyroid surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/46/7906\" title=\"figure 3\">",
"      Incision site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/37/4694\" title=\"figure 4\">",
"      Anterior retraction thyroid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/9/26768\" title=\"figure 5\">",
"      Right recurrent laryngeal nerve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/37/24146\" title=\"figure 6\">",
"      Dissection of recurrent laryngeal nerve lateral view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/49/40735\" title=\"figure 7\">",
"      Common locations of common enlarged parathyroid glands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/15/11514\" title=\"figure 8\">",
"      Exposure of occult upper parathyroid gland",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/6/41059\" title=\"figure 9\">",
"      Dissection for occult left parathyroid gland",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15039|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/21/23890\" title=\"picture 1\">",
"      Parathyroid adenoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/42/8872?source=related_link\">",
"      Approach to therapy in multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22794?source=related_link\">",
"      Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36646?source=related_link\">",
"      Clinical manifestations of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1338?source=related_link\">",
"      Clinical manifestations of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/26/5545?source=related_link\">",
"      Diagnosis and differential diagnosis of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26520?source=related_link\">",
"      Diagnosis of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19258?source=related_link\">",
"      Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/25/24984?source=related_link\">",
"      Etiology of hypocalcemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/24/1418?source=related_link\">",
"      Evaluation of the patient with neck pain and cervical spine disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/13/3287?source=related_link\">",
"      Hungry bone syndrome following parathyroidectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/57/31642?source=related_link\">",
"      Initial and reoperative thyroidectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/50/35626?source=related_link\">",
"      Management of anticoagulation before and after elective surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/47/8954?source=related_link\">",
"      Management of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/14/43240?source=related_link\">",
"      Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/61/38871?source=related_link\">",
"      Multiple endocrine neoplasia type 1: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=related_link\">",
"      Overview of anesthesia and anesthetic choices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42583?source=related_link\">",
"      Overview of dual-energy x-ray absorptiometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14279?source=related_link\">",
"      Overview of the clinical manifestations of hyperthyroidism in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/62/21482?source=related_link\">",
"      Overview of the clinical utility of ultrasonography in thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/23/13688?source=related_link\">",
"      Parathyroid carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40387?source=related_link\">",
"      Parathyroid cysts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/58/21416?source=related_link\">",
"      Parathyroid hormone assays and their clinical use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/60/18377?source=related_link\">",
"      Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/23/29045?source=related_link\">",
"      Surgical anatomy of the parathyroid glands",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/17/44310?source=related_link\">",
"      Surgical anatomy of the thyroid gland",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/37/44632?source=related_link\">",
"      Treatment of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_0_35851="Five year survival by stage RCC";
var content_f35_0_35851=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F50004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F50004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Percent five-year survival in RCC by TNM stage in several contemporary cohorts",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"        TNM",
"stage&nbsp;&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        I",
"       </td>",
"       <td class=\"subtitle2\">",
"        II",
"       </td>",
"       <td class=\"subtitle2\">",
"        III",
"       </td>",
"       <td class=\"subtitle2\">",
"        IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Javidian, 1999",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tsui, 2000",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kinouchi, 1999",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stein, 1998",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Guinan, 1994",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pantuck, AJ, Zisman, A, Belldegrun, AS. The changing natural history of renal cell carcinoma. J Urology 2001; 166:1611. Copyright &copy; 2001 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_0_35851=[""].join("\n");
var outline_f35_0_35851=null;
var title_f35_0_35852="Gout versus psuedogout";
var content_f35_0_35852=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F65326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F65326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Crystal-induced arthritis: Comparison of gout and calcium pyrophosphate deposition disease (pseudogout)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Characteristic",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gout",
"       </td>",
"       <td class=\"subtitle1\">",
"        Calcium Pyrophosphate Deposition Disease (Pseudogout)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prevalence",
"       </td>",
"       <td>",
"        17 to 20 per 1000 individuals, largely adult men and postmenopausal women",
"       </td>",
"       <td>",
"        &lt;1 per 1000 individuals experience acute pseudogout; CPPD deposition is common in osteoarthritis and increases with age",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Crystals chemistry",
"       </td>",
"       <td>",
"        Monosodium urate",
"       </td>",
"       <td>",
"        Calcium pyrophosphate dihydrate",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Appearance",
"       </td>",
"       <td>",
"        Negatively birefringent; needle-shaped or rods",
"       </td>",
"       <td>",
"        Weakly positively birefringent;&nbsp;rods or rhomboidal",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Articular involvement",
"       </td>",
"       <td>",
"        Monoarticular &gt; oligoarticular; polyarticular &lt;30 percent",
"       </td>",
"       <td>",
"        Monoarticular &gt; oligoarticular",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Most frequently affected joints",
"       </td>",
"       <td class=\"sublist1_start\">",
"        First MTP joint",
"       </td>",
"       <td rowspan=\"4\">",
"        Knee, wrist, other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Initially 50 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Eventually 90 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ankle, knees, other",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Predisposing conditions/risk factors",
"       </td>",
"       <td>",
"        Hyperuricemia*, obesity, hypertension, hyperlipidemia, alcohol ingestion, lead ingestion, hereditary enzyme defect",
"       </td>",
"       <td>",
"        Hypothyroidism, hemochromatosis,&nbsp;osteoarthritis, hypomagnesemia,&nbsp;hyperparathyroidism, hereditary (rare), and increased age",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Therapeutic options",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Acute attacks:",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Acute attacks:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        NSAIDs, glucocorticoids, colchicine",
"       </td>",
"       <td class=\"sublist1\">",
"        NSAIDs, glucocorticoids, colchicine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Chronic management",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Chronic management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Urate-lowering agents, colchicine",
"       </td>",
"       <td class=\"sublist1\">",
"        <p>",
"         NSAIDs, colchicine",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist1\">",
"        DMARDs - hydroxychloroquine, methotrexate&nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Drugs associated with hyperuricemia include diuretics, low-dose salicylates, nicotinic acid, cyclosporine, ethanol, and ethambutol.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Am J Med 1997; 103:68S.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_0_35852=[""].join("\n");
var outline_f35_0_35852=null;
var title_f35_0_35853="Contents: Pulmonary diagnostics";
var content_f35_0_35853=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?8/24/8590\">",
"       Pulmonary, Critical Care, and Sleep Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pulmonary diagnostics",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pulmonary diagnostics",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/40/32392\">",
"           Anterior mediastinal mass lesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/14/7400\">",
"           Diffusing capacity for carbon monoxide",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/24/31111\">",
"           Evaluation of mediastinal masses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/40/32391\">",
"           Evaluation of pulmonary disability",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/30/5607\">",
"           Office spirometry",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/53/4952\">",
"           Overview of pulmonary function testing in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/2/15400\">",
"           Preoperative evaluation for lung resection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/59/9141\">",
"           Reference values for pulmonary function testing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/51/13113\">",
"           Strategies to reduce postoperative pulmonary complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/18/11560\">",
"           Tests of respiratory muscle strength",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-EBAAD81B43-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f35_0_35853=[""].join("\n");
var outline_f35_0_35853=null;
var title_f35_0_35854="Diagnosis of dementia";
var content_f35_0_35854=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68789&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68789&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diagnosis of dementia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 538px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * If diagnosis of depression is uncertain, neuropsychologic testing can be helpful to distinguish from cognitive impairment due to dementia.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Corey-Bloom J, Thal LJ, Galasko D, et al. Diagnosis and evaluation of dementia. Neurology 1995; 45:211.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_0_35854=[""].join("\n");
var outline_f35_0_35854=null;
var title_f35_0_35855="Parent questionnaire A";
var content_f35_0_35855=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    Questionnaire for parents",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 603px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Speech-Language Pathology Department, Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_0_35855=[""].join("\n");
var outline_f35_0_35855=null;
